AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ Information_NN 2003_CD AZ_NNP AR_NNP OuterCovs_NNP ._.
com_NN Annual_JJ R_NN Form_NN 20_CD 2003_CD Contact_NN information_NN Registered_NNP office_NN and_CC corporate_JJ headquarters_NNS address_NN :_: Registrar_NNP and_CC transfer_VB office_NN :_: AstraZeneca_NNP PLC_NNP Lloyds_NNP TSB_NNP Registrars_NNPS 15_CD Stanhope_NNP Gate_NNP The_NNP Causeway_NNP London_NNP W1K_NNP 1LN_NNP Worthing_NNP UK_NNP West_NNP Sussex_NNP Tel_NNP :_: 44_CD 0_CD 20 7304 5000_CD BN99_NNP 6DA_NNP Fax_NNP :_: 44_CD 0_CD 20 7304 5183_CD UK_NNP Tel_NNP in_IN the_DT UK_NNP :_: 0870 600 3956_CD R&D_NNP headquarters_NN address_NN :_: Tel_NNP outside_IN the_DT UK_NNP :_: 44_CD 0_CD 121 415 7033_CD AstraZeneca_NNP AB_NNP R&D_NNP Headquarters_NNP Swedish_NNP securities_NNS registration_NN center_NN :_: SE-151_CD 85_CD Sdertlje_NNP VPC_NNP AB_NNP Sweden_NNP PO_NNP Box_NNP 7822_CD Tel_NNP :_: 46_CD 0_CD 8_CD 553_CD 260_CD 00_CD SE-103_NN 97_CD Stockholm_NNP Fax_NNP :_: 46_CD 0_CD 8_CD 553_CD 290_CD 00_CD Sweden_NNP Tel_NNP :_: 46_CD 0_CD 8_CD 402_CD 9000_CD Investor_NNP relations_NNS contacts_NNS :_: UK_NNP and_CC Sweden_NNP :_: As_IN above_IN or_CC e-mail_VB :_: US_NNP depositary_NN :_: IR@astrazeneca_NNP ._.
com_NN JPMorgan_NNP Chase_NNP Bank_NNP US_NNP :_: PO_NNP Box_NNP 43013_CD Investor_NNP Relations_NNP Providence_NNP AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP RI_NNP 02940-3013_CD 1800_CD Concord_NNP Pike_NNP US_NNP PO_NNP Box_NNP 15438_CD Tel_NNP toll_NN free_JJ in_IN the_DT US_NNP :_: 888 697 8018_CD Wilmington_NNP Tel_NNP :_: 1_CD 781 575 4328_CD fide_NN 19850-5438_CD US_NNP Tel_NNP :_: 1_CD 302 886 3000_CD Fax_NNP :_: 1_CD 302 886 2972_CD On_IN the_DT path_NN to_TO growth_NN Annual_JJ Review_NNP 2003_CD AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN Commitment_NNP The_NNP path_NN to_TO a_DT new_JJ medicine_NN is_VBZ long_JJ and_CC complex_JJ ._.
Success_NN requires_VBZ a_DT major_JJ commitment_NN of_IN time_NN ,_, money_NN and_CC resource_NN ,_, backed_VBN by_IN clear_JJ strategic_JJ objectives_NNS ._.
Here_RB we_PRP describe_VBP what_WP it_PRP takes_VBZ to_TO deliver_VB and_CC realize_VB the_DT full_JJ potential_NN of_IN the_DT innovation_NN that_WDT supports_VBZ our_PRP$ continued_JJ growth_NN ._.
Discovery_NNP Development_NNP Supply_NNP Marketing_NNP Inspiration_NNP Identification_NNP of_IN Progressing_NNP Fast_NNP ,_, flexible_JJ and_CC Building_NNP strong_JJ Driving_VBG continued_VBN compounds_NNS with_IN high_JJ potential_JJ cost-effective_JJ relationships_NNS in_IN success_NN and_CC added_VBD the_DT highest_JJS potential_JJ compounds_NNS along_IN supply_NN of_IN our_PRP$ local_JJ markets_NNS ,_, value_NN for_IN all_DT our_PRP$ to_TO become_VB new_JJ the_DT full_JJ length_NN of_IN the_DT products_NNS wherever_WRB backed_VBN by_IN our_PRP$ stakeholders_NNS ._.
Page_NNP 12_CD Page_NNP 4_CD Page_NNP 6_CD Page_NNP 8_CD Page_NNP 10_CD AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN 01_CD Key_NNP achievements_NNS Sales_NNS for_IN the_DT year_NN were_VBD $_$ 18.8_CD billion_CD ._.
Arimidex_NNP is_VBZ moving_VBG rapidly_RB towards_IN At_IN constant_JJ exchange_NN rates_NNS ,_, replacing_VBG tamoxifen_NN as_IN the_DT standard_JJ sales_NNS were_VBD unchanged_JJ whilst_NN of_IN care_NN in_IN breast_NN cancer_NN ._.
Sales_NNS up_IN absorbing_VBG the_DT loss_NN of_IN $_$ 2.6_CD billion_CD 46_CD %_NN to_TO $_$ 519_CD million_CD ._.
in_IN US_NNP sales_NNS of_IN Losec_NNP Prilosec_NNP ,_, Zestril_NNP and_CC Nolvadex_NNP following_VBG Rapid_NNP uptake_NN of_IN Iressa_NNP since_IN first_JJ anticipated_VBN patent_NN expiries_NNS ._.
launch_NN in_IN Japan_NNP in_IN 2002_CD and_CC in_IN the_DT US_NNP in_IN 2003_CD ,_, with_IN over_IN 100,000_CD Operating_NN profit_NN was_VBD down_RB 11_CD %_NN patients_NNS treated_VBD since_IN launch_NN ._.
at_IN $_$ 4.1_CD billion_CD ,_, due_JJ to_TO planned_VBN 2003_CD sales_NNS reached_VBD $_$ 228_CD million_CD ._.
investments_NNS in_IN R&D_NNP and_CC other_JJ areas_NNS required_VBN to_TO launch_VB new_JJ products_NNS and_CC Crestor_NNP sales_NNS reached_VBD $_$ 129_CD million_CD ._.
complete_JJ the_DT product_NN portfolio_NN We_PRP estimate_VBP that_IN more_JJR than_IN 1.5_CD transformation_NN ._.
million_CD prescriptions_NNS had_VBD been_VBN written_VBN for_IN ,_, and_CC over_IN 750,000_CD Dividend_NN increased_VBN by_IN 13.6_CD %_NN to_TO patients_NNS had_VBD been_VBN treated_VBN with_IN 79.5_CD cents_NNS for_IN the_DT full_JJ year_NN ._.
Crestor_NNP by_IN the_DT end_NN of_IN January_NNP 2004_CD ._.
Sales_NNS for_IN key_JJ growth_NN and_CC launch_NN Exanta_NNP received_VBD its_PRP$ first_JJ regulatory_JJ products_NNS increased_VBN by_IN 45_CD %_NN to_TO approval_NN in_IN France_NNP in_IN December_NNP $_$ 8.2_CD billion_CD and_CC now_RB represent_VBP 2003_CD ._.
Regulatory_NNP submissions_VBZ 44_CD %_NN of_IN total_JJ sales_NNS ._.
were_VBD made_VBN in_IN the_DT US_NNP and_CC Europe_NNP for_IN key_JJ chronic_NN indications_NNS ,_, including_VBG Nexium_NNP sales_NNS reached_VBD $_$ 3.3_CD billion_CD ,_, prevention_NN of_IN stroke_NN associated_VBN with_IN up_RB 62_CD %_NN atrial_JJ fibrillation_NN ._.
Seroquel_NNP sales_NNS reached_VBD $_$ 1.5_CD billion_CD ,_, R&D_NNP investment_NN totalled_VBD $_$ 3.5_CD billion_CD ._.
Approvals_NNS for_IN use_NN of_IN We_PRP now_RB have_VBP 12_CD projects_NNS in_IN phase_NN 2_CD Seroquel_NNP in_IN the_DT treatment_NN of_IN acute_JJ development_NN and_CC 28_CD projects_NNS in_IN bipolar_NN mania_NN were_VBD received_VBN in_IN the_DT phase_NN 3_CD ._.
Continued_VBN enhancement_NN of_IN supply_NN Symbicort_NNP sales_NNS reached_VBD $_$ 549_CD million_CD ,_, and_CC manufacturing_VBG processes_NNS led_VBD to_TO up_RP 61_CD %_NN ._.
Symbicort_NNP also_RB gained_VBD first_RB improved_VBN customer_NN service_NN levels_NNS approval_NN in_IN Europe_NNP for_IN use_NN in_IN the_DT and_CC reduced_VBN manufacturing_NN lead_NN treatment_NN of_IN chronic_JJ obstructive_JJ times_NNS which_WDT consequently_RB reduced_VBD pulmonary_JJ disease_NN ._.
the_DT requirement_NN for_IN stock_NN build-up_NN ._.
AstraZeneca_NNP is_VBZ one_CD of_IN the_DT worlds_NNS leading_VBG Contents_NNP Remuneration_NNP policy_NN 19_CD Chairmans_NNPS statement_NN 02_CD Summary_NNP financial_JJ review_NN 21_CD pharmaceutical_JJ companies_NNS ._.
Our_PRP$ strong_JJ Strategy_NNP 02_CD Summary_NNP financial_JJ statements_NNS 23_CD research_NN base_NN ,_, backed_VBN by_IN our_PRP$ extensive_JJ Chief_NNP Executives_NNS review_NN 03_CD Group_NNP profit_NN and_CC loss_NN account_NN 24_CD manufacturing_NN and_CC commercial_JJ skills_NNS ,_, Discovery_NNP 04_CD Group_NNP balance_NN sheet_NN 26_CD focuses_VBZ on_IN turning_VBG ideas_NNS into_IN effective_JJ Development_NNP pipeline_NN 07_CD Statement_NN of_IN Group_NNP cash_NN flow_NN 27_CD medicines_NNS that_WDT meet_VBP patient_JJ needs_NNS in_IN Supply_NNP 08_CD Dividends_NNPS 28_CD important_JJ areas_NNS of_IN healthcare_NN ._.
We_PRP Marketing_NNP 10_CD Earnings_NNS per_IN share_NN 28_CD encourage_VBP innovation_NN in_IN all_DT areas_NNS of_IN our_PRP$ Inspiration_NNP 12_CD Emoluments_NNP of_IN Directors_NNS 29_CD business_NN because_IN the_DT more_RBR good_JJ ideas_NNS Therapy_NNP area_NN review_NN 14_CD Group_NNP financial_JJ record_NN 30_CD we_PRP have_VBP ,_, the_DT more_JJR we_PRP can_MD add_VB value_NN for_IN Board_NNP of_IN Directors_NNS 16_CD Share_NN information_NN 31_CD our_PRP$ shareholders_NNS ,_, customers_NNS ,_, employees_NNS Summary_NNP Directors_NNS report_VBP 18_CD Shareholder_NN information_NN 32_CD and_CC the_DT wider_JJR community_NN ._.
com_NN 02_CD Accountability_NN Five_CD years_NNS ago_RB ,_, on_IN the_DT completion_NN of_IN the_DT Property_NNP Rights_NNPS TRIPs_NNPS and_CC the_DT public_JJ health_NN have_VBP also_RB reviewed_VBN and_CC strengthened_VBD the_DT merger_NN of_IN the_DT Astra_NNP and_CC Zeneca_NNP businesses_NNS ,_, benefits_NNS that_WDT will_MD flow_VB from_IN this_DT resolution_NN ._.
In_IN the_DT US_NNP we_PRP the_DT new_JJ Board_NNP had_VBD a_DT clear_JJ vision_NN ._.
have_VB undertaken_VBN significant_JJ compliance_NN In_IN the_DT context_NN of_IN this_DT business_NN environment_NN training_NN with_IN our_PRP$ sales_NNS and_CC other_JJ relevant_JJ AstraZeneca_NNP was_VBD to_TO be_VB a_DT creative_JJ ,_, fast_JJ and_CC and_CC recognizing_VBG the_DT specific_JJ challenges_NNS personnel_NNS pursuant_JJ to_TO the_DT Corporate_JJ Integrity_NN effective_JJ ,_, research-based_JJ pharmaceutical_JJ faced_VBN by_IN the_DT Company_NN ,_, AstraZenecas_NNP Agreement_NNP with_IN the_DT Office_NNP of_IN Inspector_NNP company_NN ._.
Its_PRP$ increased_VBN global_JJ marketing_NN financial_JJ performance_NN in_IN 2003_CD has_VBZ been_VBN General_NNP of_IN the_DT Department_NNP of_IN Health_NNP and_CC strength_NN provided_VBD the_DT platform_NN to_TO realize_VB the_DT excellent_JJ and_CC the_DT Board_NNP has_VBZ recommended_VBN a_DT Human_NNP Services_NNPS ._.
full_JJ potential_NN of_IN its_PRP$ productive_JJ R&D_NNP and_CC deliver_VB second_JJ interim_JJ dividend_NN of_IN $_$ 0.54_CD :_: 29.4_CD sustainable_JJ value_NN to_TO all_DT its_PRP$ stakeholders_NNS ._.
pence_NN :_: SEK3_CD .91_CD per_IN Ordinary_NNP Share_NNP bringing_VBG We_PRP welcome_JJ Michele_NNP Hooper_NNP and_CC Joe_NNP the_DT total_JJ dividend_NN for_IN the_DT year_NN to_TO $_$ 0.795_CD :_: 45.3_CD Jimenez_NNP ,_, who_WP joined_VBD the_DT Board_NNP in_IN July_NNP as_IN Back_NNP in_IN 1999_CD ,_, there_EX were_VBD some_DT substantial_JJ pence_NN :_: SEK5_CD .98_CD ,_, an_DT increase_NN of_IN 13.6_CD %_NN in_IN Non-Executive_JJ Directors_NNS ._.
Micheles_NNP hurdles_NNS to_TO overcome_VB before_IN this_DT vision_NN could_MD dollar_NN terms_NNS ._.
The_DT share_NN re-purchase_JJ experience_NN at_IN Caremark_NNP International_NNP and_CC be_VB turned_VBN into_IN reality_NN ._.
The_DT first_JJ of_IN these_DT was_VBD to_TO program_VB continued_VBN in_IN 2003_CD with_IN 27.2_CD Baxter_NNP Healthcare_NNP in_IN the_DT US_NNP and_CC Joes_NNP rapidly_RB complete_VB the_DT merger_NN ,_, build_VB on_IN the_DT million_CD shares_NNS re-purchased_JJ for_IN cancellation_NN background_NN as_IN President_NNP and_CC CEO_NNP of_IN Heinz_NNP strengths_NNS of_IN the_DT two_CD partners_NNS to_TO create_VB a_DT at_IN a_DT total_JJ cost_NN of_IN $_$ 1,154_CD million_CD ._.
The_DT Board_NNP is_VBZ Europe_NNP and_CC earlier_JJR positions_NNS in_IN the_DT US_NNP bring_VB single_JJ unified_JJ culture_NN and_CC realize_VB the_DT merger_NN proposing_VBG a_DT further_JJ share_NN re-purchase_JJ additional_JJ strengths_NNS to_TO the_DT Board_NNP ._.
Hkan_JJ cost_NN benefits_NNS without_IN significantly_RB disturbing_JJ program_NN of_IN $_$ 4_CD billion_CD to_TO be_VB completed_VBN by_IN Mogren_NNP stepped_VBD down_RP as_IN Executive_NNP Deputy_NNP our_PRP$ day-to-day_JJ operations_NNS ._.
This_DT was_VBD the_DT end_NN of_IN 2005_CD ,_, subject_JJ to_TO shareholders_NNS Chairman_NNP in_IN August_NNP 2003_CD and_CC continues_VBZ as_RB achieved_VBN in_IN the_DT first_JJ two_CD years_NNS ._.
renewing_VBG the_DT Companys_NNPS authority_NN to_TO Non-Executive_JJ Deputy_NNP Chairman_NNP ._.
In_IN his_PRP$ re-purchase_NN its_PRP$ own_JJ shares_NNS at_IN the_DT Annual_JJ executive_NN capacity_NN ,_, Hkan_NNP Mogren_NNP served_VBD Our_PRP$ focus_NN was_VBD then_RB on_IN another_DT major_JJ General_NNP Meeting_VBG in_IN April_NNP ._.
both_DT Astra_NNP AB_NNP and_CC AstraZeneca_NNP PLC_NNP with_IN challenge_NN :_: the_DT transformation_NN of_IN our_PRP$ product_NN distinction_NN and_CC I_PRP am_VBP delighted_JJ that_IN the_DT Board_NNP portfolio_NN from_IN its_PRP$ historic_JJ reliance_NN on_IN The_DT AstraZeneca_NNP share_NN price_NN performed_VBD well_RB will_MD continue_VB to_TO benefit_VB from_IN his_PRP$ wise_JJ counsel_NN ._.
successful_JJ but_CC maturing_VBG products_NNS ,_, such_JJ as_IN in_IN 2003_CD in_IN both_DT absolute_JJ terms_NNS and_CC when_WRB Losec_NNP Prilosec_NNP and_CC Zestril_NNP ,_, into_IN a_DT range_NN of_IN compared_VBN with_IN an_DT international_JJ group_NN of_IN I_PRP am_VBP grateful_JJ to_TO my_PRP$ colleagues_NNS on_IN the_DT Board_NNP newer_JJR high_JJ potential_NN medicines_NNS ._.
Many_JJ leading_VBG pharmaceutical_JJ companies_NNS ,_, for_IN their_PRP$ support_NN ,_, to_TO the_DT Senior_NNP Executive_NNP commentators_NNS predicted_VBD a_DT steep_JJ decline_NN in_IN reflecting_VBG the_DT markets_NNS positive_JJ view_NN of_IN the_DT Team_NNP and_CC to_TO all_DT our_PRP$ employees_NNS worldwide_JJ sales_NNS and_CC profit_NN during_IN this_DT period_NN ._.
By_IN the_DT end_NN Companys_NNP future_JJ growth_NN prospects_NNS ._.
for_IN their_PRP$ impressive_JJ contributions_NNS to_TO the_DT of_IN 2003_CD ,_, this_DT transformation_NN had_VBD largely_RB been_VBN Companys_NNP success_NN ._.
On_IN behalf_NN of_IN the_DT Board_NNP ,_, achieved_VBD ._.
There_EX have_VBP been_VBN some_DT delays_NNS in_IN During_IN a_DT busy_JJ year_NN ,_, the_DT Board_NNP analyzed_VBD I_PRP would_MD like_VB to_TO thank_VB them_PRP most_RBS warmly_RB ._.
new_JJ product_NN launches_NNS but_CC also_RB some_DT of_IN the_DT trends_NNS in_IN the_DT pharmaceutical_JJ environment_NN more_RBR mature_JJ brands_NNS have_VBP not_RB declined_VBN as_IN and_CC reviewed_VBN the_DT Companys_NNPS overall_JJ strategy_NN In_IN 2004_CD ,_, we_PRP aim_VBP to_TO deliver_VB strong_JJ sales_NNS fast_RB as_IN expected_VBN ._.
AstraZeneca_NNP is_VBZ now_RB facing_VBG and_CC performance_NN ._.
I_PRP am_VBP happy_JJ to_TO report_VB good_JJ growth_NN from_IN our_PRP$ portfolio_NN of_IN important_JJ an_DT exciting_JJ period_NN of_IN expansion_NN with_IN few_JJ progress_NN in_IN the_DT productivity_NN increase_NN medicines_NNS while_IN ,_, at_IN the_DT same_JJ time_NN ,_, patent_NN expiries_NNS and_CC growth_NN driven_VBN by_IN the_DT programs_NNS that_WDT cover_VBP all_DT parts_NNS of_IN the_DT progressing_VBG the_DT next_JJ wave_NN of_IN novel_NN products_NNS ._.
recently_RB introduced_VBN products_NNS and_CC by_IN further_JJ Company_NN ._.
In_IN line_NN with_IN this_DT culture_NN of_IN We_PRP will_MD continue_VB our_PRP$ investment_NN strategy_NN in_IN new_JJ product_NN launches_NNS ._.
Recent_JJ investments_NNS continuous_JJ improvement_NN ,_, the_DT performance_NN of_IN developing_VBG regions_NNS to_TO complement_VB our_PRP$ in_IN developing_VBG countries_NNS also_RB add_VBP to_TO the_DT the_DT Board_NNP ,_, its_PRP$ committees_NNS and_CC all_DT individual_JJ strong_JJ presence_NN in_IN the_DT major_JJ established_VBN potential_NN for_IN growth_NN ._.
members_NNS were_VBD reviewed_VBN in_IN a_DT constructive_JJ markets_NNS ._.
Through_IN strong_JJ sales_NNS growth_NN discussion_NN that_WDT identified_VBD areas_NNS for_IN further_JJ coupled_VBN with_IN productivity_NN improvements_NNS Taking_VBG a_DT wider_JJR perspective_NN ,_, the_DT improvement_NN ._.
across_IN all_DT our_PRP$ activities_NNS ,_, we_PRP expect_VBP to_TO deliver_VB pharmaceutical_JJ sector_NN continued_VBD to_TO top_VB tier_JJR financial_JJ performance_NN in_IN the_DT years_NNS experience_NN pricing_NN pressures_NNS in_IN major_JJ During_IN the_DT year_NN the_DT Board_NNP has_VBZ reviewed_VBN its_PRP$ ahead_RB ._.
markets_NNS during_IN 2003_CD and_CC the_DT AstraZeneca_NNP already_RB demanding_VBG compliance_NN procedures_NNS Board_NNP reviewed_VBD the_DT Companys_NNP approach_NN to_TO to_TO respond_VB to_TO new_JJ laws_NNS and_CC regulations_NNS in_IN the_DT product_NN pricing_NN and_CC market_NN access_NN for_IN our_PRP$ US_NNP ,_, Sweden_NNP and_CC the_DT UK_NNP ._.
We_PRP support_VBP the_DT World_NNP Trade_NNP Review_NNP ,_, our_PRP$ Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ Organisation_NNP WTO_NNP resolution_NN of_IN outstanding_JJ Information_NN and_CC Corporate_JJ Responsibility_NN issues_NNS relating_VBG to_TO the_DT Doha_NNP Agreement_NN on_IN Summary_NNP Report_NNP have_VBP all_DT been_VBN prepared_VBN in_IN Percy_NNP Barnevik_NNP Trade_NNP Related_NNP Aspects_NNPS of_IN Intellectual_NNP accordance_NN with_IN the_DT new_JJ requirements_NNS ._.
We_PRP Chairman_NNP We_PRP aspire_VBP to_TO be_VB the_DT best_JJS in_IN all_DT areas_NNS of_IN our_PRP$ Expansion_NN of_IN the_DT Successful_JJ delivery_NN AstraZeneca_NNP relative_JJ share_NN performance_NN business_NN within_IN a_DT culture_NN based_VBN on_IN innovation_NN development_NN to_TO market_NN of_IN the_DT 31_CD December_NNP 1998_CD 31_CD December_NNP 2003_CD combined_VBN with_IN the_DT disciplined_JJ and_CC pipeline_NN through_IN next_JJ wave_NN of_IN AstraZeneca_NNP responsible_JJ approach_NN required_VBN to_TO achieve_VB improved_VBN differentiated_JJ Major_JJ international_JJ pharmaceutical_JJ companies_NNS industry_NN leading_VBG productivity_NN ._.
By_IN discovering_VBG ,_, in-house_JJ discovery_NN products_NNS currently_RB 160_CD developing_VBG ,_, manufacturing_VBG and_CC marketing_VBG processes_NNS coupled_VBN in_IN late_JJ stage_NN differentiated_VBD medicines_NNS that_WDT make_VBP a_DT real_JJ with_IN complementary_JJ development_NN ._.
130_CD contribution_NN to_TO human_JJ health_NN ,_, AstraZeneca_NNP external_JJ aims_NNS to_TO create_VB enduring_VBG value_NN for_IN collaborations_NNS 100_CD shareholders_NNS and_CC society_NN and_CC deliver_VB a_DT and_CC partnerships_NNS ._.
70_CD sustained_VBD financial_JJ performance_NN that_WDT will_MD Dec_NNP Jun_NNP Dec_NNP Jun_NNP Dec_NNP Jun_NNP Dec_NNP Jun_NNP Dec_NNP Jun_NNP Dec_NNP match_VBP the_DT best_JJS in_IN the_DT industry_NN ._.
Our_PRP$ strategy_NN 98_CD 99_CD 99_CD 00_CD 00_CD 01_CD 01_CD 02_CD 02_CD 03_CD 03_CD for_IN sustainable_JJ growth_NN is_VBZ :_: Abbott_NNP Labs_NNPS ,_, AHP_NNP ,_, Aventis_NNP ,_, BMS_NNP ,_, Eli_NNP Lilly_NNP ,_, GSK_NNP ,_, JNJ_NNP ,_, Merck_NNP ,_, Novartis_NNP ,_, Pfizer_NNP ,_, Pharmacia_NNP ,_, Roche_NNP ,_, Sanofi-Synthelabo_NNP ,_, Schering_NNP and_CC Schering-Plough_NNP Source_NNP :_: Thomson_NNP Financial_NNP Datastream_NNP AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN 03_CD Performance_NNP In_IN 2003_CD ,_, AstraZeneca_NNP made_VBD excellent_JJ after_IN its_PRP$ first_JJ introduction_NN in_IN the_DT US_NNP ,_, making_VBG it_PRP Exanta_NNP met_VBD important_JJ milestones_NNS at_IN the_DT progress_NN establishing_VBG itself_PRP as_IN a_DT world_NN leading_VBG one_CD of_IN the_DT most_RBS successful_JJ launches_NNS ever_RB of_IN a_DT end_NN of_IN 2003_CD ._.
In_IN December_NNP we_PRP gained_VBD our_PRP$ pharmaceutical_JJ company_NN focused_VBD on_IN the_DT new_JJ medicine_NN ._.
first_RB approval_NN in_IN France_NNP for_IN this_DT breakthrough_NN research_NN ,_, development_NN ,_, manufacture_NN and_CC medicine_NN in_IN the_DT prevention_NN of_IN blood_NN clots_NNS marketing_NN of_IN valuable_JJ prescription_NN medicines_NNS Seroquel_NNP continues_VBZ to_TO grow_VB strongly_RB in_IN the_DT following_VBG orthopaedic_NN surgery_NN ._.
As_IN scheduled_VBN ,_, and_CC creating_VBG the_DT platform_NN for_IN top_JJ tier_NN financial_JJ anti-psychotic_JJ market_NN where_WRB its_PRP$ attractive_JJ in_IN December_NNP we_PRP also_RB filed_VBD in_IN the_DT US_NNP ,_, Canada_NNP performance_NN in_IN the_DT coming_VBG years_NNS ._.
profile_NN makes_VBZ it_PRP the_DT agent_NN of_IN choice_NN for_IN and_CC Europe_NNP our_PRP$ largest_JJS ever_RB regulatory_JJ increasing_VBG numbers_NNS of_IN physicians_NNS and_CC submission_NN ,_, this_DT time_NN for_IN long_JJ term_NN uses_NNS of_IN First_NNP launches_NNS of_IN Crestor_NNP ,_, the_DT further_JJ patients_NNS ._.
Sales_NNS in_IN 2003_CD were_VBD $_$ 1.5_CD billion_CD and_CC Exanta_NNP in_IN conditions_NNS such_JJ as_IN the_DT prevention_NN development_NN of_IN marketed_VBN products_NNS such_JJ as_IN now_RB ,_, with_IN the_DT approval_NN of_IN a_DT major_JJ new_JJ of_IN stroke_NN in_IN patients_NNS with_IN atrial_JJ fibrillation_NN ._.
Iressa_NNP ,_, Nexium_NNP and_CC Seroquel_NNP ,_, and_CC the_DT first_JJ indication_NN ,_, the_DT treatment_NN of_IN mania_NN associated_VBN approval_NN for_IN the_DT revolutionary_JJ anti-coagulant_JJ ,_, with_IN bipolar_JJ disease_NN ,_, Seroquel_NNP looks_VBZ set_VBN to_TO In_IN summary_NN ,_, 2003_CD has_VBZ been_VBN an_DT exciting_JJ Exanta_NNP ,_, herald_VBP the_DT passage_NN into_IN an_DT exciting_JJ play_NN a_DT key_JJ part_NN in_IN our_PRP$ future_JJ growth_NN ._.
I_PRP would_MD like_VB to_TO new_JJ era_NN for_IN the_DT Company_NN ._.
acknowledge_VBP the_DT tremendous_JJ support_NN I_PRP AstraZenecas_NNPS cancer_NN portfolio_NN also_RB made_VBD have_VBP received_VBN from_IN my_PRP$ executive_NN team_NN Our_PRP$ sales_NNS and_CC marketing_NN teams_NNS around_IN the_DT strong_JJ progress_NN during_IN the_DT year_NN with_IN and_CC to_TO recognize_VB the_DT immense_JJ contribution_NN world_NN now_RB have_VBP the_DT opportunity_NN to_TO realize_VB the_DT excellent_JJ data_NNS supporting_VBG the_DT use_NN of_IN Arimidex_NNP made_VBN by_IN our_PRP$ creative_JJ ,_, hardworking_VBG and_CC full_JJ potential_NN of_IN our_PRP$ successful_JJ research_NN and_CC 2003_CD sales_NNS $_$ 519_CD million_CD in_IN the_DT adjuvant_JJ committed_JJ employees_NNS around_IN the_DT world_NN ._.
development_NN and_CC ,_, through_IN wise_JJ investment_NN treatment_NN of_IN breast_NN cancer_NN ,_, strong_JJ sales_NNS for_IN Their_PRP$ combined_VBN efforts_NNS have_VBP already_RB and_CC a_DT continuing_VBG drive_NN for_IN improved_VBN Faslodex_NNP $_$ 77_CD million_CD which_WDT was_VBD launched_VBN achieved_VBD a_DT great_JJ deal_NN ._.
There_EX is_VBZ now_RB much_JJ productivity_NN ,_, deliver_VBP enduring_VBG growth_NN of_IN in_IN 2002_CD in_IN the_DT US_NNP ,_, and_CC the_DT successful_JJ US_NNP to_TO do_VB to_TO realize_VB the_DT potential_NN for_IN outstanding_JJ shareholder_NN value_NN ._.
launch_NN of_IN Iressa_NNP 2003_CD global_JJ sales_NNS $_$ 228_CD growth_NN and_CC financial_JJ performance_NN from_IN this_DT million_CD for_IN the_DT treatment_NN of_IN late_JJ stage_NN strong_JJ base_NN ._.
In_IN addition_NN to_TO good_JJ progress_NN with_IN the_DT new_JJ non-small_JJ cell_NN lung_NN cancer_NN ._.
products_NNS ,_, we_PRP have_VBP also_RB expanded_VBN our_PRP$ global_JJ The_DT external_JJ environment_NN is_VBZ changing_VBG presence_NN with_IN investments_NNS in_IN research_NN ,_, The_DT year_NN also_RB saw_VBD significant_JJ developments_NNS and_CC our_PRP$ industry_NN has_VBZ to_TO change_VB with_IN it_PRP ._.
development_NN ,_, manufacturing_NN and_CC marketing_NN in_IN AstraZenecas_NNP cardiovascular_JJ business_NN Demographics_NNS and_CC technology_NN continue_VBP in_IN important_JJ emerging_VBG markets_NNS ._.
As_IN a_DT result_NN of_IN including_VBG the_DT launch_NN in_IN the_DT US_NNP and_CC 20_CD other_JJ to_TO drive_VB demand_NN for_IN healthcare_NN and_CC for_IN our_PRP$ these_DT and_CC other_JJ initiatives_NNS ,_, AstraZeneca_NNP has_VBZ markets_NNS of_IN the_DT lipid-lowering_JJ drug_NN Crestor_NNP products_NNS with_IN the_DT result_NN that_IN governments_NNS become_VBP one_CD of_IN the_DT fastest_JJS growing_VBG 2003_CD sales_NNS $_$ 129_CD million_CD ._.
The_DT treatment_NN of_IN and_CC payers_NNS face_VBP increasing_VBG pressure_NN to_TO pharmaceutical_JJ companies_NNS in_IN ,_, among_IN others_NNS ,_, lipid_JJ disorders_NNS is_VBZ a_DT major_JJ priority_NN for_IN control_NN costs_NNS ._.
At_IN the_DT same_JJ time_NN the_DT disparity_NN Japan_NNP ,_, China_NNP and_CC Mexico_NNP ._.
healthcare_NN systems_NNS around_IN the_DT world_NN and_CC the_DT of_IN healthcare_NN between_IN the_DT developed_VBN and_CC the_DT profile_NN of_IN Crestor_NNP ,_, which_WDT allows_VBZ physicians_NNS least_JJS developed_JJ nations_NNS continues_VBZ to_TO grow_VB During_IN 2003_CD the_DT performance_NN of_IN the_DT new_JJ and_CC and_CC patients_NNS to_TO achieve_VB guideline_NN lipid_NN levels_NNS and_CC the_DT industry_NN finds_VBZ itself_PRP at_IN the_DT center_NN of_IN growth_NN products_NNS in_IN the_DT Companys_NNPS revitalised_VBD quickly_RB and_CC easily_RB ,_, gives_VBZ us_PRP an_DT opportunity_NN to_TO much_JJ of_IN this_DT debate_NN ._.
It_PRP is_VBZ in_IN this_DT environment_NN portfolio_NN $_$ 8.2_CD billion_CD largely_RB offset_VBP the_DT decline_NN build_VB a_DT major_JJ new_JJ franchise_NN in_IN one_CD of_IN the_DT that_WDT AstraZeneca_NNP has_VBZ to_TO succeed_VB if_IN it_PRP is_VBZ to_TO in_IN global_JJ sales_NNS of_IN Losec_NNP Prilosec_NNP ,_, Zestril_NNP and_CC largest_JJS sectors_NNS of_IN medicine_NN ._.
Following_VBG create_VB value_NN for_IN all_DT its_PRP$ stakeholders_NNS ._.
This_DT transformation_NN ,_, successful_JJ introduction_NN into_IN a_DT number_NN of_IN work_NN of_IN the_DT last_JJ five_CD years_NNS has_VBZ positioned_VBN us_PRP achieved_VBD without_IN a_DT decline_NN in_IN top-line_JJ sales_NNS ,_, other_JJ markets_NNS ,_, launch_NN in_IN the_DT very_RB important_JJ well_RB ._.
We_PRP recognize_VBP and_CC understand_VBP the_DT from_IN a_DT company_NN that_WDT faced_VBD the_DT biggest_JJS threat_NN US_NNP market_NN has_VBZ gone_VBN well_RB and_CC early_RB sales_NNS challenges_VBZ the_DT future_JJ holds_VBZ and_CC we_PRP look_VBP from_IN patent_NN expiries_NNS in_IN the_DT industrys_NNS history_NN ,_, progress_NN is_VBZ encouraging_VBG ._.
An_DT important_JJ new_JJ forward_RB to_TO meeting_VBG those_DT challenges_NNS in_IN into_IN the_DT one_CD with_IN perhaps_RB the_DT best_JJS growth_NN study_NN CHARM_NNP supporting_VBG the_DT use_NN of_IN 2004_CD and_CC beyond_IN ._.
portfolio_NN ,_, is_VBZ something_NN of_IN which_WDT our_PRP$ Atacand_NNP 2003_CD sales_NNS $_$ 750_CD million_CD in_IN heart_NN employees_NNS are_VBP justifiably_RB proud_JJ ._.
failure_NN and_CC the_DT continued_JJ growth_NN of_IN Seloken_NNP Toprol-XL_NNP 2003_CD sales_NNS $_$ 1.3_CD billion_CD Nexium_NNP ,_, for_IN gastrointestinal_JJ disorders_NNS ,_, has_VBZ have_VBP also_RB helped_VBN to_TO reinforce_VB a_DT leading_VBG maintained_VBN strong_JJ momentum_NN despite_IN an_DT position_NN in_IN cardiovascular_JJ medicine_NN ._.
In_IN the_DT US_NNP alone_RB ,_, Nexium_NNP achieved_VBD sales_NNS of_IN After_IN a_DT lengthy_JJ development_NN program_NN $_$ 2.5_CD billion_CD in_IN the_DT year_NN ._.
Globally_RB annual_JJ sales_NNS involving_VBG more_JJR than_IN 30,000_CD patients_NNS ,_, I_PRP am_VBP Sir_NNP Tom_NNP McKillop_NNP reached_VBD $_$ 3.3_CD billion_CD ,_, less_JJR than_IN three_CD years_NNS pleased_JJ to_TO report_VB that_IN the_DT oral_JJ anti-coagulant_JJ Chief_NNP Executive_NNP Realising_VBG the_DT full_JJ Further_JJ Enhancing_VBG our_PRP$ Pursuing_NNP Continuing_NNP Delivering_NNP our_PRP$ potential_NN of_IN our_PRP$ strengthening_VBG our_PRP$ presence_NN in_IN value_NN creating_VBG to_TO improve_VB core_NN values_NNS therapies_NNS through_IN commercial_JJ skills_NNS important_JJ new_JJ ,_, investment_NN in_IN productivity_NN through_IN a_DT investment_NN in_IN to_TO drive_VB success_NN emerging_VBG markets_NNS significant_JJ targeted_VBN in_IN pursuit_NN of_IN responsible_JJ projects_NNS that_WDT will_MD in_IN our_PRP$ key_JJ markets_NNS ._.
through_IN organic_JJ licensing_NN and_CC operational_JJ approach_NN extend_VBP their_PRP$ use_NN growth_NN and_CC acquisition_NN excellence_NN to_TO business_NN ._.
and_CC bring_VB benefits_NNS strategic_JJ regional_JJ opportunities_NNS ._.
in_IN all_DT our_PRP$ to_TO new_JJ patient_JJ investments_NNS ._.
com_NN 04_CD Discovery_NNP We_PRP use_VBP leading_VBG edge_NN science_NN and_CC technology_NN to_TO identify_VB the_DT compounds_NNS with_IN the_DT highest_JJS potential_NN to_TO become_VB new_JJ medicines_NNS ._.
In_IN 2003_CD ,_, our_PRP$ We_PRP have_VBP over_IN During_IN 2003_CD ,_, We_PRP continue_VBP During_IN the_DT year_NN ,_, we_PRP entered_VBD into_IN more_JJR than_IN research_NN and_CC 11,500_CD people_NNS a_DT further_JJ 15_CD to_TO invest_VB in_IN our_PRP$ 200_CD new_JJ collaborations_NNS including_VBG with_IN the_DT development_NN dedicated_VBN to_TO the_DT candidate_NN drugs_NNS facilities_NNS and_CC University_NNP of_IN Dundee_NNP ,_, the_DT University_NNP of_IN investment_NN discovery_NN and_CC were_VBD selected_VBN and_CC ,_, in_IN 2003_CD ,_, new_JJ Gratz_NNP ,_, Sumitomo_NNP Pharmaceutical_NNP Co._NNP ._.
Ltd._NNP totalled_VBD $_$ 3.5_CD billion_CD development_NN of_IN in_IN addition_NN ,_, 10_CD or_CC upgraded_VBN NeoGenesis_NNP Pharmaceuticals_NNP ,_, Inc._NNP up_IN from_IN $_$ 3.1_CD new_JJ medicines_NNS at_IN early_JJ development_NN laboratories_NNS Cytokinetics_NNP ,_, Inc._NNP ._.
Biosignal_NNP Inc._NNP ._.
11_CD R&D_NNP centres_NNS in_IN projects_NNS reached_VBN were_VBD opened_VBN in_IN Biopharma_NNP and_CC Abgenix_NNP Inc._NNP seven_CD countries_NNS the_DT stage_NN of_IN Sweden_NNP ,_, the_DT UK_NNP ,_, the_DT UK_NNP ,_, the_DT US_NNP ,_, human_JJ testing_NN ._.
Sweden_NNP ,_, France_NNP ,_, Canada_NNP ,_, India_NNP and_CC Japan_NNP ._.
com_NN 05_CD AstraZeneca_NNP focuses_VBZ its_PRP$ skills_NNS ,_, experience_NN We_PRP are_VBP continuously_RB improving_VBG the_DT and_CC resources_NNS on_IN six_CD therapy_NN areas_NNS :_: productivity_NN and_CC efficiency_NN of_IN our_PRP$ Cardiovascular_NNP ,_, Gastrointestinal_NNP ,_, discovery_NN and_CC development_NN by_IN Infection_NNP ,_, Neuroscience_NNP ,_, Oncology_NNP ,_, simplifying_VBG our_PRP$ processes_NNS ,_, speeding_VBG and_CC Respiratory_NNP and_CC Inflammation_NNP up_IN decision_NN making_VBG and_CC investing_VBG in_IN important_JJ areas_NNS of_IN healthcare_NN which_WDT areas_NNS directly_RB linked_VBN to_TO increasing_VBG the_DT represent_VBP the_DT majority_NN of_IN the_DT worldwide_JJ quality_NN and_CC number_NN of_IN new_JJ products_NNS ._.
We_PRP have_VBP a_DT powerful_JJ During_IN 2003_CD we_PRP significantly_RB increased_VBD range_NN of_IN products_NNS that_WDT meet_VBP patient_JJ the_DT number_NN of_IN new_JJ discovery_NN projects_NNS ,_, needs_VBZ in_IN these_DT areas_NNS and_CC a_DT commitment_NN delivered_VBD a_DT more_RBR consistent_JJ flow_NN of_IN to_TO delivering_VBG more_JJR new_JJ ,_, medically_RB quality_JJ candidate_NN drugs_NNS throughout_IN the_DT important_JJ and_CC commercially_RB successful_JJ year_NN ,_, increased_VBD the_DT number_NN of_IN drugs_NNS products_NNS to_TO the_DT market_NN every_DT year_NN ._.
reaching_VBG clinical_JJ testing_NN and_CC progressed_VBD a_DT greater_JJR number_NN of_IN products_NNS that_WDT Medical_NNP research_NN is_VBZ more_RBR exciting_JJ than_IN showed_VBD therapeutic_JJ potential_NN ._.
ever_RB as_IN new_JJ technology_NN is_VBZ applied_VBN to_TO understanding_VBG what_WP causes_VBZ disease_NN On_IN average_NN ,_, at_IN least_JJS one_CD quality_NN CD_NNP now_RB and_CC how_WRB it_PRP may_MD be_VB prevented_VBN or_CC treated_VBN ._.
enters_VBZ pre-clinical_JJ development_NN each_DT month_NN ._.
During_IN 2003_CD ,_, a_DT further_JJ 15_CD CDs_NNS We_PRP have_VBP six_CD major_JJ joint_JJ discovery_NN and_CC were_VBD selected_VBN and_CC ,_, in_IN addition_NN ,_, 10_CD early_JJ development_NN facilities_NNS in_IN the_DT UK_NNP ,_, the_DT US_NNP development_NN projects_NNS reached_VBD the_DT stage_NN and_CC Sweden_NNP :_: a_DT further_JJ four_CD sites_NNS in_IN the_DT of_IN human_JJ testing_NN ._.
US_NNP ,_, Canada_NNP ,_, India_NNP and_CC France_NNP which_WDT focus_VBP only_RB on_IN discovery_NN ,_, and_CC a_DT facility_NN Our_PRP$ global_JJ Enabling_NNP Science_NNP and_CC in_IN Japan_NNP for_IN development_NN only_RB ._.
These_DT Technology_NNP group_NN supports_VBZ all_DT research_NN resources_NNS are_VBP complemented_VBN by_IN clinical_JJ areas_NNS with_IN skills_NNS in_IN compound_NN managedevelopment_NN at_IN 43_CD sites_NNS around_IN the_DT ment_NN ,_, natural_JJ product_NN screening_NN ,_, world_NN ._.
structural_JJ chemistry_NN ,_, bio-imaging_NN ,_, genetics_NNS ,_, transgenics_NNS ,_, protein_NN science_NN In_IN AstraZeneca_NNP Discovery_NNP ,_, our_PRP$ scientists_NNS and_CC informatics_NNS ._.
New_NNP enabling_VBG techfocus_NN on_IN finding_VBG new_JJ compounds_NNS with_IN nologies_NNS for_IN drug_NN searching_VBG have_VBP been_VBN high_JJ potential_NN as_IN new_JJ medicines_NNS in_IN our_PRP$ introduced_VBN and_CC a_DT global_JJ compound_NN chosen_VBN areas_NNS of_IN activity_NN ,_, working_VBG across_IN collection_NN enhancement_NN project_NN is_VBZ boundaries_NNS to_TO exchange_VB ideas_NNS ,_, to_TO share_VB ongoing_JJ ._.
best_RB practice_NN and_CC to_TO make_VB the_DT most_JJS of_IN the_DT efficiencies_NNS that_WDT global_JJ working_VBG offers_NNS ._.
Broadening_VBG the_DT approach_NN In_IN todays_NNS world_NN of_IN rapid_JJ scientific_JJ and_CC Our_PRP$ efforts_NNS to_TO improve_VB the_DT links_NNS between_IN technological_JJ advance_NN ,_, no_DT company_NN can_MD basic_JJ science_NN and_CC clinical_JJ medicine_NN are_VBP rely_VBP exclusively_RB on_IN its_PRP$ own_JJ discovery_NN and_CC already_RB proving_VBG valuable_JJ to_TO the_DT drug_NN development_NN ._.
We_PRP also_RB work_VBP with_IN leading_VBG discovery_NN process_NN ,_, as_IN we_PRP gain_VBP a_DT better_JJR academic_JJ centres_NNS and_CC biotechnology_NN understanding_NN of_IN human_JJ diseases_NNS companies_NNS with_IN skills_NNS that_WDT complement_VBP and_CC how_WRB future_JJ medicines_NNS will_MD work_VB our_PRP$ own_JJ capabilities_NNS and_CC broaden_VB the_DT to_TO prevent_VB and_CC treat_VB them_PRP ._.
We_PRP also_RB base_NN for_IN disease_NN research_NN ._.
continue_VB to_TO introduce_VB earlier_JJR in_IN the_DT process_NN more_RBR stringent_JJ testing_NN of_IN drug_NN safety_NN and_CC how_WRB a_DT medicine_NN gets_VBZ distributed_VBN around_RB ,_, and_CC out_RB ,_, of_IN the_DT human_JJ body_NN ._.
This_DT helps_VBZ us_PRP to_TO eliminate_VB the_DT candidate_NN drugs_NNS CDs_NNS that_WDT are_VBP less_RBR likely_JJ to_TO succeed_VB earlier_JJR in_IN the_DT process_NN ._.
com_NN 06_CD Development_NNP We_PRP are_VBP continuously_RB improving_VBG our_PRP$ development_NN processes_VBZ to_TO ensure_VB that_IN we_PRP get_VBP life_NN changing_VBG medicines_NNS to_TO patients_NNS as_RB quickly_RB as_IN possible_JJ ._.
AstraZeneca_NNP Our_PRP$ high_JJ quality_NN As_IN part_NN of_IN our_PRP$ drive_NN to_TO speed_VB development_NN ,_, currently_RB has_VBZ 12_CD pipeline_NN is_VBZ geared_VBN we_PRP introduced_VBD a_DT number_NN of_IN e-based_JJ clinical_JJ projects_NNS in_IN phase_NN 2_CD to_TO continued_VBN and_CC and_CC regulatory_JJ systems_NNS during_IN the_DT year_NN development_NN and_CC long_JJ term_NN innovation_NN which_WDT make_VBP data_NNS more_RBR quickly_RB and_CC easily_RB 28_CD in_IN phase_NN 3_CD ._.
that_IN meets_VBZ the_DT accessible_JJ worldwide_NN ._.
needs_NNS of_IN patients_NNS and_CC the_DT healthcare_NN professionals_NNS who_WP treat_VBP them_PRP ._.
com_NN 07_CD Our_PRP$ aim_NN is_VBZ to_TO develop_VB better_JJR drugs_NNS Compound_NN Areas_NNS under_IN investigation_NN Estimated_VBN filing_NN date_NN Stage_NN of_IN development_NN MAA_NNP NDA_NNP PC_NNP 1_CD 2_CD 3_CD faster_JJR ._.
People_NNS in_IN our_PRP$ Development_NNP Cardiovascular_NNP organization_NN work_NN globally_RB in_IN therapy_NN Exanta_NNP prevention_NN of_IN VTE_NNP Approved_NNP Filed_NNP area_NN led_VBD product_NN teams_NNS that_WDT bring_VBP Exanta_JJ together_RB all_PDT the_DT relevant_JJ functional_JJ skills_NNS SC_NNP formulation_NN prevention_NN of_IN VTE_NNP Approved_NNP 2006_CD Galida_NNP diabetes_NN metabolic_JJ syndrome_NN 2006_CD 2006_CD and_CC experience_VB needed_VBN for_IN the_DT robust_JJ ,_, AZD6140_JJ arterial_JJ thrombosis_NN 2006_CD 2006_CD rapid_JJ progress_NN of_IN new_JJ medicines_NNS ._.
AZD7009_CD atrial_JJ fibrillation_NN 2006_CD 2006_CD AZD9684_NNP thrombosis_NN 2006_CD 2006_CD In_IN 2003_CD ,_, we_PRP successfully_RB completed_VBD AZD0837_NNP thrombosis_NN 2006_CD 2006_CD the_DT development_NN programs_NNS ,_, and_CC AZD7806_NNP dyslipidemia_NN 2006_CD 2006_CD AZD6610_NNP dyslipidemia_NN 2006_CD 2006_CD provided_VBD the_DT regulatory_JJ support_NN required_VBN AZD4619_NNP dyslipidemia_NN 2006_CD 2006_CD for_IN the_DT approval_NN of_IN Exanta_NNP and_CC for_IN the_DT AZD0303_NNP thrombosis_NN 2006_CD 2006_CD approval_NN and_CC launch_NN of_IN Crestor_NNP and_CC Iressa_NNP ._.
AZD8294_CD dyslipidemia_NN 2006_CD 2006_CD France_NNP ,_, Reference_NNP Member_NNP State_NNP for_IN the_DT EU_NNP Mutual_NNP Recognition_NNP Procedure_NNP ._.
We_PRP also_RB explore_VBP all_PDT the_DT ways_NNS our_PRP$ Gastrointestinal_NNP launched_VBD products_NNS can_MD be_VB used_VBN AZD0865_CD acid_NN related_VBN GI_NNP disease_NN 2006_CD 2006_CD or_CC improved_VBN to_TO get_VB the_DT most_RBS benefit_VB for_IN AZD3355_NNP GERD_NNP 2006_CD 2006_CD patients_NNS ._.
During_IN the_DT year_NN ,_, we_PRP delivered_VBD AZD7371_NNP functional_JJ GI_NNP disorders_NNS 2006_CD 2006_CD further_JJ product_NN development_NN designed_VBN AZD9343_NNP GERD_NNP 2006_CD 2006_CD to_TO maximize_VB the_DT potential_NN of_IN key_JJ Neuroscience_NNP marketed_VBD brands_NNS ,_, including_VBG Nexium_NNP ,_, Cerovive_NNP Seroquel_NNP and_CC Symbicort_NNP ._.
previously_RB NXY059_CD stroke_NN 2006_CD 2006_CD The_DT table_NN on_IN the_DT right_JJ summarises_NNS ZD0947_NNP overactive_JJ bladder_NN 2006_CD 2006_CD AR-A2_NN anxiety_NN depression_NN 2006_CD 2006_CD the_DT new_JJ chemical_NN entities_NNS currently_RB AZD4282_CD neuropathic_JJ pain_NN 2006_CD 2006_CD in_IN development_NN ._.
A_DT fuller_JJR description_NN AZD4750_NNP multiple_JJ sclerosis_NN 2006_CD 2006_CD of_IN our_PRP$ development_NN pipeline_NN ,_, including_VBG AZD5455_NNP anxiety_NN disorders_NNS 2006_CD 2006_CD line_NN extensions_NNS ,_, can_MD be_VB found_VBN in_IN the_DT AZD0328_NNP Alzheimers_NNP disease_NN 2006_CD 2006_CD AZD2858_NNP Alzheimers_NNP disease_NN 2006_CD 2006_CD separate_JJ AstraZeneca_NNP 2003_CD Annual_JJ AZD3102_NNP Alzheimers_NNP disease_NN 2006_CD 2006_CD Report_NNP and_CC Form_NN 20-F_JJ Information_NN or_CC on_IN our_PRP$ website_NN ._.
Oncology_NNP Faslodex_NNP 2nd_JJ line_NN advanced_VBD breast_NN cancer_NN Filed_NNP Launched_NNP IressaNSCLC_NNP FiledLaunched_NNP ZD6474_NNP solid_JJ tumors_NNS 2006_CD 2006_CD ZD4054_NNP solid_JJ tumors_NNS 2006_CD 2006_CD ZD6126_NNP solid_JJ tumors_NNS 2006_CD 2006_CD AZD2171_NNP solid_JJ tumors_NNS and_CC hematological_JJ malignancies_NNS 2006_CD 2006_CD AZD3409_NNP solid_JJ tumors_NNS 2006_CD 2006_CD AZD0530_NNP solid_JJ tumors_NNS 2006_CD 2006_CD AZD5438_NNP solid_JJ tumors_NNS 2006_CD 2006_CD AZD4440_NNP solid_JJ tumors_NNS 2006_CD 2006_CD AZD9935_NNP solid_JJ tumors_NNS 2006_CD 2006_CD AZD0424_NNP solid_JJ tumors_NNS 2006_CD 2006_CD AZD1152_NNP solid_JJ tumors_NNS 2006_CD 2006_CD AZD6244_NNP solid_JJ tumors_NNS 2006_CD 2006_CD Respiratory_NNP and_CC Inflammation_NNP AZD9056_NNP rheumatoid_VBD arthritis_NNS 2006_CD 2006_CD AZD8309_NNP rheumatoid_JJ arthritis_NNS 2006_CD 2006_CD Abbreviations_NNS used_VBN in_IN pipeline_NN table_NN :_: AZD8309_CD COPD_NNP 2006_CD 2006_CD COPD_NNP chronic_NN obstructive_JJ pulmonary_JJ disease_NN AZD9056_NNP COPD_NNP 2006_CD 2006_CD GERD_NNP gastro-oesophageal_JJ reflux_NN disease_NN AZD3342_NNP COPD_NNP 2006_CD 2006_CD GI_NNP gastrointestinal_JJ MAA_NNP marketing_NN authorisation_NN 2006_CD 2006_CD Europe_NNP AZD0902_NNP rheumatoid_VBD arthritis_NNS 2006_CD 2006_CD NDA_NNP new_JJ drug_NN application_NN US_NNP AZD9056_NNP osteoarthritis_VBZ 2006_CD 2006_CD NSCLC_NNP non-small_JJ cell_NN lung_NN cancer_NN AZD8955_NNP osteoarthritis_VBZ 2006_CD 2006_CD PC_NN pre-clinical_JJ :_: candidate_NN drug_NN accepted_VBN for_IN AZD3778_NNP asthma_NN rhinitis_VBZ 2006_CD 2006_CD development_NN but_CC not_RB yet_RB administered_VBN to_TO man_VB AZD6067_NNP COPD_NNP 2006_CD 2006_CD SC_NNP subcutaneous_JJ AZD2098_NNP asthma_NN 2006_CD 2006_CD VTE_NNP venous_JJ thromboembolism_NN AZD1981_NNP asthma_NN 2006 2006 2006_CD not_RB earlier_JJR than_IN 2007_CD AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN 08_CD Supply_NNP We_PRP aim_VBP to_TO provide_VB fast_JJ ,_, flexible_JJ and_CC reliable_JJ manufacturing_NN and_CC supply_NN of_IN all_PDT the_DT products_NNS in_IN our_PRP$ range_NN ,_, wherever_WRB they_PRP are_VBP needed_VBN ._.
We_PRP have_VBP 31_CD Around_IN 16,000_CD We_PRP complement_VBP Our_PRP$ investment_NN In_IN the_DT US_NNP ,_, supplies_VBZ manufacturing_VBG sites_NNS people_NNS worldwide_JJ our_PRP$ in-house_NN in_IN supply_NN and_CC of_IN our_PRP$ new_JJ statin_NN ,_, in_IN 20_CD countries_NNS ._.
work_NN in_IN supply_NN and_CC manufacturing_NN manufacturing_NN Crestor_NNP ,_, were_VBD manufacturing_VBG ,_, capabilities_NNS facilities_NNS in_IN 2003_CD available_JJ to_TO including_VBG some_DT with_IN strategic_JJ totalled_VBD $_$ 496_CD million_CD ._.
wholesalers_NNS within_IN 13,000_CD people_NNS in_IN outsourcing_VBG three_CD days_NNS of_IN FDA_NNP formulation_NN and_CC to_TO external_JJ approval_NN of_IN the_DT packaging_NN ,_, and_CC contractors_NNS ._.
therapy_NN and_CC the_DT 1,750_CD in_IN active_JJ majority_NN of_IN retail_JJ pharmaceutical_JJ stores_NNS were_VBD ingredient_NN supply_NN ._.
com_NN 09_CD Cost_NN management_NN Customer_NN service_NN Safety_NN ,_, health_NN and_CC environment_NN SHE_NNP Our_PRP$ supply_NN chains_NNS are_VBP designed_VBN to_TO The_DT continued_VBN implementation_NN of_IN a_DT operating_NN standards_NNS are_VBP increasingly_RB maximize_VB our_PRP$ flexibility_NN and_CC ensure_VB the_DT new_JJ supply_NN system_NN across_IN our_PRP$ global_JJ stringent_JJ with_IN regulators_NNS placing_VBG fast_RB ,_, efficient_JJ introduction_NN of_IN new_JJ network_NN achieved_VBD positive_JJ results_NNS in_IN particular_JJ emphasis_NN on_IN environmental_JJ medicines_NNS ._.
Manufacturing_NNP lead_JJ times_NNS have_VBP issues_NNS and_CC the_DT safety_NN of_IN chemicals_NNS ._.
product_NN launches_NNS ,_, major_JJ products_NNS and_CC been_VBN shortened_VBN ,_, which_WDT has_VBZ reduced_VBN the_DT Our_PRP$ manufacturing_NN sites_NNS operate_VBP under_IN line_NN extensions_NNS were_VBD successfully_RB need_VB for_IN build_VB up_IN of_IN stock_NN and_CC customer_NN various_JJ licensing_NN regimes_NNS and_CC we_PRP are_VBP supported_VBN with_IN supplies_NNS available_JJ to_TO service_NN levels_NNS have_VBP improved_VBN ._.
committed_VBN to_TO meeting_VBG all_DT regulatory_JJ meet_VBP market_NN demand_NN ._.
The_DT new_JJ supply_NN system_NN has_VBZ also_RB There_EX are_VBP currently_RB no_DT environmental_JJ As_IN part_NN of_IN our_PRP$ overall_JJ risk_NN management_NN ,_, enabled_VBD more_RBR effective_JJ management_NN issues_NNS that_WDT constrain_VBP AstraZeneca_NNP from_IN we_PRP carefully_RB consider_VBP the_DT timing_NN of_IN of_IN the_DT costs_NNS of_IN a_DT product_NN ,_, prior_RB to_TO making_VBG full_JJ use_NN of_IN its_PRP$ sites_NNS ._.
investment_NN relating_VBG to_TO the_DT launch_NN of_IN new_JJ launch_NN and_CC throughout_IN its_PRP$ lifecycle_NN ._.
Secure_VB supply_NN chains_NNS are_VBP in_IN Developments_NNS include_VBP the_DT use_NN of_IN We_PRP are_VBP making_VBG steady_JJ progress_NN against_IN place_NN for_IN all_PDT the_DT products_NNS currently_RB in_IN late_JJ e-based_JJ supply_NN chain_NN management_NN our_PRP$ targets_NNS for_IN the_DT reduction_NN of_IN waste_NN stage_NN development_NN ._.
systems_NNS to_TO improve_VB efficiencies_NNS with_IN and_CC energy_NN usage_NN and_CC the_DT level_NN of_IN suppliers_NNS and_CC drive_VB down_RP costs_NNS ._.
accidents_NNS with_IN injury_NN has_VBZ been_VBN reduced_VBN ._.
Supply_NNP capability_NN Within_IN AstraZeneca_NNP ,_, we_PRP have_VBP active_JJ Cost_NN efficiencies_NNS are_VBP also_RB driven_VBN by_IN our_PRP$ Our_PRP$ aim_NN for_IN continuous_JJ improvement_NN ingredient_NN manufacturing_VBG sites_NNS in_IN the_DT UK_NNP ,_, continuous_JJ review_NN of_IN manufacturing_NN includes_VBZ learning_VBG from_IN incidences_NNS of_IN Sweden_NNP ,_, France_NNP and_CC Puerto_NNP Rico_NNP and_CC a_DT assets_NNS to_TO make_VB sure_JJ that_IN they_PRP are_VBP being_VBG non-compliance_JJ and_CC sharing_VBG best_JJS bulk_NN drug_NN purification_NN plant_NN in_IN Germany_NNP ._.
used_VBN most_RBS effectively_RB ,_, whilst_IN preserving_VBG practice_NN to_TO further_JJ promote_VB high_JJ We_PRP also_RB make_VBP strategic_JJ use_NN of_IN outthe_NN flexibility_NN we_PRP need_VBP to_TO respond_VB to_TO standards_NNS ._.
We_PRP also_RB work_VBP closely_RB with_IN sourcing_VBG to_TO external_JJ specialty_NN chemical_NN fluctuations_NNS in_IN demand_NN ._.
In_IN 2003_CD ,_, we_PRP our_PRP$ suppliers_NNS to_TO encourage_VB standards_NNS manufacturers_NNS to_TO extend_VB our_PRP$ in-house_NN closed_VBD a_DT number_NN of_IN obsolete_JJ units_NNS and_CC similar_JJ to_TO our_PRP$ own_JJ ,_, share_NN best_JJS practice_NN capacity_NN ._.
sold_VBN our_PRP$ facility_NN in_IN Sanda_NNP ,_, Japan_NNP ._.
We_PRP will_MD and_CC where_WRB needed_VBN ,_, stimulate_VBP continue_VB to_TO make_VB further_JJ adjustments_NNS to_TO improvements_NNS ._.
We_PRP make_VBP our_PRP$ various_JJ product_NN formuor_NN manufacturing_NN base_NN to_TO ensure_VB best_JJS lations_NNS tablets_NNS ,_, capsules_NNS ,_, injectable_JJ and_CC use_NN of_IN production_NN facilities_NNS ._.
More_JJR information_NN about_IN our_PRP$ SHE_NNP inhalation_NN at_IN sites_NNS in_IN the_DT US_NNP ,_, the_DT UK_NNP ,_, performance_NN can_MD be_VB found_VBN in_IN the_DT Sweden_NNP ,_, France_NNP ,_, Germany_NNP and_CC Puerto_NNP Licence_NNP to_TO operate_VB separate_JJ 2003_CD Corporate_JJ Responsibility_NN Rico_NNP ._.
Ensuring_VBG the_DT quality_NN ,_, safety_NN and_CC efficacy_NN Summary_NNP Report_NNP or_CC on_IN our_PRP$ website_NN ._.
of_IN our_PRP$ medicines_NNS is_VBZ a_DT core_NN priority_NN ._.
As_IN Product_NNP packaging_NN is_VBZ done_VBN at_IN a_DT large_JJ part_NN of_IN this_DT ,_, reports_NNS from_IN internal_JJ routine_JJ number_NN of_IN sites_NNS worldwide_JJ ,_, both_DT inspections_NNS as_RB well_RB as_IN those_DT by_IN AstraZenecas_NNP and_CC contractors_NNS regulatory_JJ authorities_NNS are_VBP rigorously_RB all_DT located_VBN close_NN to_TO our_PRP$ marketing_NN reviewed_VBN and_CC if_IN required_VBN ,_, actions_NNS taken_VBN companies_NNS to_TO support_VB rapid_JJ response_NN to_TO further_RBR enhance_VB compliance_NN ._.
results_NNS of_IN all_DT external_JJ inspections_NNS carried_VBD out_RP during_IN 2003_CD were_VBD satisfactory_JJ and_CC New_JJ facilities_NNS opened_VBN during_IN 2003_CD we_PRP did_VBD not_RB experience_VB any_DT delays_NNS in_IN included_VBN additional_JJ active_JJ ingredient_NN product_NN approvals_NNS due_JJ to_TO regulatory_JJ capacity_NN for_IN Crestor_NNP in_IN the_DT UK_NNP ,_, compliance_NN issues_NNS at_IN our_PRP$ sites_NNS or_CC those_DT formulation_NN capacity_NN for_IN Crestor_NNP in_IN of_IN our_PRP$ contractors_NNS ._.
Puerto_NNP Rico_NNP and_CC additional_JJ capacity_NN for_IN Pulmicort_NNP in_IN the_DT US_NNP ._.
Looking_VBG ahead_RB ,_, plans_NNS are_VBP in_IN place_NN to_TO expand_VB capacity_NN in_IN the_DT US_NNP ,_, France_NNP ,_, Sweden_NNP and_CC Puerto_NNP Rico_NNP to_TO meet_VB the_DT growing_VBG demands_NNS of_IN our_PRP$ product_NN portfolio_NN including_VBG Crestor_NNP ,_, Pulmicort_NNP Respules_NNP and_CC Symbicort_NNP ._.
com_NN 10_CD Marketing_NNP We_PRP combine_VBP our_PRP$ global_JJ capabilities_NNS with_IN high_JJ quality_NN relationships_NNS in_IN local_JJ markets_NNS and_CC focus_VB on_IN responding_VBG quickly_RB and_CC effectively_RB to_TO our_PRP$ customers_NNS changing_VBG needs_NNS ._.
Key_NNP products_NNS :_: Cardiovascular_NNP Key_NNP products_NNS :_: Gastrointestinal_NNP Key_NNP products_NNS :_: Neuroscience_NN 1_CD Atacand_NNP candesartan_NN cilexetil_NN angiotensin_NN II_NNP Losec_NNP Prilosec_NNP omeprazole_NN proton_NN pump_NN inhibitor_NN Diprivan_NNP propofol_NN intravenous_JJ general_JJ anesthetic_NN for_IN antagonist_NN for_IN hypertension_NN for_IN acid_NN related_VBN diseases_NNS induction_JJ maintenance_NN of_IN anaesthesia_NN and_CC sedation_NN of_IN intensive_JJ care_NN patients_NNS 2_CD Crestor_NNP rosuvastatin_NN HMG-CoA_NNP reductase_NN inhibitor_NN Losec_NNP MUPS_NNP omeprazole_NN in_IN tablet_NN form_NN statin_NN for_IN dyslipidemia_NN Naropin_NNP ropivacaine_NN local_JJ anesthetic_JJ for_IN surgical_JJ Nexium_NNP esomeprazole_NN proton_NN pump_NN inhibitor_NN for_IN anaesthesia_NN and_CC acute_JJ pain_NN management_NN Exanta_NNP ximelagatran_JJ oral_JJ direct_JJ thrombin_NN inhibitor_NN for_IN acid_NN related_VBN diseases_NNS prevention_NN of_IN thrombosis_NN in_IN association_NN with_IN major_JJ Seroquel_NNP quetiapine_NN atypical_JJ anti-psychotic_JJ for_IN orthopaedic_JJ surgery_NN schizophrenia_NN and_CC other_JJ psychotic_JJ disorders_NNS Key_NNP products_NNS :_: Infection_NNP Plendil_NNP felodipine_NN calcium_NN antagonist_NN for_IN hypertension_NN Xylocaine_NNP lidocaine_NN local_JJ anesthetic_JJ for_IN use_NN in_IN 4_CD Merrem_NNP Meronem_NNP meropenem_NN ultra_NN broad_JJ and_CC angina_NN surgery_NN and_CC dentistry_NN spectrum_NN injectable_JJ antibiotic_JJ for_IN serious_JJ bacterial_JJ Seloken_NNP Toprol-XL_NNP metoprolol_NN beta_NN blocker_NN for_IN Zomig_NNP zolmitriptan_NN for_IN the_DT treatment_NN of_IN acute_JJ infection_NN hypertension_NN ,_, angina_NN ,_, heart_NN failure_NN and_CC other_JJ uses_NNS migraine_VBP with_IN or_CC without_IN aura_NN 3_CD Zestril_NNP lisinopril_NN angiotensin_NN converting_VBG enzyme_NN inhibitor_NN for_IN hypertension_NN ,_, heart_NN failure_NN and_CC diabetic_JJ nephropathy_NN AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN 11_CD Sales_NNS and_CC marketing_NN Product_NN strategy_NN and_CC licensing_NN We_PRP continued_VBD to_TO be_VB the_DT fastest_JJS growing_VBG To_TO ensure_VB the_DT success_NN of_IN our_PRP$ medicines_NNS ,_, We_PRP have_VBP an_DT extensive_JJ ,_, high_JJ quality_NN pharmaceutical_JJ company_NN in_IN Japan_NNP we_PRP must_MD address_VB unmet_JJ medical_JJ needs_NNS ,_, sales_NNS and_CC marketing_NN network_NN worldduring_VBG 2003_CD ,_, with_IN sales_NNS of_IN $_$ 1.2_CD billion_CD ._.
find_VB novel_JJ solutions_NNS ,_, minimize_VBP technical_JJ wide_JJ ,_, structured_VBN to_TO anticipate_VB and_CC We_PRP now_RB rank_VBP 14th_JJ by_IN sales_NNS in_IN this_DT ,_, the_DT risk_NN and_CC make_VB the_DT most_JJS of_IN our_PRP$ respond_NN to_TO local_JJ market_NN needs_NNS ._.
We_PRP sell_VBP worlds_NNS second_RB largest_JJS pharmaceutical_JJ commercial_JJ opportunities_NNS ._.
mostly_RB through_IN our_PRP$ own_JJ local_JJ marketing_NN market_NN ._.
companies_NNS and_CC our_PRP$ products_NNS are_VBP Our_PRP$ product_NN strategy_NN and_CC licensing_NN marketed_VBN mainly_RB to_TO physicians_NNS and_CC other_JJ In_IN Europe_NNP ,_, pharmaceutical_JJ cost_NN control_NN organization_NN ,_, working_VBG closely_RB with_IN healthcare_NN professionals_NNS ._.
We_PRP also_RB pressure_NN ,_, generic_JJ substitution_NN and_CC the_DT our_PRP$ R&D_NNP community_NN and_CC our_PRP$ major_JJ explain_VBP the_DT economic_JJ as_RB well_RB as_IN the_DT movement_NN of_IN products_NNS from_IN lower_JJR price_NN marketing_NN companies_NNS ,_, leads_VBZ the_DT therapeutic_JJ advantages_NNS of_IN our_PRP$ products_NNS countries_NNS ,_, all_DT contribute_VBP to_TO creating_VBG commercial_JJ aspects_NNS of_IN drug_NN developto_NN governments_NNS and_CC healthcare_NN buying_NN another_DT challenging_JJ environment_NN for_IN our_PRP$ ment_NN and_CC co-ordinates_NNS global_JJ market_NN groups_NNS ,_, such_JJ as_IN managed_VBN care_NN industry_NN ._.
This_DT includes_VBZ selecting_VBG the_DT right_JJ organizations_NNS in_IN the_DT US_NNP ._.
Crestor_NNP ,_, coupled_VBN with_IN our_PRP$ strong_JJ growth_NN products_NNS and_CC projects_NNS for_IN investment_NN ,_, in_IN central_JJ and_CC eastern_JJ Europe_NNP ,_, give_VBP us_PRP a_DT developing_VBG effective_JJ marketing_NN platforms_NNS Success_NNP in_IN key_JJ markets_NNS is_VBZ a_DT priority_NN solid_JJ platform_NN for_IN future_JJ growth_NN in_IN the_DT in_IN time_NN for_IN new_JJ product_NN launches_NNS and_CC objective_NN ._.
We_PRP aim_VBP to_TO retain_VB and_CC build_VB on_IN region_NN ._.
Sales_NNS totalled_VBD $_$ 6.7_CD billion_CD in_IN 2003_CD directing_VBG the_DT creation_NN and_CC delivery_NN of_IN our_PRP$ leading_VBG positions_NNS in_IN major_JJ markets_NNS ,_, and_CC AstraZeneca_NNP ranks_VBZ fifth_JJ in_IN Europe_NNP ._.
product_NN marketing_NN strategies_NNS that_WDT especially_RB the_DT US_NNP ,_, Europe_NNP and_CC Japan_NNP successfully_RB align_JJ global_JJ and_CC national_JJ whilst_NN increasing_VBG our_PRP$ strength_NN through_IN Elsewhere_RB ,_, significant_JJ growth_NN in_IN China_NNP plans_NNS ._.
strategic_JJ investment_NN in_IN the_DT small_JJ but_CC fast_JJ 37_CD %_NN ,_, South_NNP Korea_NNP and_CC India_NNP growing_VBG markets_NNS of_IN the_DT future_NN the_DT strengthened_VBD the_DT platform_NN for_IN regional_JJ Our_PRP$ rigorous_JJ lifecycle_NN management_NN of_IN emerging_VBG economies_NNS ._.
expansion_NN plans_NNS and_CC future_JJ growth_NN ._.
key_JJ marketed_VBN brands_NNS aims_VBZ to_TO ensure_VB that_IN we_PRP maximize_VBP the_DT commercial_JJ Continued_VBN success_NN in_IN the_DT US_NNP ,_, the_DT E-marketing_JJ potential_NN as_RB well_RB as_IN the_DT benefit_NN that_IN new_JJ worlds_NNS largest_JJS pharmaceutical_JJ market_NN ,_, To_TO boost_VB our_PRP$ marketing_NN effectiveness_NN ,_, uses_VBZ for_IN our_PRP$ medicines_NNS bring_VBP to_TO patients_NNS depends_VBZ on_IN effectively_RB managing_VBG the_DT we_PRP have_VBP integrated_VBN e-marketing_VBG into_IN our_PRP$ lives_NNS ._.
increasing_VBG regulatory_JJ and_CC cost_NN control_NN commercial_JJ activities_NNS worldwide_JJ and_CC pressures_NNS whilst_VBP making_VBG the_DT most_JJS of_IN the_DT have_VBP a_DT broad_JJ range_NN of_IN internet-based_JJ In_IN common_JJ with_IN other_JJ leading_VBG opportunities_NNS presented_VBN by_IN the_DT growing_VBG physician_NN resources_NNS in_IN key_JJ therapy_NN pharmaceutical_JJ companies_NNS ,_, we_PRP also_RB demand_VBP for_IN innovative_JJ medicines_NNS ._.
In_IN the_DT US_NNP ,_, we_PRP maximize_VBP the_DT look_NN to_TO strengthen_VB our_PRP$ portfolio_NN with_IN Our_PRP$ sales_NNS of_IN $_$ 8.7_CD billion_CD in_IN the_DT US_NNP in_IN opportunities_NNS for_IN direct_JJ communication_NN attractive_JJ products_NNS or_CC technologies_NNS from_IN 2003_CD reflect_VBP our_PRP$ commitment_NN to_TO driving_VBG with_IN patients_NNS and_CC their_PRP$ carers_NNS ,_, by_IN external_JJ sources_NNS and_CC we_PRP continuously_RB growth_NN in_IN this_DT key_JJ area_NN ._.
With_IN a_DT 5_CD %_NN providing_VBG online_JJ information_NN about_IN our_PRP$ monitor_NN the_DT opportunities_NNS for_IN licensing_NN market_NN share_NN ,_, AstraZeneca_NNP is_VBZ the_DT fifth_JJ medicines_NNS and_CC the_DT conditions_NNS for_IN which_WDT partnerships_NNS ._.
largest_JJS pharmaceutical_JJ company_NN in_IN they_PRP are_VBP prescribed_VBN ._.
Asia_NNP ,_, we_PRP have_VBP e-business_JJ pilot_NN studies_NNS underway_VBP to_TO improve_VB interaction_NN with_IN healthcare_NN professionals_NNS ._.
1_CD Key_NNP products_NNS :_: Oncology_NNP Key_NNP products_NNS :_: Respiratory_NNP &_CC Inflammation_NNP Licensed_VBD from_IN Takeda_NNP Chemical_NNP Industries_NNPS Ltd._NNP 2_CD Licensed_VBN from_IN Shionogi_NNP &_CC Co._NNP ._.
Ltd._NNP ._.
Arimidex_NNP anastrozole_NN aromatase_NN inhibitor_NN for_IN Accolate_NNP zafirlukast_NN oral_JJ leukotriene_NN receptor_NN 3_CD Licensed_VBN from_IN Merck_NNP &_CC Co._NNP ._.
Inc._NNP breast_NN cancer_NN antagonist_NN for_IN control_NN of_IN asthma_NN 4_CD Licensed_VBN from_IN Sumitomo_NNP Pharmaceuticals_NNP Co._NNP ._.
Ltd._NNP ._.
Casodex_NNP bicalutamide_NN anti-androgen_NN for_IN prostate_NN Oxis_NNP formoterol_NN inhaled_VBD fast_RB onset_NN long-acting_JJ cancer_NN bronchodilator_NN for_IN relief_NN of_IN asthma_NN symptoms_NNS Faslodex_NNP fulvestrant_JJ estrogen_NN receptor_NN antagonist_NN Pulmicort_NNP budesonide_NN inhaled_VBD anti-inflammatory_JJ with_IN no_DT agonist_JJ effects_NNS for_IN breast_NN cancer_NN for_IN asthma_NN control_NN Iressa_NNP gefitinib_NN signal_NN transduction_NN inhibitor_NN for_IN nonRhinocort_NNP budesonide_NN topical_JJ nasal_JJ small_JJ cell_NN lung_NN cancer_NN anti-inflammatory_JJ for_IN control_NN of_IN rhinitis_NN Nolvadex_NNP tamoxifen_JJ anti-oestrogen_NN for_IN breast_NN cancer_NN Symbicort_NNP budesonide_NN formoterol_NN inhaled_VBD combination_NN of_IN anti-inflammatory_JJ and_CC fast_JJ onset_NN Zoladex_NNP goserelin_NN LHRH_NNP agonist_NN for_IN prostate_NN and_CC long-acting_JJ bronchodilator_NN in_IN a_DT single_JJ inhaler_NN pre-menopausal_JJ breast_NN cancer_NN ,_, certain_JJ benign_JJ gynaecological_JJ disorders_NNS and_CC assisted_VBN reproduction_NN AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN 12_CD Inspiration_NNP The_DT success_NN of_IN our_PRP$ business_NN is_VBZ based_VBN on_IN our_PRP$ commitment_NN to_TO new_JJ ideas_NNS ideas_NNS that_WDT are_VBP inspired_VBN by_IN life_NN and_CC which_WDT in_IN turn_NN help_NN to_TO inspire_VB the_DT lives_NNS of_IN our_PRP$ stakeholders_NNS ._.
We_PRP turn_VBP good_JJ We_PRP also_RB focus_VB We_PRP aim_VB to_TO stimulate_VB We_PRP encourage_VBP Along_IN with_IN our_PRP$ Our_PRP$ core_NN values_NNS are_VBP :_: ideas_NNS into_IN effective_JJ on_IN getting_VBG the_DT continued_VBN creativity_NN the_DT sharing_NN of_IN commitment_NN Integrity_NN and_CC high_JJ medicines_NNS most_RBS benefit_VB for_IN by_IN maintaining_VBG knowledge_NN and_CC to_TO competitiveness_NN ethical_JJ standards_NNS designed_VBN to_TO patients_NNS from_IN every_DT a_DT culture_NN in_IN which_WDT ideas_NNS across_IN and_CC performance_NN ,_, Respect_NN for_IN the_DT improve_VB the_DT health_NN medicine_NN we_PRP make_VBP our_PRP$ people_NNS feel_VBP functional_JJ and_CC we_PRP will_MD continue_VB to_TO individual_JJ and_CC diversity_NN and_CC quality_NN of_IN by_IN exploring_VBG all_DT valued_VBN ,_, energised_VBN territorial_JJ boundaries_NNS be_VB led_VBN by_IN our_PRP$ core_NN Openness_NN ,_, honesty_NN ,_, life_NN of_IN patients_NNS the_DT ways_NNS it_PRP can_MD be_VB and_CC rewarded_VBD for_IN to_TO further_RBR stimulate_VB values_NNS to_TO achieve_VB trust_NN and_CC support_NN around_IN the_DT world_NN ._.
their_PRP$ ideas_NNS and_CC creativity_NN and_CC best_JJS sustainable_JJ for_IN each_DT other_JJ contribution_NN to_TO our_PRP$ practice_NN across_IN the_DT success_NN ._.
Leadership_NN by_IN success_NN ideas_NNS Company_NN ._.
example_NN at_IN all_DT levels_NNS which_WDT can_MD make_VB a_DT difference_NN in_IN all_DT aspects_NNS of_IN our_PRP$ business_NN ._.
com_NN 13_CD designed_VBN to_TO take_VB account_NN of_IN individual_JJ The_DT path_NN to_TO growth_NN We_PRP are_VBP a_DT creative_JJ ,_, fast_JJ and_CC effective_JJ needs_NNS by_IN introducing_VBG elements_NNS of_IN company_NN with_IN a_DT powerful_JJ range_NN of_IN personal_JJ choice_NN and_CC flexibility_NN in_IN how_WRB high_JJ quality_NN products_NNS that_WDT will_MD drive_VB benefits_NNS are_VBP taken_VBN ._.
Inspiring_JJ leadership_NN is_VBZ key_JJ to_TO stimulating_VBG In_IN recent_JJ years_NNS ,_, we_PRP have_VBP launched_VBN a_DT high_JJ performance_NN ._.
We_PRP have_VBP global_JJ range_NN of_IN important_JJ new_JJ medicines_NNS ,_, programs_NNS designed_VBN to_TO strengthen_VB including_VBG high_JJ potential_JJ therapies_NNS for_IN leadership_NN capabilities_NNS ,_, enhance_VB core_NN treating_VBG cancer_NN Casodex_NNP ,_, Arimidex_NNP ,_, management_NN skills_NNS and_CC help_NN leaders_NNS Faslodex_NNP and_CC Iressa_NNP ,_, gastrointestinal_JJ develop_VB good_JJ working_VBG relationships_NNS disease_NN Nexium_NNP ,_, asthma_NN Symbicort_NNP ,_, across_IN the_DT organization_NN ._.
These_DT hypertension_NN Atacand_NNP ,_, high_JJ cholesterol_NN programs_NNS are_VBP complemented_JJ Crestor_NNP ,_, migraine_NN Zomig_NNP and_CC schizoby_JJ local_JJ initiatives_NNS ,_, which_WDT include_VBP phrenia_NN Seroquel_NNP ._.
These_DT and_CC the_DT first_JJ functional_JJ or_CC country_NN specific_JJ aspects_NNS approval_NN of_IN Exanta_NNP in_IN France_NNP in_IN of_IN leadership_NN development_NN ._.
December_NNP 2003_CD mark_NN the_DT start_NN of_IN an_DT exciting_JJ new_JJ era_NN for_IN the_DT Company_NN ._.
The_DT sharing_NN of_IN information_NN is_VBZ essential_JJ to_TO maintaining_VBG employee_NN confidence_NN in_IN Making_VBG it_PRP happen_VB AstraZeneca_NNP and_CC its_PRP$ objectives_NNS ._.
We_PRP use_VBP a_DT Without_IN the_DT creativity_NN ,_, energy_NN and_CC range_NN of_IN communications_NNS media_NNS ,_, as_RB well_RB commitment_NN of_IN our_PRP$ people_NNS ,_, our_PRP$ as_IN face_NN to_TO face_VB meetings_NNS ,_, to_TO ensure_VB our_PRP$ business_NN would_MD not_RB succeed_VB ._.
We_PRP are_VBP people_NNS are_VBP kept_VBN up_RP to_TO date_NN with_IN business_NN very_RB proud_JJ of_IN our_PRP$ 60,000_CD employees_NNS developments_NNS and_CC are_VBP clear_JJ about_IN their_PRP$ in_IN 45_CD countries_NNS and_CC value_NN the_DT diversity_NN individual_NN and_CC team_NN roles_NNS and_CC targets_NNS ._.
of_IN skills_NNS and_CC abilities_NNS that_IN they_PRP bring_VBP to_TO our_PRP$ business_NN ._.
Feedback_NNP is_VBZ very_RB important_JJ to_TO us_PRP and_CC opportunities_NNS for_IN giving_VBG feedback_NN are_VBP We_PRP encourage_VB and_CC support_VB all_DT our_PRP$ built_VBN in_IN to_TO all_DT levels_NNS of_IN communication_NN ._.
people_NNS in_IN developing_VBG their_PRP$ capabilities_NNS We_PRP also_RB use_VBP a_DT two-yearly_JJ global_JJ to_TO the_DT full_JJ with_IN high_JJ quality_NN learning_NN and_CC employee_NN survey_NN to_TO identify_VB areas_NNS development_NN opportunities_NNS ,_, backed_VBN by_IN of_IN both_DT satisfaction_NN and_CC concern_NN ._.
management_NN responsibility_NN for_IN ensuring_VBG Priority_NN attention_NN is_VBZ given_VBN to_TO areas_NNS that_WDT individually_RB tailored_VBD development_NN for_IN improvement_NN highlighted_VBN in_IN plans_NNS are_VBP in_IN place_NN for_IN each_DT member_NN of_IN these_DT surveys_NNS ._.
their_PRP$ team_NN ,_, throughout_IN their_PRP$ careers_NNS ._.
Equal_NNP opportunity_NN for_IN all_DT is_VBZ a_DT cornerstone_NN A_DT responsible_JJ approach_NN of_IN our_PRP$ culture_NN in_IN which_WDT personal_JJ success_NN With_IN a_DT global_JJ business_NN comes_VBZ a_DT global_JJ is_VBZ based_VBN solely_RB on_IN individual_JJ ability_NN and_CC responsibility_NN for_IN high_JJ standards_NNS of_IN contribution_NN ._.
We_PRP aim_VBP to_TO manage_VB that_DT responsibility_NN effectively_RB The_DT wellbeing_NN of_IN our_PRP$ people_NNS is_VBZ a_DT core_NN to_TO ensure_VB that_IN we_PRP continue_VBP to_TO be_VB priority_NN and_CC we_PRP have_VBP a_DT broad_JJ range_NN of_IN welcomed_VBN as_IN a_DT trusted_VBN and_CC valued_VBN initiatives_NNS aimed_VBN at_IN promoting_VBG the_DT health_NN ,_, member_NN of_IN the_DT global_JJ community_NN ._.
safety_NN and_CC welfare_NN of_IN all_DT our_PRP$ employees_NNS worldwide_VBP ._.
These_DT include_VBP behaviourYou_NNP can_MD read_VB more_RBR about_IN our_PRP$ approach_NN based_VBN safety_NN and_CC occupational_JJ health_NN to_TO corporate_JJ responsibility_NN ,_, and_CC our_PRP$ 2003_CD programs_NNS as_RB well_RB as_IN initiatives_NNS that_WDT performance_NN ,_, in_IN the_DT separate_JJ 2003_CD encourage_VBP and_CC support_VBP work_NN life_NN Corporate_JJ Responsibility_NN Summary_NNP balance_NN through_IN flexible_JJ working_VBG hours_NNS Report_NNP or_CC visit_VB our_PRP$ website_NN for_IN full_JJ details_NNS ._.
and_CC opportunities_NNS to_TO work_VB from_IN home_NN ._.
Looking_VBG to_TO the_DT future_JJ Rewarding_NN people_NNS for_IN their_PRP$ contribution_NN We_PRP are_VBP committed_VBN to_TO continued_VBN isnt_NN ,_, we_PRP believe_VBP ,_, just_RB about_IN offering_VBG a_DT achievement_NN in_IN all_DT our_PRP$ activities_NNS competitive_JJ benefits_NNS package_NN ._.
Our_PRP$ to_TO ensure_VB a_DT healthy_JJ future_NN for_IN our_PRP$ integrated_VBN reward_NN schemes_NNS are_VBP business_NN and_CC added_VBD value_NN for_IN all_PDT those_DT who_WP benefit_VBP from_IN it_PRP ._.
com_NN 14_CD Therapy_NNP area_NN review_NN Gastrointestinal_NNP Cardiovascular_NNP Infection_NNP Our_PRP$ world_NN leading_VBG position_NN in_IN cardioWe_NNP are_VBP the_DT world_NN number_NN one_CD in_IN the_DT World_NNP demand_NN for_IN antibiotics_NNS remains_VBZ vascular_JJ CV_NNP is_VBZ based_VBN on_IN over_IN 40_CD years_NNS treatment_NN of_IN gastrointestinal_JJ GI_NNP disease_NN high_JJ due_JJ to_TO escalating_VBG resistance_NN and_CC experience_NN in_IN this_DT field_NN ._.
Backed_NNP by_IN our_PRP$ and_CC aim_NN to_TO maintain_VB that_IN leading_VBG position_NN the_DT increased_VBN risk_NN of_IN serious_JJ infections_NNS ._.
powerful_JJ range_NN of_IN products_NNS and_CC quality_NN through_IN continued_VBN sales_NNS and_CC further_JJ research_NN ,_, we_PRP aim_VBP to_TO build_VB on_IN our_PRP$ strong_JJ development_NN of_IN Nexium_NNP ,_, the_DT latest_JJS Infectious_JJ diseases_NNS cause_VBP more_JJR than_IN 11_CD position_NN ,_, focusing_VBG on_IN important_JJ areas_NNS of_IN addition_NN to_TO our_PRP$ GI_NNP range_NN ._.
need_NN such_JJ as_IN hypertension_NN and_CC thrombosis_NN ._.
40_CD %_NN of_IN adults_NNS in_IN the_DT western_JJ world_NN 2003_CD saw_VBD steady_JJ sales_NNS growth_NN globally_RB regularly_RB experience_VB heartburn_NN and_CC 10_CD %_NN for_IN Merrem_NNP ,_, our_PRP$ antibiotic_JJ for_IN the_DT CV_NNP diseases_NNS account_VBP for_IN 17_CD million_CD have_VBP gastro-oesophageal_JJ reflux_NN disease_NN ._.
treatment_NN of_IN serious_JJ hospital-acquired_JJ deaths_NNS worldwide_JJ each_DT year_NN ,_, making_VBG it_PRP infections_NNS ._.
Clinical_JJ studies_NNS are_VBP in_IN place_NN the_DT greatest_JJS risk_NN to_TO life_NN for_IN most_JJS adults_NNS ._.
Nexium_NNP continues_VBZ to_TO establish_VB a_DT new_JJ to_TO support_VB a_DT supplementary_JJ new_JJ drug_NN improved_VBN treatment_NN standard_NN and_CC this_DT application_NN in_IN the_DT US_NNP in_IN 2004_CD aimed_VBN at_IN During_IN the_DT year_NN ,_, Crestor_NNP ,_, our_PRP$ new_JJ statin_NN was_VBD reflected_VBN in_IN its_PRP$ global_JJ sales_NNS ,_, which_WDT securing_VBG an_DT indication_NN for_IN skin_NN and_CC skin_NN for_IN controlling_VBG high_JJ cholesterol_NN levels_NNS ,_, exceeded_VBD $_$ 3_CD billion_CD in_IN 2003_CD ._.
structure_NN infections_NNS in_IN 2005_CD ._.
gained_VBN regulatory_JJ approval_NN in_IN more_JJR than_IN 40_CD countries_NNS ._.
By_IN the_DT end_NN of_IN January_NNP First_NNP launched_VBD in_IN Sweden_NNP in_IN August_NNP In_IN June_NNP 2003_CD ,_, we_PRP opened_VBD our_PRP$ new_JJ 2004_CD ,_, it_PRP was_VBD launched_VBN in_IN over_IN 25_CD 2000_CD ,_, it_PRP is_VBZ now_RB available_JJ in_IN 100_CD markets_NNS ,_, laboratories_NNS at_IN our_PRP$ research_NN facility_NN countries_NNS including_VBG the_DT US_NNP ,_, Canada_NNP ,_, including_VBG the_DT US_NNP ,_, Canada_NNP and_CC all_DT in_IN Bangalore_NNP ,_, India_NNP where_WRB work_NN is_VBZ the_DT UK_NNP and_CC the_DT Netherlands_NNP ,_, and_CC we_PRP European_JJ countries_NNS ._.
It_PRP has_VBZ been_VBN well_RB focused_VBN on_IN finding_VBG a_DT new_JJ treatment_NN estimate_NN that_WDT more_JJR than_IN 1.5_CD million_CD received_VBN by_IN patients_NNS and_CC physicians_NNS alike_RB for_IN tuberculosis_NN ,_, the_DT single_JJ largest_JJS prescriptions_NNS had_VBD been_VBN written_VBN for_IN ,_, and_CC and_CC over_IN 145_CD million_CD patient_JJ treatments_NNS cause_NN of_IN adult_NN death_NN from_IN infectious_JJ over_IN 750,000_CD patients_NNS had_VBD been_VBN treated_VBN had_VBD been_VBN administered_VBN by_IN the_DT end_NN of_IN disease_NN in_IN the_DT world_NN ._.
Its_PRP$ strong_JJ performance_NN in_IN the_DT US_NNP makes_VBZ Nexium_NNP one_CD of_IN the_DT most_RBS We_PRP gained_VBD first_JJ approval_NN in_IN France_NNP for_IN successful_JJ pharmaceutical_JJ launches_NNS Exanta_NNP ,_, the_DT first_JJ new_JJ oral_JJ anti-coagulant_JJ ever_RB ._.
in_IN almost_RB 60_CD years_NNS for_IN chronic_JJ indications_NNS ._.
We_PRP also_RB made_VBD regulatory_JJ An_DT injectable_JJ formulation_NN of_IN Nexium_NNP submissions_NNS in_IN the_DT US_NNP ,_, Canada_NNP and_CC was_VBD approved_VBN in_IN Europe_NNP in_IN late_JJ 2003_CD ,_, Europe_NNP towards_IN the_DT end_NN of_IN the_DT year_NN ._.
for_IN use_NN when_WRB an_DT oral_JJ treatment_NN of_IN gastro-oesophageal_JJ reflux_NN disease_NN is_VBZ Seloken_NNP Toprol-XL_NNP sales_NNS continued_VBD to_TO not_RB applicable_JJ ._.
grow_VB strongly_RB and_CC Atacand_NNP increased_VBD its_PRP$ market_NN share_NN ._.
As_IN anticipated_VBN ,_, sales_NNS of_IN Zestril_NNP continued_VBD to_TO decline_VB as_IN patents_NNS expired_VBD in_IN major_JJ markets_NNS ._.
com_NN 15_CD Oncology_NNP Neuroscience_NNP Respiratory_NNP and_CC Inflammation_NNP We_PRP aim_VBP to_TO be_VB a_DT leader_NN in_IN neuroscience_NN We_PRP aim_VBP to_TO maintain_VB our_PRP$ position_NN as_IN a_DT Already_RB a_DT leader_NN in_IN the_DT treatment_NN of_IN by_IN continuing_VBG to_TO deliver_VB a_DT range_NN of_IN life_NN world_NN leader_NN in_IN cancer_NN treatment_NN asthma_NN ,_, we_PRP plan_VBP to_TO expand_VB our_PRP$ range_NN changing_VBG medicines_NNS in_IN three_CD key_JJ areas_NNS through_IN continued_VBN growth_NN for_IN key_NN through_IN the_DT introduction_NN of_IN new_JJ treatments_NNS of_IN psychiatry_NN ,_, analgesia_NN and_CC neurology_NN ,_, products_NNS in_IN our_PRP$ portfolio_NN ,_, continued_VBD and_CC new_JJ uses_NNS for_IN our_PRP$ key_JJ products_NNS in_IN and_CC by_IN maintaining_VBG our_PRP$ world_NN leading_VBG launches_NNS for_IN our_PRP$ new_JJ products_NNS and_CC the_DT other_JJ areas_NNS of_IN inflammatory_JJ disease_NN ,_, position_NN in_IN anaesthesia_NN ._.
successful_JJ introduction_NN of_IN novel_NN such_JJ as_IN chronic_JJ obstructive_JJ pulmonary_JJ approaches_NNS currently_RB in_IN the_DT pipeline_NN ._.
disease_NN COPD_NNP and_CC rheumatoid_JJ Health_NNP problems_NNS related_VBN to_TO the_DT function_NN arthritis_NN ._.
of_IN the_DT central_JJ nervous_JJ system_NN ,_, including_VBG Over_IN 12_CD million_CD people_NNS are_VBP diagnosed_VBN the_DT brain_NN ,_, are_VBP a_DT complex_JJ area_NN of_IN with_IN cancer_NN each_DT year_NN ._.
It_PRP is_VBZ predicted_VBN to_TO The_DT World_NNP Health_NNP Organisation_NNP significant_JJ medical_JJ need_NN that_WDT touches_NNS be_VB the_DT leading_VBG cause_NN of_IN death_NN in_IN the_DT US_NNP estimates_VBZ that_IN 100_CD million_CD people_NNS many_JJ peoples_NNS lives_NNS ._.
by_IN 2005_CD ._.
worldwide_JJ suffer_VBP from_IN asthma_NN and_CC that_IN COPD_NNP is_VBZ the_DT fourth_JJ greatest_JJS cause_NN of_IN Sales_NNS of_IN Seroquel_NNP ,_, our_PRP$ schizophrenia_NN Sales_NNS of_IN Casodex_NNP and_CC Arimidex_NNP ,_, for_IN death_NN worldwide_NN ._.
therapy_NN ,_, have_VBP now_RB exceeded_VBN $_$ 4_CD billion_CD treating_VBG prostate_NN and_CC breast_NN cancer_NN since_IN launch_NN and_CC in_IN 2003_CD ,_, showed_VBD respectively_RB ,_, grew_VBD strongly_RB in_IN 2003_CD ._.
Clinical_JJ data_NNS confirmed_VBD the_DT efficacy_NN and_CC continued_VBD strong_JJ growth_NN globally_RB ._.
Arimidex_NNP is_VBZ rapidly_RB moving_VBG towards_IN safety_NN of_IN Symbicort_NNP as_IN an_DT adjustable_JJ Seroquel_NNP is_VBZ now_RB widely_RB approved_VBN in_IN replacing_VBG tamoxifen_NN as_IN the_DT standard_NN of_IN maintenance_NN treatment_NN for_IN asthma_NN ._.
Europe_NNP and_CC the_DT US_NNP ,_, for_IN the_DT treatment_NN of_IN care_NN in_IN breast_NN cancer_NN ._.
During_IN the_DT year_NN ,_, we_PRP filed_VBD for_IN approval_NN in_IN bipolar_NN mania_NN which_WDT affects_VBZ over_IN 17_CD Europe_NNP of_IN Symbicort_NNP as_IN a_DT single_JJ inhaler_NN million_CD people_NNS in_IN the_DT major_JJ markets_NNS ._.
Good_JJ sales_NNS for_IN Faslodex_NNP reflected_VBD a_DT treatment_NN for_IN asthma_NN ._.
Symbicort_NNP also_RB steady_JJ increase_NN in_IN use_NN for_IN the_DT treatment_NN became_VBD the_DT first_JJ fixed_VBN combination_NN of_IN Zomig_NNP Nasal_NNP Spray_NNP ,_, a_DT new_JJ formulation_NN of_IN advanced_JJ breast_NN cancer_NN in_IN the_DT US_NNP ._.
inhaled_JJ corticosteroid_JJ and_CC fast_JJ onset_NN ,_, of_IN our_PRP$ Zomig_NNP migraine_NN therapy_NN in_IN a_DT Approval_NN for_IN Faslodex_NNP in_IN Europe_NNP is_VBZ long_JJ acting_VBG bronchodilator_NN approved_VBD for_IN convenient_JJ device_NN that_WDT delivers_VBZ fast_RB anticipated_VBN early_RB in_IN 2004_CD following_VBG a_DT COPD_NNP in_IN Europe_NNP ._.
pain_NN relief_NN ,_, was_VBD successfully_RB launched_VBN positive_JJ opinion_NN from_IN the_DT Committee_NNP in_IN Europe_NNP and_CC the_DT US_NNP ._.
for_IN Proprietary_NNP Medicinal_NNP Products_NNPS in_IN In_IN the_DT US_NNP ,_, growth_NN of_IN 32_CD %_NN in_IN total_NN late_JJ 2003_CD ._.
prescriptions_NNS for_IN Pulmicort_NNP Respules_NNP Our_PRP$ leading_VBG range_NN of_IN anaesthetics_NNS reflected_VBD the_DT products_NNS beneficial_JJ continued_VBN to_TO perform_VB well_RB ,_, despite_IN the_DT There_EX has_VBZ been_VBN rapid_JJ uptake_NN of_IN our_PRP$ new_JJ profile_NN and_CC strengthened_VBD its_PRP$ position_NN anticipated_VBD slowing_VBG in_IN sales_NNS growth_NN for_IN lung_NN cancer_NN therapy_NN ,_, Iressa_NNP over_IN as_IN the_DT inhaled_JJ corticosteroid_NN of_IN choice_NN Diprivan_NNP general_JJ anesthetic_NN following_VBG 100,000_CD patients_NNS have_VBP been_VBN treated_VBN for_IN the_DT treatment_NN of_IN children_NNS under_IN five_CD patent_NN expiries_NNS ._.
since_IN its_PRP$ first_JJ launch_NN in_IN Japan_NNP in_IN 2002_CD with_IN asthma_NN ._.
com_NN Board_NNP of_IN Directors_NNS As_IN at_IN 31_CD December_NNP 2003_CD Percy_NNP Barnevik_NNP Sir_NNP Tom_NNP McKillop_NNP Jonathan_NNP Symonds_NNP Non-Executive_NNP Chairman_NNP Executive_NNP Director_NNP Executive_NNP Director_NNP Chief_NNP Executive_NNP Chief_NNP Financial_NNP Officer_NNP Hkan_NNP Mogren_NNP Non-Executive_NNP Deputy_NNP Chairman_NNP Sir_NNP Peter_NNP Bonfield_NNP Dame_NNP Bridget_NNP Ogilvie_NNP Senior_NNP Non-Executive_NNP Director_NNP Non-Executive_NNP Director_NNP Jane_NNP Henney_NNP Non-Executive_NNP Director_NNP Marcus_NNP Wallenberg_NNP Michele_NNP Hooper_NNP Non-Executive_NNP Director_NNP Non-Executive_NNP Director_NNP Karl_NNP von_NNP der_NN Heyden_NNP Non-Executive_NNP Director_NNP John_NNP Buchanan_NNP Joe_NNP Jimenez_NNP Non-Executive_NNP Director_NNP Non-Executive_NNP Director_NNP Erna_NNP Mller_NNP Non-Executive_NNP Director_NNP AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN 17_CD Sir_NNP Tom_NNP McKillop_NNP 60_CD Jonathan_NNP Symonds_NNP 44_CD Percy_NNP Barnevik_NNP 62_CD Non-Executive_NNP Chairman_NNP Executive_NNP Director_NNP and_CC Chief_NNP Executive_NNP Executive_NNP Director_NNP and_CC Chief_NNP Financial_NNP Chairman_NNP of_IN the_DT Nomination_NNP Committee_NNP Appointed_VBD as_IN a_DT Director_NNP 1_CD January_NNP 1996_CD ._.
Officer_NNP Appointed_VBD as_IN a_DT Director_NNP 6_CD April_NNP 1999_CD ._.
Non-Executive_JJ Director_NNP of_IN Lloyds_NNP TSB_NNP Group_NNP Appointed_VBD as_IN a_DT Director_NNP 1_CD October_NNP 1997_CD ._.
Honorary_NNP Chairman_NNP of_IN Sandvik_NNP AB_NNP ._.
President_NNP of_IN the_DT European_JJ Federation_NNP of_IN Also_RB has_VBZ overall_JJ responsibility_NN for_IN Information_NNP Executive_NNP Director_NNP of_IN General_NNP Motors_NNPS Pharmaceutical_NNP Industries_NNPS and_CC Associations_NNPS ._.
Non-Executive_JJ Director_NNP of_IN QinetiQ_NNP Corporation_NNP ._.
Member_NNP of_IN the_DT Academies_NNPS of_IN Pro-Chancellor_NNP of_IN the_DT University_NNP of_IN Leicester_NNP ._.
Member_NNP of_IN the_DT UK_NNP Accounting_NNP Engineering_NNP Sciences_NNPS in_IN Sweden_NNP and_CC Finland_NNP Chairman_NNP of_IN the_DT British_JJ Pharma_NNP Group_NNP and_CC Standards_NNP Board_NNP ._.
Chairman_NNP of_IN The_DT Hundred_NNP and_CC Honorary_NNP Member_NNP of_IN the_DT Royal_NNP Academy_NNP the_DT North_NNP West_NNP Science_NNP Council_NNP ._.
Group_NNP of_IN Finance_NNP Directors_NNS in_IN the_DT UK_NNP ._.
Member_NNP of_IN Advisory_NNP Councils_NNPS in_IN Korea_NNP ,_, India_NNP and_CC the_DT Investment_NN Sir_NNP Peter_NNP Bonfield_NNP CBE_NNP ,_, FREng_NNP 59_CD Dame_NNP Bridget_NNP Ogilvie_NNP 65_CD Council_NNP advising_VBG the_DT South_JJ African_JJ Senior_JJ Non-Executive_JJ Director_NNP Non-Executive_NNP Director_NNP Government_NNP ._.
Member_NNP of_IN the_DT Business_NNP Chairman_NNP of_IN the_DT Remuneration_NNP Member_NNP of_IN the_DT Audit_NNP Committee_NNP and_CC the_DT Council_NNP of_IN American_NNP CEOs_NNS ._.
Member_NNP of_IN the_DT Committee_NNP and_CC Member_NNP of_IN the_DT Science_NNP Committee_NNP Advisory_NNP Board_NNP ,_, Centre_NNP for_IN European_JJ Nomination_NNP Committee_NNP Appointed_VBD as_IN a_DT Director_NNP 1_CD January_NNP 1997_CD ._.
Also_RB has_VBZ responsibility_NN for_IN overseeing_VBG Fellow_NNP of_IN the_DT Royal_NNP Academy_NNP of_IN Engineering_NNP ._.
Non-Executive_JJ Hkan_NNP Mogren_NNP 59_CD Non-Executive_NNP Director_NNP of_IN Director_NNP of_IN the_DT Manchester_NNP Technology_NNP Non-Executive_NNP Deputy_NNP Chairman_NNP Telefonaktiebolaget_NNP LM_NNP Ericsson_NNP ,_, Mentor_NNP Fund_NNP Limited_NNP ._.
Chairman_NNP of_IN the_DT Medicines_NNP Member_NNP of_IN the_DT Nomination_NNP Committee_NNP Graphics_NNP Corporation_NNP and_CC Taiwan_NNP for_IN Malaria_NNP Venture_NNP and_CC the_DT Association_NNP of_IN Appointed_VBN as_IN a_DT Director_NNP 6_CD April_NNP 1999_CD ._.
Semiconductor_NNP Manufacturing_NNP Company_NNP ,_, Medical_NNP Research_NNP Charities_NNPS ._.
Trustee_NN of_IN Formerly_RB CEO_NNP and_CC a_DT Director_NNP of_IN Astra_NNP AB_NNP Ltd._NNP ._.
Vice-President_NN of_IN The_DT British_JJ Quality_NNP Cancer_NNP Research_NNP UK_NNP ._.
Chairman_NNP of_IN the_DT appointed_VBN 18_CD May_NNP 1988_CD ._.
Member_NNP of_IN Citigroup_NNP Trustees_NNPS of_IN the_DT AstraZeneca_NNP Science_NNP Affibody_NNP AB_NNP and_CC the_DT Sweden-America_NNP International_NNP Advisory_NNP Board_NNP ._.
Member_NNP of_IN the_DT Board_NNP of_IN Directors_NNS of_IN Investor_NNP Marcus_NNP Wallenberg_NNP 47_CD Michele_NNP Hooper_NNP 52_CD AB_NNP ,_, Rmy_NNP Cointreau_NNP S._NNP A._NNP Groupe_NNP Danone_NNP Non-Executive_NNP Director_NNP Non-Executive_NNP Director_NNP and_CC Norsk_NNP Hydro_NNP ASA_NNP ._.
Director_NNP of_IN the_DT Member_NNP of_IN the_DT Audit_NNP Committee_NNP Appointed_VBD as_IN a_DT Director_NNP 1_CD July_NNP 2003_CD ._.
Marianne_NNP and_CC Marcus_NNP Wallenberg_NNP Appointed_VBD as_IN a_DT Director_NNP 6_CD April_NNP 1999_CD ._.
President_NNP and_CC Chief_NNP Executive_NNP Officer_NNP of_IN Foundation_NNP ._.
Formerly_RB a_DT Director_NNP of_IN Astra_NNP AB_NNP appointed_VBD Stadtlander_NNP Drug_NNP Company_NNP 1998-1999_CD ._.
President_NNP and_CC Chief_NNP Executive_NNP Corporate_NNP Vice-President_NNP and_CC President_NNP ,_, Jane_NNP Henney_NNP 56_CD Officer_NNP of_IN Investor_NNP AB_NNP ._.
Non-Executive_JJ ViceInternational_NNP Businesses_NNS of_IN Caremark_NNP Non-Executive_NNP Director_NNP Chairman_NNP of_IN Saab_NNP AB_NNP ,_, Skandinaviska_NNP International_NNP 1992-1998_CD ._.
Non-Executive_JJ Member_NNP of_IN the_DT Audit_NNP Committee_NNP ,_, the_DT Enskilda_NNP Banken_NNP AB_NNP and_CC Telefonaktiebolaget_NNP Director_NNP of_IN PPG_NNP Industries_NNPS ,_, Inc._NNP ._.
Target_NNP Nomination_NNP Committee_NNP and_CC the_DT Science_NN LM_NNP Ericsson_NNP ._.
Non-Executive_JJ Director_NNP of_IN Corporation_NNP and_CC Davita_NNP Inc._NNP ._.
Committee_NNP Scania_NNP AB_NNP ,_, Stora_NNP Enso_NNP Oyj_NNP and_CC the_DT Knut_NNP and_CC Appointed_VBN as_IN a_DT Director_NNP 24_CD September_NNP 2001_CD ._.
Joe_NNP Jimenez_NNP 44_CD Senior_JJ Vice-President_NNP &_CC Provost_NNP for_IN Health_NNP Non-Executive_NNP Director_NNP Affairs_NNP ,_, University_NNP of_IN Cincinnati_NNP Medical_NNP John_NNP Buchanan_NNP 60_CD Member_NNP of_IN the_DT Nomination_NNP Committee_NNP Center_NNP ._.
Commissioner_NNP of_IN Food_NNP and_CC Drugs_NNPS Non-Executive_NNP Director_NNP Appointed_VBD as_IN a_DT Director_NNP 1_CD July_NNP 2003_CD ._.
1998-2001_CD and_CC Deputy_NNP Commissioner_NNP for_IN Member_NNP of_IN the_DT Audit_NNP Committee_NNP and_CC the_DT Executive_NNP Vice-President_NNP of_IN H_NNP J_NNP Heinz_NNP Operations_NNP 1992-1994_CD ,_, US_NNP Food_NNP and_CC Drug_NNP Remuneration_NNP Committee_NNP Company_NNP and_CC President_NNP and_CC Chief_NNP Executive_NNP Administration_NNP ._.
Deputy_NNP Director_NNP ,_, US_NNP National_NNP Appointed_VBD as_IN a_DT Director_NNP 25_CD April_NNP 2002_CD ._.
Officer_NNP of_IN Heinz_NNP Europe_NNP since_IN 2002_CD ._.
Non-Executive_JJ Executive_NNP Director_NNP and_CC Group_NNP Chief_NNP Financial_NNP Corporate_NNP Vice-President_NNP then_RB Senior_JJ ViceDirector_NNP of_IN AmerisourceBergen_NNP Corporation_NNP ._.
Member_NNP of_IN President_NNP and_CC President_NNP of_IN Heinz_NNP North_NNP Member_NNP of_IN the_DT Board_NNP of_IN Trustees_NNPS of_IN the_DT the_DT UK_NNP Accounting_NNP Standards_NNP Board_NNP 1997_CD -_: America_NNP 1998-2002_CD ._.
Non-Executive_JJ Director_NNP Commonwealth_NNP Fund_NNP and_CC the_DT Scripps_NNP 2001_CD ._.
Senior_JJ Independent_NNP Non-Executive_NNP of_IN Hain_NNP Celestial_NNP Group_NNP ,_, Inc._NNP ._.
Research_NNP Institute_NNP ._.
Member_NNP of_IN the_DT Medical_NNP &_CC Director_NNP of_IN BHP_NNP Billiton_NNP Plc_NNP and_CC NonScientific_NNP Advisory_NNP Board_NNP of_IN MPM_NNP Capital_NNP ._.
Executive_NNP Director_NNP of_IN Vodafone_NNP Group_NNP Plc._NNP ._.
Other_JJ officers_NNS of_IN the_DT Company_NN at_IN 31_CD December_NNP 2003_CD included_VBD members_NNS of_IN Karl_NNP von_NNP der_NN Heyden_NNP 67_CD Erna_NNP Mller_NNP 63_CD the_DT Senior_NNP Executive_NNP Team_NNP ,_, as_IN set_VBN out_RP on_IN Non-Executive_JJ Director_NNP Non-Executive_NNP Director_NNP page_NN 19_CD ,_, and_CC :_: Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP Member_NNP of_IN the_DT Remuneration_NNP Committee_NNP Appointed_VBD as_IN a_DT Director_NNP 1_CD October_NNP 1998_CD ._.
and_CC the_DT Science_NNP Committee_NNP Graeme_NNP Musker_NNP Executive_NNP Vice-President_NNP 1989-1992_CD and_CC Appointed_VBN as_IN a_DT Director_NNP 6_CD April_NNP 1999_CD ._.
Group_NNP Secretary_NNP and_CC Solicitor_NNP Co-Chairman_NNP and_CC Chief_NNP Executive_NNP Officer_NNP Formerly_RB a_DT Director_NNP of_IN Astra_NNP AB_NNP appointed_VBD 15_CD Appointed_VBN as_IN Company_NNP Secretary_NNP 1993_CD of_IN RJR_NNP Nabisco_NNP ._.
Executive_NNP Director_NNP of_IN the_DT Knut_NNP 6June_NNP 1993_CD ._.
Executive_NNP Officer_NNP of_IN Metallgesellschaft_NNP Corp._NNP and_CC Alice_NNP Wallenberg_NNP Foundation_NNP ._.
Vice-Chairman_NNP of_IN PepsiCo_NNP ,_, Inc._NNP of_IN Clinical_NNP Immunology_NNP and_CC Member_NNP of_IN the_DT 1996-2001_CD ._.
Non-Executive_JJ Director_NNP of_IN Nobel_NNP Assembly_NNP and_CC of_IN the_DT Nobel_NNP Federated_NNP Department_NNP Stores_NNPS Inc._NNP ._.
Committee_NNP ,_, Karolinska_NNP Institutet_NNP ._.
Member_NNP of_IN ARAMARK_NNP Inc._NNP and_CC Exult_NNP ,_, Inc._NNP the_DT Royal_NNP Swedish_NNP Academy_NNP of_IN Engineering_NNP Sciences_NNPS and_CC the_DT Royal_NNP Swedish_NNP Academy_NNP of_IN Science_NNP ._.
com_NN Summary_NNP Directors_NNS report_VBP subject_JJ to_TO those_DT provisions_NNS of_IN the_DT Act_NNP Board_NNP of_IN Directors_NNS At_IN its_PRP$ meeting_NN in_IN December_NNP 2003_CD ,_, the_DT Board_NNP Details_NNS of_IN the_DT Board_NNP at_IN 31_CD December_NNP 2003_CD applicable_JJ to_TO foreign_JJ issuers_NNS ._.
reviewed_VBN and_CC assessed_VBN how_WRB it_PRP operates_VBZ ._.
This_DT are_VBP set_VBN out_RP on_IN pages_NNS 16_CD and_CC 17_CD ._.
included_VBD consideration_NN and_CC discussion_NN of_IN the_DT The_DT Company_NN either_CC already_RB complies_VBZ with_IN or_CC nature_NN and_CC level_NN of_IN its_PRP$ interaction_NN with_IN the_DT Board_NNP changes_NNS will_MD comply_VB with_IN those_DT provisions_NNS of_IN the_DT Act_NNP Companys_NNP management_NN :_: the_DT quality_NN ,_, ke_FW Stavling_NNP ,_, Executive_NNP Director_NNP ,_, left_VBD the_DT applicable_JJ to_TO foreign_JJ issuers_NNS as_IN and_CC when_WRB quantity_NN and_CC coverage_NN of_IN information_NN which_WDT Company_NN at_IN the_DT end_NN of_IN January_NNP 2003_CD ._.
they_PRP become_VBP effective_JJ ._.
The_DT Board_NNP believes_VBZ flows_VBZ to_TO the_DT Board_NNP from_IN management_NN :_: the_DT that_DT ,_, prior_RB to_TO the_DT Act_NNP coming_VBG into_IN force_NN ,_, the_DT balance_NN of_IN the_DT Boards_NNPS time_NN spent_VBD In_IN July_NNP 2003_CD ,_, the_DT Board_NNP appointed_VBN Michele_NNP Company_NNP already_RB had_VBD a_DT sound_JJ corporate_JJ considering_VBG strategic_JJ issues_NNS compared_VBN to_TO Hooper_NNP and_CC Joe_NNP Jimenez_NNP as_IN Non-Executive_JJ governance_NN framework_NN ,_, good_JJ processes_NNS for_IN other_JJ matters_NNS :_: the_DT content_NN of_IN Board_NNP meetings_NNS Directors_NNS ._.
the_DT accurate_JJ and_CC timely_JJ reporting_NN of_IN its_PRP$ and_CC presentations_NNS to_TO Board_NNP meetings_NNS :_: the_DT financial_JJ position_NN and_CC results_NNS of_IN operations_NNS composition_NN of_IN the_DT Board_NNP :_: the_DT practical_JJ At_IN the_DT end_NN of_IN August_NNP 2003_CD ,_, Hkan_NNP Mogren_NNP and_CC an_DT effective_JJ and_CC robust_JJ system_NN of_IN internal_JJ arrangements_NNS for_IN the_DT work_NN of_IN the_DT Board_NNP :_: and_CC ceased_VBD to_TO be_VB Executive_NNP Deputy_NNP Chairman_NNP and_CC controls_NNS ._.
Consequently_RB ,_, the_DT Companys_NNPS the_DT work_NN and_CC operation_NN of_IN the_DT Boards_NNPS became_VBD Non-Executive_JJ Deputy_NNP Chairman_NNP ._.
approach_NN to_TO compliance_NN with_IN the_DT Act_NNP has_VBZ committees_NNS ._.
Overall_RB ,_, Board_NNP members_NNS principally_RB involved_VBD the_DT development_NN and_CC concluded_VBD that_IN the_DT Board_NNP and_CC its_PRP$ committees_NNS Election_NNP and_CC re-election_NN of_IN Directors_NNS adjustment_NN of_IN its_PRP$ existing_VBG corporate_JJ were_VBD operating_VBG in_IN an_DT effective_JJ and_CC All_DT of_IN the_DT Directors_NNS will_MD retire_VB under_IN Article_NNP 65_CD governance_NN framework_NN and_CC associated_VBN constructive_JJ manner_NN ._.
of_IN the_DT Companys_NNP Articles_NNPS of_IN Association_NNP at_IN processes_NNS concerning_VBG reporting_NN ,_, internal_JJ the_DT Annual_JJ General_NNP Meeting_VBG AGM_NNP in_IN April_NNP controls_NNS and_CC other_JJ relevant_JJ matters_NNS ._.
At_IN the_DT same_JJ meeting_NN ,_, the_DT Chairman_NNP also_RB 2004_CD ._.
The_DT Notice_NNP of_IN AGM_NNP will_MD give_VB details_NNS of_IN reported_VBN to_TO the_DT Board_NNP on_IN his_PRP$ conversations_NNS those_DT Directors_NNS presenting_VBG themselves_PRP for_IN Board_NNP structure_NN and_CC processes_VBZ with_IN each_DT Non-Executive_JJ Director_NNP about_IN their_PRP$ election_NN or_CC re-election_NN at_IN the_DT AGM_NNP ._.
Board_NNP composition_NN ,_, responsibilities_NNS and_CC individual_JJ performance_NN and_CC that_IN of_IN the_DT Board_NNP appointments_NNS as_IN a_DT whole_NN ,_, which_WDT took_VBD place_NN during_IN the_DT Annual_JJ General_NNP Meeting_VBG The_DT Board_NNP comprises_VBZ Executive_NNP and_CC Nonfourth_NNP quarter_NN of_IN 2003_CD ._.
The_DT Chairman_NNP then_RB The_DT Companys_NNPS AGM_NNP will_MD be_VB held_VBN on_IN 29_CD April_NNP Executive_NNP Directors_NNS ._.
In_IN the_DT view_NN of_IN the_DT Board_NNP ,_, left_VBD the_DT meeting_NN while_IN Sir_NNP Peter_NNP Bonfield_NNP ,_, 2004_CD ._.
The_DT principal_JJ meeting_NN place_NN will_MD be_VB in_IN the_DT majority_NN of_IN Board_NNP members_NNS excluding_VBG the_DT senior_JJ Non-Executive_NNP Director_NNP ,_, led_VBD a_DT review_NN London_NNP ._.
There_EX will_MD be_VB a_DT simultaneous_JJ satellite_NN Chairman_NNP are_VBP independent_JJ Non-Executive_JJ of_IN the_DT Chairmans_NNPS performance_NN ._.
On_IN the_DT meeting_NN in_IN Stockholm_NNP ._.
The_DT differing_VBG roles_NNS of_IN Executive_NNP Chairmans_NNPS return_NN to_TO the_DT meeting_NN ,_, the_DT Board_NNP Directors_NNS and_CC Non-Executive_JJ Directors_NNS are_VBP reviewed_VBN the_DT performance_NN of_IN the_DT Chief_NNP Corporate_NNP governance_NN clearly_RB delineated_JJ ,_, with_IN both_DT having_VBG fiduciary_JJ Executive_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP UK_NNP Combined_NNP Code_NNP on_IN Corporate_NNP duties_NNS towards_IN shareholders_NNS and_CC all_DT being_VBG who_WP ,_, in_IN each_DT case_NN ,_, left_VBD the_DT meeting_NN while_IN Governance_NNP collectively_RB responsible_JJ for_IN the_DT success_NN of_IN the_DT review_NN took_VBD place_NN ._.
In_IN July_NNP 2003_CD ,_, the_DT Financial_NNP Reporting_NNP Council_NNP the_DT Company_NN ._.
However_RB ,_, Executive_NNP Directors_NNS in_IN the_DT UK_NNP issued_VBD the_DT revised_VBN Combined_NNP Code_NNP have_VBP direct_JJ responsibility_NN for_IN business_NN Chief_NNP Executive_NNP and_CC the_DT Senior_JJ on_IN Corporate_JJ Governance_NN which_WDT operations_NNS whereas_IN the_DT Non-Executive_NNP Executive_NNP Team_NNP superseded_VBD and_CC replaced_VBD the_DT Combined_VBN Directors_NNS have_VBP a_DT responsibility_NN to_TO bring_VB The_DT Chief_NNP Executive_NNP ,_, Sir_NNP Tom_NNP McKillop_NNP ,_, has_VBZ Code_NNP published_VBN by_IN the_DT Hampel_NNP Committee_NNP independent_JJ ,_, objective_JJ judgement_NN to_TO bear_VB on_IN delegated_JJ authority_NN from_IN ,_, and_CC is_VBZ responsible_JJ on_IN Corporate_JJ Governance_NN in_IN 1998_CD ._.
This_DT includes_VBZ constructively_RB to_TO ,_, the_DT Board_NNP for_IN directing_VBG and_CC promoting_VBG the_DT for_IN reporting_VBG years_NNS beginning_VBG on_IN or_CC after_IN 1_CD challenging_JJ management_NN and_CC helping_VBG to_TO profitable_JJ operation_NN and_CC development_NN of_IN the_DT November_NNP 2003_CD ._.
develop_VB the_DT Companys_NNPS strategy_NN ._.
The_DT NonCompany_NNP ,_, consistent_JJ with_IN the_DT primary_JJ aim_NN of_IN Executive_NNP Directors_NNS scrutinise_VBP the_DT enhancing_VBG long_JJ term_NN shareholder_NN value_NN ._.
Although_IN the_DT Company_NN is_VBZ not_RB strictly_RB required_VBN performance_NN of_IN management_NN and_CC have_VBP to_TO report_VB against_IN the_DT revised_VBN Combined_NNP Code_NNP various_JJ responsibilities_NNS concerning_VBG the_DT The_DT Chief_NNP Executive_NNP is_VBZ responsible_JJ to_TO the_DT until_IN its_PRP$ Directors_NNS Report_NNP for_IN 2004_CD ,_, the_DT Board_NNP integrity_NN of_IN financial_JJ information_NN ,_, internal_JJ Board_NNP for_IN the_DT management_NN and_CC performance_NN did_VBD review_VB the_DT revised_VBN Combined_NNP Code_NNP at_IN its_PRP$ controls_NNS and_CC risk_VB management_NN ._.
To_TO help_VB of_IN the_DT Companys_NNPS businesses_NNS within_IN the_DT meeting_NN in_IN October_NNP 2003_CD and_CC has_VBZ prepared_VBN maintain_VBP a_DT strong_JJ executive_NN presence_NN on_IN the_DT framework_NN of_IN Company_NN policies_NNS ,_, reserved_VBN this_DT Directors_NNS Report_VBP with_IN reference_NN to_TO the_DT Board_NNP in_IN addition_NN to_TO the_DT two_CD Executive_NNP powers_NNS and_CC routine_JJ reporting_NN requirements_NNS ._.
Directors_NNS the_DT Chief_NNP Executive_NNP and_CC the_DT Chief_NNP He_PRP is_VBZ obliged_VBN to_TO refer_VB certain_JJ major_JJ matters_NNS Financial_JJ Officer_NNP ,_, Board_NNP meetings_NNS are_VBP defined_VBN in_IN the_DT formal_JJ delegation_NN of_IN the_DT The_DT Company_NN is_VBZ applying_VBG all_DT of_IN the_DT main_JJ and_CC attended_VBN by_IN two_CD members_NNS of_IN the_DT Senior_JJ Boards_NNS authority_NN back_RB to_TO the_DT Board_NNP ._.
The_DT supporting_VBG principles_NNS of_IN good_JJ governance_NN in_IN Executive_NNP Team_NNP ._.
roles_NNS of_IN the_DT Board_NNP ,_, the_DT Boards_NNPS committees_NNS ,_, the_DT revised_VBN Combined_NNP Code_NNP ._.
The_DT way_NN in_IN the_DT Chairman_NNP ,_, the_DT Chief_NNP Executive_NNP and_CC the_DT which_WDT these_DT principles_NNS are_VBP being_VBG applied_VBN is_VBZ The_DT Board_NNP sets_VBZ the_DT Companys_NNP strategy_NN Senior_NNP Executive_NNP Team_NNP are_VBP documented_VBN ,_, as_IN described_VBN below_IN ._.
and_CC policies_NNS and_CC monitors_NNS progress_NN towards_IN are_VBP the_DT Companys_NNPS delegated_VBD authorities_NNS and_CC meeting_VBG its_PRP$ objectives_NNS ._.
It_PRP also_RB assesses_VBZ reserved_JJ powers_NNS ,_, the_DT means_NNS of_IN operation_NN of_IN The_DT Company_NN is_VBZ complying_VBG with_IN all_DT of_IN the_DT whether_IN its_PRP$ obligations_NNS to_TO the_DT Companys_NNPS the_DT business_NN and_CC the_DT roles_NNS of_IN corporate_JJ provisions_NNS of_IN the_DT revised_VBN Combined_NNP Code_NNP ._.
shareholders_NNS and_CC others_NNS are_VBP understood_VBN functions_NNS ._.
This_DT includes_VBZ regular_JJ reviews_NNS of_IN The_DT US_NNP Sarbanes-Oxley_NNP Act_NNP of_IN 2002_CD the_DT Companys_NNPS financial_JJ performance_NN and_CC The_DT Chief_NNP Executive_NNP has_VBZ established_VBN and_CC AstraZeneca_NNP PLC_NNP American_NNP Depositary_NNP critical_JJ business_NN issues_NNS ._.
The_DT Board_NNP met_VBD six_CD chairs_NNS the_DT Senior_NNP Executive_NNP Team_NNP ._.
While_IN the_DT Shares_NNS are_VBP traded_VBN on_IN the_DT New_NNP York_NNP Stock_NNP times_NNS in_IN 2003_CD ._.
Chief_NNP Executive_NNP retains_VBZ full_JJ responsibility_NN for_IN Exchange_NNP NYSE_NNP and_CC the_DT Company_NN is_VBZ the_DT authority_NN delegated_VBD to_TO him_PRP by_IN the_DT Board_NNP ,_, subject_JJ to_TO the_DT reporting_NN and_CC other_JJ There_EX is_VBZ an_DT established_VBN and_CC transparent_JJ the_DT Senior_NNP Executive_NNP Team_NNP is_VBZ the_DT vehicle_NN requirements_NNS of_IN the_DT US_NNP Securities_NNPS and_CC procedure_NN for_IN appointments_NNS of_IN new_JJ directors_NNS through_IN which_WDT he_PRP exercises_VBZ that_IN authority_NN in_IN Exchange_NNP Commission_NNP SEC_NNP applicable_JJ to_TO to_TO the_DT Board_NNP which_WDT is_VBZ operated_VBN by_IN the_DT respect_NN of_IN the_DT Companys_NNPS business_NN including_VBG foreign_JJ issuers_NNS ._.
The_DT US_NNP Sarbanes-Oxley_NNP Act_NNP Nomination_NNP Committee_NNP ._.
All_DT of_IN the_DT Directors_NNS Salick_NNP Health_NNP Care_NNP and_CC Astra_NNP Tech_NNP ._.
came_VBD into_IN force_NN at_IN the_DT end_NN of_IN July_NNP 2002_CD ._.
As_IN a_DT retire_VB at_IN each_DT AGM_NNP and_CC may_MD offer_VB themselves_PRP result_VB of_IN its_PRP$ NYSE_NNP listing_NN ,_, the_DT Company_NN is_VBZ for_IN re-election_NN by_IN shareholders_NNS ._.
com_NN 19_CD Remuneration_NNP policy_NN The_DT members_NNS of_IN the_DT Senior_NNP Executive_NNP Team_NNP During_IN the_DT year_NN ,_, the_DT Code_NNP of_IN Conduct_NNP was_VBD Overall_JJ remuneration_NN policy_NN and_CC purpose_NN are_VBP Jonathan_NNP Symonds_NNP ,_, Chief_NNP Financial_NNP reviewed_VBD and_CC revised_VBD ._.
The_DT amended_VBN version_NN The_DT Company_NN is_VBZ committed_VBN to_TO maintaining_VBG a_DT Officer_NNP :_: Bruno_NNP Angelici_NNP ,_, Executive_NNP Vicewas_NNP approved_VBN by_IN the_DT Board_NNP in_IN July_NNP 2003_CD ._.
To_TO dynamic_JJ performance_NN culture_NN in_IN which_WDT every_DT President_NNP ,_, Europe_NNP ,_, Japan_NNP ,_, Asia_NNP Pacific_NNP and_CC coincide_VB with_IN the_DT launch_NN of_IN the_DT new_JJ Code_NNP of_IN employee_NN champions_NNS the_DT growth_NN of_IN ROW_NNP :_: David_NNP Brennan_NNP ,_, Executive_NNP ViceConduct_NNP ,_, the_DT Company_NN also_RB updated_VBN and_CC shareholder_NN value_NN ,_, is_VBZ clear_JJ about_IN the_DT President_NNP ,_, North_NNP America_NNP :_: Jan_NNP Lundberg_NNP ,_, extended_VBD its_PRP$ procedures_NNS for_IN raising_VBG integrity_NN Companys_NNP objectives_NNS ,_, knows_VBZ how_WRB their_PRP$ work_NN Executive_NNP Vice-President_NNP ,_, Discovery_NNP concerns_NNS which_WDT include_VBP a_DT confidential_JJ impacts_NNS on_IN those_DT objectives_NNS and_CC that_IN they_PRP will_MD Research_NNP :_: John_NNP Patterson_NNP ,_, Executive_NNP Vicehelpline_NNP for_IN employees_NNS worldwide_VBP ._.
benefit_NN from_IN achieving_VBG high_JJ levels_NNS of_IN President_NNP ,_, Product_NNP Strategy_NNP &_CC Licensing_NNP and_CC performance_NN ._.
Business_NNP Development_NNP :_: Martin_NNP Nicklasson_NNP ,_, Purchase_NNP of_IN own_JJ shares_NNS Executive_NNP Vice-President_NNP ,_, Development_NNP :_: The_DT Companys_NNPS stated_VBD distribution_NN policy_NN The_NNP Board_NNP has_VBZ confirmed_VBN that_IN the_DT Barrie_NNP Thorpe_NNP ,_, Executive_NNP Vice-President_NNP ,_, contains_VBZ both_PDT a_DT regular_JJ dividend_NN cash_NN flow_NN Companys_NNP overall_JJ remuneration_NN policy_NN and_CC Operations_NNPS :_: and_CC Tony_NNP Bloxham_NNP ,_, Executive_NNP and_CC a_DT share_NN re-purchase_JJ component_NN to_TO give_VB purpose_NN is_VBZ :_: Vice-President_NNP ,_, Human_NNP Resources_NNPS ._.
the_DT Company_NN more_RBR flexibility_NN in_IN managing_VBG its_PRP$ capital_NN structure_NN over_IN time_NN ._.
In_IN August_NNP 1999_CD ,_, to_TO attract_VB and_CC retain_VB people_NNS of_IN the_DT quality_NN Internal_NNP controls_NNS and_CC management_NN of_IN risk_NN the_DT Company_NN announced_VBD a_DT $_$ 2_CD billion_CD share_NN necessary_JJ to_TO sustain_VB the_DT Company_NN as_IN one_CD of_IN The_NNP Board_NNP has_VBZ overall_JJ responsibility_NN for_IN the_DT re-purchase_JJ program_NN to_TO be_VB completed_VBN the_DT best_JJS pharmaceutical_JJ companies_NNS in_IN the_DT Companys_NNP system_NN of_IN internal_JJ controls_NNS which_WDT by_IN the_DT end_NN of_IN 2002_CD ._.
This_DT program_NN was_VBD world_NN :_: and_CC aims_VBZ to_TO safeguard_VB shareholders_NNS investments_NNS completed_VBN ahead_RB of_IN schedule_NN in_IN the_DT second_JJ to_TO motivate_VB them_PRP to_TO achieve_VB the_DT level_NN of_IN and_CC the_DT Companys_NNPS assets_NNS ,_, ensure_VB that_IN quarter_NN of_IN 2002_CD ._.
In_IN January_NNP 2002_CD ,_, the_DT performance_NN necessary_JJ to_TO create_VB sustained_VBN proper_JJ accounting_NN records_NNS are_VBP maintained_VBN Company_NN announced_VBD an_DT additional_JJ $_$ 2_CD billion_CD growth_NN in_IN shareholder_NN value_NN ._.
and_CC that_IN the_DT financial_JJ information_NN used_VBN within_IN re-purchase_JJ program_NN which_WDT was_VBD the_DT business_NN and_CC for_IN publication_NN is_VBZ accurate_JJ ,_, completed_VBN on_IN schedule_NN by_IN the_DT end_NN of_IN 2003_CD ._.
In_IN order_NN to_TO achieve_VB this_DT ,_, remuneration_NN policy_NN reliable_JJ and_CC fairly_RB presents_VBZ the_DT financial_JJ and_CC practice_NN is_VBZ designed_VBN :_: position_NN of_IN the_DT Company_NN and_CC the_DT results_NNS of_IN its_PRP$ During_IN 2003_CD ,_, the_DT Company_NN purchased_VBD 27.2_CD business_NN operations_NNS ._.
The_DT Board_NNP is_VBZ also_RB million_CD of_IN its_PRP$ own_JJ Ordinary_NNP Shares_NNP with_IN a_DT to_TO closely_RB align_VB individual_JJ and_CC team_NN responsible_JJ for_IN reviewing_VBG the_DT effectiveness_NN of_IN nominal_JJ value_NN of_IN $_$ 0.25_CD each_DT for_IN an_DT aggregate_JJ reward_NN with_IN business_NN performance_NN at_IN each_DT the_DT system_NN of_IN internal_JJ controls_NNS ._.
The_DT system_NN is_VBZ cost_NN of_IN $_$ 1,154_CD million_CD ._.
Following_VBG the_DT level_NN :_: designed_VBN to_TO provide_VB reasonable_JJ assurance_NN of_IN purchase_NN of_IN these_DT shares_NNS ,_, they_PRP were_VBD all_DT to_TO encourage_VB employees_NNS to_TO perform_VB to_TO effective_JJ operations_NNS and_CC compliance_NN with_IN canceled_VBN as_IN required_VBN by_IN applicable_JJ English_NNP their_PRP$ fullest_JJS capacity_NN :_: laws_NNS and_CC regulations_NNS ,_, although_IN any_DT system_NN of_IN law_NN ._.
This_DT number_NN of_IN shares_NNS represents_VBZ 1.6_CD %_NN to_TO encourage_VB employees_NNS to_TO align_VB their_PRP$ internal_JJ controls_NNS can_MD only_RB provide_VB reasonable_JJ ,_, of_IN the_DT Companys_NNPS total_VBP issued_VBN share_NN capital_NN at_IN interests_NNS with_IN those_DT of_IN shareholders_NNS :_: not_RB absolute_JJ ,_, assurance_NN against_IN material_NN 31_CD December_NNP 2003_CD ._.
to_TO support_VB managers_NNS responsibility_NN to_TO misstatement_NN or_CC loss_NN ._.
achieve_VB business_NN performance_NN through_IN Since_IN the_DT beginning_NN of_IN the_DT re-purchase_JJ people_NNS and_CC for_IN them_PRP to_TO recognize_VB superior_JJ The_DT Company_NN views_VBZ the_DT careful_JJ management_NN program_NN in_IN 1999_CD ,_, the_DT Company_NN has_VBZ performance_NN ,_, in_IN the_DT short_JJ and_CC longer_JJR term_NN :_: of_IN risk_NN as_IN a_DT key_JJ management_NN activity_NN ._.
purchased_VBN for_IN cancellation_NN in_IN total_JJ 92.8_CD to_TO be_VB as_IN locally_RB focused_VBN and_CC flexible_JJ as_IN is_VBZ Managing_VBG business_NN risks_NNS to_TO deliver_VB million_CD of_IN its_PRP$ own_JJ Ordinary_NNP Shares_NNP with_IN a_DT practicable_JJ and_CC beneficial_JJ :_: opportunities_NNS is_VBZ a_DT key_JJ element_NN of_IN all_DT activities_NNS ._.
nominal_JJ value_NN of_IN $_$ 0.25_CD each_DT for_IN an_DT aggregate_NN to_TO be_VB competitive_JJ and_CC cost-effective_JJ in_IN This_DT is_VBZ done_VBN using_VBG a_DT simple_JJ and_CC flexible_JJ cost_NN of_IN $_$ 3,959_CD million_CD ._.
This_DT number_NN of_IN shares_NNS each_DT of_IN the_DT relevant_JJ employment_NN markets_NNS :_: framework_NN which_WDT provides_VBZ a_DT consistent_JJ and_CC represents_VBZ 5.5_CD %_NN of_IN the_DT Companys_NNP total_NN and_CC sustained_VBD way_NN of_IN implementing_VBG the_DT issued_VBN share_NN capital_NN at_IN 31_CD December_NNP 2003_CD ._.
to_TO be_VB as_IN internally_RB consistent_JJ as_IN is_VBZ Companys_NNP values_NNS ._.
These_DT business_NN risks_NNS ,_, practicable_JJ and_CC beneficial_JJ taking_VBG due_JJ account_NN which_WDT may_MD be_VB strategic_JJ ,_, operational_JJ ,_, The_DT Company_NN continues_VBZ to_TO maintain_VB robust_JJ of_IN market_NN need_NN ._.
reputational_JJ ,_, financial_JJ or_CC environmental_JJ ,_, controls_NNS in_IN respect_NN of_IN all_DT aspects_NNS of_IN the_DT share_NN should_MD be_VB understood_VBN and_CC visible_JJ ._.
The_DT re-purchase_JJ program_NN to_TO ensure_VB The_DT cost_NN and_CC value_NN of_IN the_DT components_NNS of_IN the_DT business_NN context_NN determines_VBZ in_IN each_DT compliance_NN with_IN English_JJ law_NN and_CC the_DT Listing_NN remuneration_NN package_NN are_VBP considered_VBN as_IN a_DT situation_NN the_DT level_NN of_IN acceptable_JJ risk_NN and_CC Rules_NNS of_IN the_DT UK_NNP Listing_NNP Authority_NNP ._.
In_IN particular_JJ ,_, whole_JJ and_CC are_VBP designed_VBN :_: controls_NNS ._.
the_DT Companys_NNP Disclosure_NNP Committee_NNP meets_VBZ to_TO ensure_VB that_IN the_DT Company_NN does_VBZ not_RB to_TO ensure_VB a_DT proper_JJ balance_NN of_IN fixed_VBN and_CC Code_NNP of_IN Conduct_NNP purchase_NN its_PRP$ own_JJ shares_NNS during_IN prohibited_VBN variable_JJ performance-related_JJ components_NNS ,_, The_DT policy_NN of_IN the_DT Company_NN is_VBZ to_TO require_VB all_DT of_IN periods_NNS ._.
At_IN the_DT AGM_NNP on_IN 29_CD April_NNP 2004_CD ,_, the_DT linked_VBN to_TO short_JJ and_CC longer_JJR term_NN objectives_NNS :_: its_PRP$ subsidiaries_NNS ,_, and_CC their_PRP$ employees_NNS ,_, to_TO Company_NNP will_MD seek_VB a_DT renewal_NN of_IN its_PRP$ current_JJ and_CC observe_VB the_DT highest_JJS ethical_JJ standards_NNS of_IN permission_NN from_IN shareholders_NNS to_TO purchase_VB its_PRP$ to_TO reflect_VB market_NN competitiveness_NN taking_VBG integrity_NN and_CC honesty_NN and_CC act_NN with_IN due_JJ skill_NN ,_, own_JJ shares_NNS ._.
account_NN of_IN the_DT total_JJ value_NN of_IN all_DT of_IN the_DT benefit_NN care_NN ,_, diligence_NN and_CC fairness_NN in_IN the_DT conduct_NN of_IN components_NNS ._.
The_DT Companys_NNP management_NN recognizes_VBZ that_IN such_JJ standards_NNS make_VB a_DT The_DT principal_JJ components_NNS contained_VBN in_IN the_DT significant_JJ contribution_NN to_TO the_DT overall_JJ control_NN total_JJ remuneration_NN package_NN ,_, for_IN employees_NNS environment_NN and_CC seeks_VBZ ,_, by_IN its_PRP$ words_NNS and_CC as_IN a_DT whole_NN ,_, are_VBP :_: actions_NNS ,_, to_TO reinforce_VB them_PRP throughout_IN the_DT business_NN ._.
In_IN particular_JJ ,_, all_DT employees_NNS are_VBP annual_JJ salary_NN based_VBN on_IN conditions_NNS in_IN required_VBN to_TO comply_VB with_IN the_DT letter_NN and_CC spirit_NN of_IN the_DT relevant_JJ geographic_JJ market_NN ,_, with_IN the_DT the_DT AstraZeneca_NNP Code_NNP of_IN Conduct_NNP and_CC with_IN provision_NN to_TO recognize_VB ,_, in_IN addition_NN ,_, the_DT value_NN the_DT high_JJ ethical_JJ standards_NNS detailed_VBN by_IN the_DT of_IN individuals_NNS sustained_VBN personal_JJ Company_NN in_IN support_NN of_IN it_PRP ._.
performance_NN ,_, resulting_VBG from_IN their_PRP$ ability_NN and_CC experience_NN :_: annual_JJ bonus_NN a_DT lump_NN sum_NN payment_NN related_VBN to_TO the_DT targeted_JJ achievement_NN of_IN AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD 20_CD astrazeneca_NN ._.
com_NN Remuneration_NNP policy_NN continued_VBD of_IN responsibility_NN :_: the_DT bonus_NN payable_JJ is_VBZ on_IN corporate_JJ ,_, functional_JJ and_CC individual_JJ goals_NNS ,_, pension_NN element_NN was_VBD $_$ 193,000_CD :_: measured_VBN over_IN a_DT year_NN within_IN a_DT specific_JJ plan_NN :_: a_DT scale_NN of_IN 0-100_CD %_NN of_IN salary_NN and_CC 50_CD %_NN of_IN the_DT corporate_JJ goals_NNS are_VBP derived_VBN from_IN the_DT salary_NN is_VBZ payable_JJ for_IN the_DT achievement_NN of_IN Swedish_NNP Executive_NNP Directors_NNS pension_NN annual_JJ budget_NN set_VBN by_IN the_DT Board_NNP and_CC take_VB target_NN business_NN performance_NN :_: 80_CD %_NN of_IN the_DT arrangements_NNS normally_RB ,_, Swedish_NNP into_IN account_NN external_JJ expectations_NNS of_IN bonus_NN relates_VBZ to_TO the_DT achievement_NN of_IN the_DT Executive_NNP Directors_NNS participate_VB in_IN the_DT performance_NN :_: the_DT functional_JJ goals_NNS are_VBP agreed_VBN earnings_NNS per_IN share_NN target_NN and_CC 20_CD %_NN to_TO the_DT collectively_RB bargained_VBN ITP_NNP pension_NN plan_NN ,_, by_IN the_DT Remuneration_NNP Committee_NNP at_IN the_DT start_NN other_JJ performance_NN measures_NNS :_: which_WDT provides_VBZ pensions_NNS ,_, dependents_NNS of_IN ,_, and_CC are_VBP monitored_VBN throughout_IN ,_, the_DT year_NN :_: pensions_NNS and_CC lump_NN sums_NNS on_IN death_NN in_IN longer_JJR term_NN incentive_NN for_IN selected_VBN longer_JJR term_NN incentive_NN Executive_NNP service_NN :_: in_IN respect_NN of_IN those_DT Swedish_JJ groups_NNS ,_, a_DT longer_JJR term_NN incentive_NN targeted_VBN at_IN Directors_NNS are_VBP also_RB rewarded_VBN for_IN improvement_NN Directors_NNS or_CC former_JJ Directors_NNS ,_, namely_RB the_DT achievement_NN of_IN strategic_JJ objectives_NNS with_IN in_IN the_DT share_NN price_NN performance_NN of_IN the_DT Hkan_NNP Mogren_NNP and_CC ke_NNP Stavling_NNP ,_, whose_WP$ close_JJ alignment_NN to_TO the_DT interests_NNS of_IN Company_NN over_IN a_DT period_NN of_IN years_NNS by_IN the_DT grant_NN pensionable_JJ earnings_NNS are_VBP or_CC were_VBD in_IN shareholders_NNS :_: of_IN share_NN options_NNS :_: the_DT grant_NN of_IN options_NNS under_IN excess_NN of_IN the_DT earnings_NNS limit_NN imposed_VBN by_IN pension_NN arrangements_NNS which_WDT are_VBP the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN is_VBZ the_DT Swedish_JJ Communal_NNP Tax_NNP Law_NNP appropriate_JJ to_TO the_DT relevant_JJ market_NN :_: determined_VBN by_IN the_DT Remuneration_NNP Kommunalskattelagen_NNP ,_, supplementary_JJ other_JJ benefits_NNS such_JJ as_IN holidays_NNS and_CC Committee_NNP ,_, as_RB are_VBP the_DT performance_NN targets_VBZ pension_NN commitments_NNS are_VBP made_VBN :_: the_DT sickness_NN benefit_NN which_WDT are_VBP cost-effective_JJ and_CC that_DT will_MD apply_VB and_CC whether_IN they_PRP will_MD apply_VB to_TO Company_NN has_VBZ agreed_VBN to_TO pay_VB 70_CD %_NN of_IN compatible_JJ with_IN the_DT relevant_JJ national_JJ welfare_NN the_DT grant_NN and_CC or_CC exercise_NN of_IN options_NNS :_: and_CC pensionable_JJ salary_NN from_IN age_NN 60_CD to_TO age_NN 65_CD arrangements_NNS :_: and_CC and_CC 50_CD %_NN of_IN such_JJ earnings_NNS from_IN age_NN 65_CD :_: share_NN participation_NN various_JJ plans_NNS pension_NN arrangements_NNS :_: the_DT ITP_NNP provisions_NNS are_VBP included_VBN in_IN this_DT provide_VB the_DT opportunity_NN for_IN employees_NNS to_TO additional_JJ commitment_NN :_: paid_VBN in_IN pension_NN take_VBP a_DT personal_JJ stake_NN in_IN the_DT Companys_NNPS UK_NNP Executive_NNP Directors_NNS pension_NN capital_NN may_MD also_RB be_VB used_VBN in_IN the_DT event_NN of_IN wealth_NN as_IN shareholders_NNS ._.
arrangements_NNS the_DT Chief_NNP Executive_NNP is_VBZ retirement_NN or_CC termination_NN before_IN the_DT age_NN a_DT member_NN of_IN the_DT Companys_NNPS main_JJ UK_NNP of_IN 60_CD :_: on_IN death_NN in_IN retirement_NN the_DT accrued_VBN The_DT way_NN in_IN which_WDT these_DT elements_NNS are_VBP defined_VBN benefit_NN pension_NN plan_NN :_: the_DT normal_JJ pension_NN is_VBZ payable_JJ to_TO a_DT surviving_VBG spouse_NN combined_VBN and_CC applied_VBN varies_VBZ depending_VBG ,_, pension_NN age_NN under_IN this_DT plan_NN is_VBZ 62_CD :_: or_CC other_JJ dependent_JJ ._.
for_IN example_NN ,_, on_IN market_NN need_NN and_CC practice_NN however_RB ,_, a_DT members_NNS accrued_VBN pension_NN in_IN various_JJ countries_NNS ._.
is_VBZ available_JJ from_IN age_NN 60_CD without_IN any_DT Other_JJ customary_JJ benefits_NNS such_JJ as_IN a_DT car_NN and_CC actuarial_JJ reduction_NN :_: in_IN addition_NN the_DT health_NN benefits_NNS are_VBP also_RB made_VBN available_JJ ._.
This_DT For_IN each_DT Executive_NNP Director_NNP ,_, the_DT individual_JJ accrued_VBN pension_NN is_VBZ available_JJ ,_, unreduced_JJ ,_, happens_VBZ by_IN way_NN of_IN the_DT Executive_NNP Directors_NNS components_NNS are_VBP :_: from_IN age_NN 57_CD if_IN the_DT Company_NN consents_NNS participation_NN in_IN the_DT Companys_NNP flexible_JJ to_TO a_DT request_NN for_IN early_JJ retirement_NN and_CC benefits_NNS arrangements_NNS ,_, which_WDT apply_VBP to_TO the_DT annual_JJ salary_NN the_DT actual_JJ salary_NN for_IN each_DT from_IN age_NN 50_CD if_IN the_DT retirement_NN is_VBZ at_IN the_DT vast_JJ majority_NN of_IN the_DT Companys_NNPS UK_NNP and_CC of_IN the_DT Executive_NNP Directors_NNS is_VBZ determined_VBN by_IN Companys_NNP request_NN :_: Swedish_NNP employees_NNS ._.
the_DT Remuneration_NNP Committee_NNP on_IN behalf_NN of_IN the_DT Board_NNP :_: these_DT salaries_NNS reflect_VBP the_DT On_NNP death_NN in_IN retirement_NN ,_, the_DT accrued_VBN Graph_NNP showing_VBG total_JJ shareholder_NN return_NN experience_NN and_CC sustained_VBD performance_NN of_IN pension_NN is_VBZ guaranteed_VBN payable_JJ for_IN the_DT The_DT UK_NNP Directors_NNS Remuneration_NNP Report_NNP the_DT individuals_NNS to_TO whom_WP they_PRP apply_VBP ,_, as_IN judged_VBN first_RB five_CD years_NNS of_IN retirement_NN and_CC then_RB Regulations_NNPS 2002_CD require_VBP the_DT inclusion_NN in_IN the_DT annually_RB by_IN the_DT Remuneration_NNP Committee_NNP ,_, reduces_VBZ to_TO two-thirds_NNS of_IN this_DT amount_NN Annual_JJ Review_NNP of_IN a_DT graph_NN showing_VBG total_JJ taking_VBG account_NN also_RB of_IN market_NN should_MD there_RB be_VB a_DT surviving_VBG spouse_NN or_CC shareholder_NN return_NN TSR_NNP over_IN a_DT five_CD year_NN competitiveness_NN :_: other_JJ dependent_JJ :_: any_DT member_NN may_MD period_NN in_IN respect_NN of_IN a_DT holding_NN of_IN the_DT choose_VB higher_JJR or_CC lower_JJR levels_NNS of_IN survivors_NNS Companys_NNP shares_NNS ,_, plotted_VBN against_IN TSR_NNP in_IN short_JJ term_NN bonus_NN :_: pensions_NNS at_IN retirement_NN ,_, subject_JJ to_TO respect_NN of_IN a_DT hypothetical_JJ holding_NN of_IN shares_NNS of_IN Inland_NNP Revenue_NNP limits_NNS ,_, in_IN return_NN for_IN an_DT a_DT similar_JJ kind_NN and_CC number_NN by_IN reference_NN to_TO The_DT Chief_NNP Executive_NNP is_VBZ eligible_JJ for_IN an_DT adjustment_NN to_TO their_PRP$ own_JJ pension_NN of_IN which_WDT a_DT broad_JJ equity_NN market_NN index_NN is_VBZ annual_JJ bonus_NN related_VBN solely_RB to_TO the_DT equivalent_JJ actuarial_JJ value_NN :_: pensions_NNS calculated_VBN ._.
This_DT illustrates_VBZ the_DT Companys_NNP achievement_NN of_IN the_DT targeted_VBN are_VBP also_RB payable_JJ to_TO dependent_JJ children_NNS :_: TSR_NNP performance_NN against_IN the_DT broad_JJ equity_NN performance_NN of_IN earnings_NNS per_IN share_NN :_: the_DT pensions_NNS in_IN payment_NN are_VBP increased_VBN market_NN index_NN selected_VBN ._.
For_IN the_DT purposes_NNS of_IN bonus_NN payable_JJ is_VBZ on_IN a_DT scale_NN of_IN 0-100_CD %_NN of_IN annually_RB in_IN line_NN with_IN inflation_NN ,_, as_IN this_DT graph_NN ,_, set_VBN out_RP below_IN ,_, we_PRP have_VBP selected_VBN salary_NN and_CC 50_CD %_NN of_IN salary_NN is_VBZ payable_JJ for_IN measured_VBN by_IN the_DT UK_NNP Retail_NNP Prices_NNS the_DT FTSE_NNP 100_CD Index_NNP as_IN the_DT appropriate_JJ index_NN ._.
the_DT achievement_NN of_IN target_NN performance_NN :_: Index_NNP ,_, up_RB to_TO a_DT maximum_NN of_IN 5_CD %_NN :_: as_IN referred_VBN to_TO above_RB ,_, this_DT is_VBZ derived_VBN from_IN the_DT budget_NN set_VBN by_IN the_DT Board_NNP and_CC takes_VBZ In_IN respect_NN of_IN UK_NNP Executive_NNP Directors_NNS into_IN account_NN external_JJ expectations_NNS of_IN whose_WP$ pensionable_JJ earnings_NNS are_VBP capped_JJ performance_NN :_: by_IN the_DT earnings_NNS limit_NN imposed_VBN by_IN the_DT Finance_NNP Act_NNP 1989_CD ,_, unapproved_JJ defined_VBN The_DT Deputy_NNP Chairman_NNP was_VBD also_RB eligible_JJ contribution_NN schemes_NNS are_VBP made_VBN Graph_NNP showing_VBG total_JJ shareholder_NN return_NN for_IN this_DT annual_JJ bonus_NN related_VBN solely_RB to_TO available_JJ :_: currently_RB ,_, only_RB the_DT Chief_NNP 1_CD January_NNP 1999_CD 31_CD December_NNP 2003_CD earnings_NNS per_IN share_NN for_IN that_DT part_NN of_IN 2003_CD Financial_NNP Officer_NNP is_VBZ affected_VBN by_IN this_DT limit_NN :_: AstraZeneca_NNP during_IN which_WDT he_PRP served_VBD as_IN an_DT Executive_NNP the_DT Company_NN has_VBZ agreed_VBN to_TO pay_VB annually_RB FTSE100_CD Director_NNP 1_CD January_NNP 2003_CD until_IN 31_CD August_NNP 50_CD %_NN of_IN base_NN salary_NN in_IN excess_NN of_IN the_DT 140_CD 2003_CD :_: statutory_JJ earnings_NNS cap_NN for_IN the_DT pension_NN 120_CD and_CC associated_VBN tax_NN liability_NN ,_, with_IN the_DT 100_CD The_DT Chief_NNP Financial_NNP Officer_NNP is_VBZ eligible_JJ intention_NN of_IN providing_VBG equivalence_NN of_IN for_IN an_DT annual_JJ bonus_NN related_VBN to_TO the_DT benefits_NNS with_IN non-capped_JJ UK_NNP Executive_NNP 80_CD achievement_NN of_IN both_DT the_DT targeted_VBN Directors_NNS :_: if_IN this_DT does_VBZ not_RB provide_VB 60_CD performance_NN of_IN earnings_NNS per_IN share_NN equivalence_NN ,_, the_DT Company_NN has_VBZ agreed_VBN to_TO Jan_NNP 99_CD Jan_NNP 00_CD Jan_NNP 01_CD Jan_NNP 02_CD Jan_NNP 03_CD Dec_NNP 03_CD and_CC the_DT achievement_NN of_IN performance_NN make_VBP up_RP the_DT difference_NN :_: the_DT Company_NN Source_NN :_: Thomson_NNP Financial_NNP Datastream_NNP measures_VBZ relevant_JJ to_TO his_PRP$ particular_JJ area_NN contribution_NN in_IN 2003_CD in_IN respect_NN of_IN the_DT AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN 21_CD Summary_NNP financial_JJ review_NN as_IN Nexium_NNP ,_, Crestor_NNP ,_, Symbicort_NNP and_CC Seroquel_NNP ._.
The_DT purpose_NN of_IN the_DT summary_NN financial_JJ review_NN ,_, We_PRP continue_VBP to_TO have_VB operations_NNS through_IN together_RB with_IN the_DT therapy_NN area_NN review_NN is_VBZ to_TO However_RB ,_, cost_NN containment_NN initiatives_NNS have_VBP Astra_NNP Tech_NNP medical_JJ equipment_NN and_CC Salick_JJ provide_VBP understanding_NN and_CC analysis_NN of_IN our_PRP$ restricted_VBN underlying_VBG cost_NN growth_NN in_IN these_DT Health_NNP Care_NNP healthcare_NN services_NNS and_CC results_NNS for_IN the_DT year_NN 2003_CD and_CC of_IN the_DT progress_NN areas_NNS to_TO just_RB under_IN 6_CD %_NN ._.
through_IN our_PRP$ non-core_JJ joint_JJ venture_NN ,_, Advanta_NNP ._.
In_IN the_DT year_NN we_PRP disposed_VBD of_IN the_DT Quorn_NNP Continued_VBD good_JJ performance_NN from_IN newer_JJR business_NN ,_, Marlow_NNP Foods_NNP ._.
Our_PRP$ operations_NNS are_VBP focused_VBN on_IN prescription_NN products_NNS should_MD deliver_VB strong_JJ sales_NNS and_CC pharmaceuticals_NNS and_CC more_JJR than_IN 97_CD %_NN of_IN our_PRP$ profit_NN growth_NN over_IN the_DT next_JJ several_JJ years_NNS as_IN Geographic_JJ analysis_NN sales_NNS are_VBP made_VBN in_IN that_DT sector_NN ._.
Sales_NNS of_IN the_DT impact_NN of_IN generic_JJ erosion_NN on_IN the_DT business_NN In_IN the_DT US_NNP ,_, sales_NNS declined_VBD by_IN 6_CD %_NN for_IN the_DT full_JJ pharmaceutical_JJ products_NNS tend_VBP to_TO be_VB relatively_RB diminishes_VBZ ._.
We_PRP believe_VBP that_IN our_PRP$ financial_JJ year_NN but_CC ,_, excluding_VBG the_DT three_CD products_NNS which_WDT insensitive_JJ to_TO general_JJ economic_JJ performance_NN over_IN this_DT period_NN is_VBZ likely_JJ to_TO rank_VB faced_VBN generic_JJ erosion_NN Losec_NNP Prilosec_NNP ,_, circumstances_NNS in_IN the_DT short_JJ term_NN ._.
They_PRP are_VBP amongst_IN the_DT best_JJS in_IN the_DT global_JJ peer_VBP group_NN of_IN Zestril_NNP and_CC Nolvadex_NNP increased_VBD 36_CD %_NN ._.
more_RBR directly_RB influenced_VBN by_IN medical_JJ needs_NNS large_JJ pharmaceutical_JJ companies_NNS ._.
Growth_NN products_NNS with_IN strong_JJ performances_NNS and_CC are_VBP generally_RB financed_VBN by_IN health_NN included_VBD Nexium_NNP up_IN 62_CD %_NN ,_, Seloken_NNP insurance_NN schemes_NNS or_CC national_JJ healthcare_NN Results_NNS of_IN operations_NNS Toprol-XL_NNP up_IN 47_CD %_NN and_CC Seroquel_NNP up_IN 22_CD %_NN ._.
Results_NNS described_VBD in_IN this_DT section_NN exclude_VBP the_DT addition_NN ,_, Iressa_NNP and_CC Crestor_NNP were_VBD launched_VBN in_IN effects_NNS of_IN exchange_NN rate_NN movements_NNS unless_IN the_DT US_NNP in_IN 2003_CD ._.
Our_PRP$ operating_NN results_NNS in_IN the_DT short_JJ term_NN and_CC otherwise_RB stated_VBN to_TO reflect_VB underlying_VBG long_JJ term_NN can_MD be_VB affected_VBN by_IN a_DT number_NN of_IN performance_NN ._.
Sales_NNS in_IN Europe_NNP increased_VBD 2_CD %_NN for_IN the_DT full_JJ year_NN ,_, factors_NNS other_JJ than_IN normal_JJ competition_NN :_: as_IN strong_JJ sales_NNS growth_NN for_IN Nexium_NNP up_IN 55_CD %_NN ,_, Sales_NNS Symbicort_NNP up_IN 53_CD %_NN ,_, Seroquel_NNP up_IN 40_CD %_NN and_CC exposure_NN to_TO currency_NN fluctuations_NNS :_: After_IN the_DT effects_NNS of_IN changing_VBG product_NN mix_NN ,_, the_DT oncology_NN products_NNS up_IN 18_CD %_NN more_JJR than_IN the_DT risk_NN of_IN loss_NN or_CC expiration_NN of_IN patents_NNS and_CC excluding_VBG the_DT effects_NNS of_IN exchange_NN ,_, our_PRP$ offset_VBN declines_NNS in_IN Losec_NNP Prilosec_NNP ,_, Zestril_NNP and_CC and_CC the_DT potential_JJ adverse_JJ affect_VB on_IN sales_NNS underlying_VBG sales_NNS remained_VBD virtually_RB Pulmicort_NNP ._.
Sales_NNS volumes_NNS increased_VBN by_IN 5_CD %_NN volumes_NNS and_CC prices_NNS from_IN generic_JJ unchanged_JJ ._.
Our_PRP$ sales_NNS performance_NN was_VBD but_CC overall_JJ prices_NNS were_VBD lower_JJR by_IN 3_CD %_NN ._.
competition_NN :_: affected_VBN by_IN the_DT loss_NN of_IN $_$ 3.0_CD billion_CD underlying_VBG Performance_NNP in_IN Europe_NNP was_VBD also_RB affected_VBN the_DT rate_NN of_IN growth_NN and_CC costs_NNS associated_VBN sales_NNS in_IN Losec_NNP Prilosec_NNP ,_, Zestril_NNP and_CC Nolvadex_NNP by_IN the_DT significant_JJ increase_NN in_IN movements_NNS of_IN with_IN new_JJ product_NN launches_NNS ,_, the_DT timings_NNS which_WDT was_VBD compensated_VBN by_IN strong_JJ products_NNS between_IN countries_NNS ,_, usually_RB from_IN of_IN those_DT launches_NNS and_CC the_DT risk_NN that_IN such_JJ performances_NNS elsewhere_RB in_IN the_DT portfolio_NN ._.
In_IN southern_JJ Europe_NNP where_WRB prices_NNS tend_VBP to_TO be_VB new_JJ products_NNS do_VBP not_RB succeed_VB as_IN particular_JJ ,_, underlying_VBG sales_NNS for_IN key_JJ growth_NN lower_JJR than_IN in_IN northern_JJ Europe_NNP ._.
anticipated_VBN :_: and_CC and_CC launch_NN products_NNS increased_VBN by_IN $_$ 2.4_CD billion_CD the_DT adverse_JJ impact_NN on_IN pharmaceutical_JJ up_IN 45_CD %_NN to_TO $_$ 8.2_CD billion_CD ._.
Sales_NNS in_IN Japan_NNP were_VBD up_RB 14_CD %_NN for_IN the_DT full_JJ year_NN ,_, prices_NNS as_IN a_DT result_NN of_IN the_DT regulatory_JJ as_IN a_DT result_NN of_IN increases_NNS in_IN Losec_NNP up_IN 39_CD %_NN ,_, environment_NN ._.
Gastrointestinal_NNP is_VBZ still_RB our_PRP$ largest_JJS therapy_NN Seroquel_NNP up_IN 67_CD %_NN and_CC a_DT strong_JJ oncology_JJ area_NN ,_, accounting_VBG for_IN over_IN 31_CD %_NN of_IN total_JJ sales_NNS portfolio_NN up_RB 16_CD %_NN ._.
Sales_NNS in_IN the_DT rest_NN of_IN the_DT Over_IN the_DT longer_JJR term_NN ,_, the_DT success_NN of_IN our_PRP$ down_RP from_IN over_IN 37_CD %_NN in_IN 2002_CD :_: continued_JJ world_NN grew_VBD by_IN 16_CD %_NN ._.
research_NN and_CC development_NN is_VBZ crucial_JJ ._.
In_IN strong_JJ growth_NN from_IN Nexium_NNP ,_, where_WRB sales_NNS common_JJ with_IN other_JJ pharmaceutical_JJ grew_VBN by_IN 62_CD %_NN to_TO $_$ 3.3_CD billion_CD ,_, restricted_VBN the_DT Operating_NN margin_NN and_CC retained_VBD profit_NN companies_NNS we_PRP devote_VBP substantial_JJ resources_NNS declines_VBZ seen_VBN in_IN the_DT Losec_NNP Prilosec_NNP area_NN ._.
Underlying_JJ operating_NN profit_NN declined_VBD by_IN 11_CD %_NN to_TO R&D_NNP ,_, the_DT benefit_NN of_IN which_WDT emerges_VBZ over_IN although_IN exchange_NN effects_NNS reduced_VBD the_DT the_DT long_JJ term_NN and_CC carries_VBZ considerable_JJ In_IN Cardiovascular_NNP ,_, Crestor_NNP sales_NNS were_VBD $_$ 129_CD reported_VBN decline_NN to_TO 6_CD %_NN ._.
Operating_VBG margin_NN uncertainty_NN as_IN to_TO whether_IN it_PRP will_MD generate_VB million_CD for_IN the_DT full_JJ year_NN and_CC Seloken_NNP Toprol-XL_NNP fell_VBD from_IN 24.4_CD %_NN to_TO 21.8_CD %_NN ._.
sales_NNS exceeded_VBD the_DT $_$ 1_CD billion_CD mark_NN for_IN the_DT improved_VBN primarily_RB as_IN a_DT result_NN of_IN lower_JJR first_JJ time_NN up_RP 38_CD %_NN to_TO $_$ 1,280_CD million_CD :_: these_DT payments_NNS to_TO Merck_NNP ._.
Aggregate_JJ R&D_NNP and_CC In_IN the_DT last_JJ two_CD years_NNS ,_, our_PRP$ key_JJ challenge_NN has_VBZ performances_NNS more_JJR than_IN offset_VB the_DT 50_CD %_NN SG&A_NNP grew_VBD by_IN just_RB under_IN 6_CD %_NN with_IN spending_NN been_VBN to_TO effect_VB a_DT portfolio_NN transformation_NN decline_NN in_IN Zestril_NNP sales_NNS resulting_VBG in_IN an_DT overall_JJ including_VBG several_JJ up-front_JJ payments_NNS for_IN whereby_WRB sales_NNS lost_VBD to_TO patent_NN expiries_NNS are_VBP underlying_VBG performance_NN up_IN 3_CD %_NN ._.
collaboration_NN agreements_NNS ,_, costs_NNS of_IN the_DT replaced_VBN by_IN new_JJ products_NNS and_CC a_DT new_JJ launches_NNS of_IN Crestor_NNP and_CC some_DT field_NN force_NN product_NN portfolio_NN created_VBN ._.
In_IN 2003_CD ,_, the_DT effect_NN Despite_IN the_DT generic_JJ erosion_NN of_IN Nolvadex_NNP in_IN increases_NNS in_IN Europe_NNP and_CC Japan_NNP ._.
of_IN this_DT product_NN portfolio_NN transformation_NN and_CC the_DT US_NNP ,_, Oncology_NNP sales_NNS increased_VBN by_IN 8_CD %_NN with_IN prioritisation_NN is_VBZ clearly_RB demonstrated_VBN by_IN the_DT Arimidex_NNP up_IN 46_CD %_NN to_TO $_$ 519_CD million_CD ,_, Iressa_NNP up_IN Other_JJ income_NN was_VBD $_$ 43_CD million_CD lower_JJR fact_NN that_IN an_DT underlying_VBG $_$ 3.0_CD billion_CD of_IN sales_NNS 227_CD %_NN to_TO $_$ 228_CD million_CD and_CC Casodex_NNP up_IN 22_CD %_NN principally_RB due_JJ to_TO the_DT gain_NN on_IN disposal_NN lost_VBN to_TO generic_JJ competition_NN Losec_NNP Prilosec_NNP ,_, to_TO $_$ 854_CD million_CD all_DT mitigating_VBG the_DT fall_NN in_IN of_IN Sular_NNP in_IN the_DT first_JJ quarter_NN of_IN 2002_CD ._.
Zestril_NNP and_CC Nolvadex_NNP have_VBP been_VBN Nolvadex_JJ sales_NNS down_IN 66_CD %_NN to_TO $_$ 178_CD million_CD ._.
Net_JJ interest_NN and_CC dividend_NN income_NN was_VBD compensated_VBN by_IN the_DT performance_NN of_IN our_PRP$ key_JJ Neuroscience_NNP growth_NN was_VBD 12_CD %_NN driven_VBN by_IN $_$ 91_CD million_CD for_IN the_DT year_NN ,_, benefiting_VBG in_IN growth_NN and_CC launch_NN products_NNS ._.
Sales_NNS from_IN a_DT 27_CD %_NN increase_NN in_IN Seroquel_NNP sales_NNS whilst_VBP comparison_NN with_IN 2002_CD as_IN several_JJ small_JJ these_DT growth_NN and_CC launch_NN products_NNS amounted_VBD Respiratory_NNP and_CC Inflammation_NNP improved_VBN by_IN exchange_NN and_CC market_NN revaluation_NN losses_NNS to_TO $_$ 8.2_CD billion_CD in_IN 2003_CD ._.
15_CD %_NN ,_, with_IN the_DT most_RBS significant_JJ performance_NN were_VBD absent_JJ in_IN 2003_CD ._.
from_IN Symbicort_NNP up_IN 61_CD %_NN ._.
Increased_VBN investment_NN has_VBZ continued_VBN in_IN R&D_NNP The_NNP effective_JJ tax_NN rate_NN for_IN the_DT year_NN was_VBD 27.2_CD %_NN and_CC in_IN selling_NN and_CC marketing_NN activities_NNS ._.
In_IN both_DT Although_IN wholesaler_NN stocking_VBG patterns_NNS compared_VBN to_TO 26.8_CD %_NN in_IN 2002_CD ._.
In_IN the_DT fourth_JJ areas_NNS ,_, prioritisation_NN of_IN resources_NNS across_IN the_DT continue_VBP to_TO have_VB an_DT impact_NN on_IN the_DT quarterly_JJ quarter_NN we_PRP concluded_VBD a_DT negotiated_VBN portfolio_NN is_VBZ actively_RB managed_VBN to_TO avoid_VB phasing_VBG of_IN sales_NNS ,_, for_IN the_DT year_NN as_IN a_DT whole_NN we_PRP settlement_NN with_IN the_DT UK_NNP and_CC the_DT US_NNP committing_VBG resources_NNS before_IN opportunities_NNS estimate_VBP that_IN changes_NNS in_IN excess_JJ wholesaler_NN governments_NNS in_IN respect_NN of_IN ex-Zeneca_NN are_VBP clear_JJ ._.
R&D_NNP spend_VBP was_VBD particularly_RB focused_VBN inventories_NNS had_VBD little_JJ or_CC no_DT effect_NN on_IN sales_NNS products_NNS for_IN the_DT years_NNS 1987_CD to_TO 2001_CD ._.
on_IN completing_VBG the_DT development_NN programs_NNS growth_NN ._.
At_IN the_DT year_NN end_NN ,_, we_PRP estimate_VBP that_IN for_IN Crestor_NNP ,_, Iressa_NNP and_CC Exanta_NNP ._.
Selling_VBG and_CC excess_JJ wholesaler_NN inventories_NNS were_VBD well_RB Dividend_NN and_CC share_NN re-purchases_NNS marketing_VBG resources_NNS were_VBD prioritised_VBN to_TO under_IN $_$ 100_CD million_CD ._.
We_PRP paid_VBD a_DT first_JJ interim_JJ dividend_NN for_IN 2003_CD on_IN recently_RB launched_VBN and_CC growth_NN products_NNS such_JJ 6_CD October_NNP 2003_CD of_IN $_$ 0.255_CD per_IN Ordinary_NNP AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD 22_CD astrazeneca_NN ._.
com_NN Summary_NNP financial_JJ review_NN continued_VBD Share_NN ._.
A_DT second_JJ interim_JJ dividend_NN for_IN 2003_CD Sales_NNS $_$ m_CD Cash_NN flow_NN of_IN $_$ 0.540_CD per_IN Ordinary_NNP Share_NNP has_VBZ been_VBN All_DT data_NNS in_IN this_DT section_NN is_VBZ on_IN an_DT actual_JJ basis_NN declared_VBD ,_, which_WDT the_DT Annual_JJ General_NNP Meeting_VBG unless_IN noted_VBN otherwise_RB ._.
will_MD be_VB asked_VBN to_TO confirm_VB as_IN the_DT final_JJ dividend_NN ._.
This_DT ,_, together_RB with_IN the_DT first_JJ interim_JJ dividend_NN ,_, We_PRP continue_VBP to_TO be_VB a_DT highly_RB cash_NN generative_JJ 03_CD 18,849_CD makes_VBZ a_DT total_JJ dividend_NN of_IN $_$ 0.795_CD for_IN the_DT year_NN ._.
We_PRP believe_VBP our_PRP$ cash_NN resources_NNS will_MD It_PRP is_VBZ our_PRP$ intention_NN that_IN dividends_NNS will_MD increase_VB be_VB sufficient_JJ for_IN our_PRP$ present_JJ requirements_NNS and_CC 02_CD 17,841_CD broadly_RB in_IN line_NN with_IN earnings_NNS growth_NN whilst_NN includes_VBZ sufficient_JJ cash_NN for_IN our_PRP$ existing_VBG 01_CD 16,222_CD bringing_VBG dividend_NN cover_NN to_TO around_IN the_DT middle_JJ capital_NN program_NN ,_, share_NN re-purchases_NNS and_CC of_IN the_DT 2-3_CD times_NNS range_NN ._.
any_DT costs_NNS of_IN launching_VBG new_JJ products_NNS ._.
Profit_NN $_$ m_CD In_IN 2003_CD ,_, we_PRP re-purchased_VBD 27.2_CD million_CD Cash_NN generated_VBD from_IN operating_VBG activities_NNS Ordinary_NNP Shares_NNP for_IN cancellation_NN at_IN a_DT total_NN before_IN exceptional_JJ cash_NN outflows_NNS was_VBD $_$ 4,617_CD cost_NN of_IN $_$ 1,154_CD million_CD bringing_VBG the_DT total_JJ million_CD compared_VBN with_IN $_$ 5,686_CD million_CD in_IN 2002_CD ._.
03_CD number_NN of_IN shares_NNS re-purchased_JJ since_IN the_DT This_DT decrease_NN was_VBD primarily_RB a_DT result_NN of_IN a_DT start_NN of_IN the_DT re-purchase_JJ program_NN in_IN 1999_CD $_$ 1,101_CD million_CD outflow_NN on_IN working_VBG capital_NN 4,202_CD to_TO 92.8_CD million_CD at_IN a_DT cumulative_JJ cost_NN of_IN $_$ 3,959_CD $_$ 540_CD million_CD in_IN debtors_NNS ,_, $_$ 430_CD million_CD in_IN 4,202_CD million_CD ._.
The_DT Board_NNP has_VBZ approved_VBN a_DT new_JJ recreditors_NNS and_CC $_$ 131_CD million_CD in_IN stock_NN ._.
This_DT was_VBD 02_CD purchase_NN program_NN of_IN $_$ 4_CD billion_CD to_TO be_VB principally_RB a_DT consequence_NN of_IN factors_NNS set_VBN out_RP 4,387_CD completed_VBN by_IN the_DT end_NN of_IN 2005_CD ,_, assuming_VBG in_IN the_DT discussions_NNS on_IN stocks_NNS and_CC debtors_NNS and_CC 4,037_CD continued_JJ market_NN access_NN and_CC the_DT absence_NN of_IN creditors_NNS above_IN ._.
The_DT stronger_JJR European_JJ and_CC strategic_JJ needs_NNS for_IN cash_NN ._.
Japanese_JJ currencies_NNS also_RB increased_VBD the_DT cash_NN 01_CD flow_NN effect_NN compared_VBN to_TO 2002_CD ._.
Cash_NN 4,269_CD Financial_NNP position_NN expenditure_NN on_IN exceptional_JJ items_NNS was_VBD $_$ 391_CD 4,077_CD All_DT data_NNS in_IN this_DT section_NN is_VBZ on_IN an_DT actual_JJ basis_NN million_CD compared_VBN with_IN $_$ 93_CD million_CD in_IN 2002_CD ,_, unless_IN noted_VBN otherwise_RB ._.
following_VBG the_DT payment_NN of_IN $_$ 355_CD million_CD in_IN Key_NNP settlement_NN of_IN the_DT Zoladex_NNP investigation_NN ._.
Tax_NNP Profit_NN before_IN exceptional_JJ items_NNS The_DT net_JJ book_NN value_NN of_IN our_PRP$ assets_NNS increased_VBD paid_VBN was_VBD $_$ 886_CD million_CD and_CC includes_VBZ the_DT Profit_NN before_IN tax_NN from_IN $_$ 11,226_CD million_CD at_IN 31_CD December_NNP 2002_CD transfer_NN pricing_NN settlement_NN ._.
R&D_NNP investment_NN $_$ m_CD Capital_NN expenditure_NN on_IN tangible_JJ fixed_JJ assets_NNS Capital_NNP expenditure_NN ,_, including_VBG new_JJ fixed_VBN asset_NN totalled_VBD $_$ 1,239_CD million_CD ,_, with_IN major_JJ investments_NNS and_CC intangible_JJ assets_NNS ,_, totalled_VBD investments_NNS in_IN Nexium_NNP manufacturing_NN and_CC $_$ 1,597_CD million_CD ._.
Although_IN this_DT is_VBZ similar_JJ to_TO cash_VB Investment_NN as_IN %_NN R&D_NN facilities_NNS ._.
Additions_NNS to_TO goodwill_NN and_CC expenditure_NN in_IN 2002_CD ,_, it_PRP reflects_VBZ slightly_RB lower_JJR of_IN sales_NNS intangible_JJ assets_NNS amounted_VBD to_TO $_$ 113_CD million_CD expenditure_NN on_IN tangible_JJ fixed_JJ assets_NNS ,_, offset_VBN by_IN 03_CD 3,451_CD 18.3_CD and_CC fixed_VBN asset_NN investment_NN expenditure_NN exchange_NN and_CC higher_JJR fixed_JJ asset_NN investments_NNS ._.
included_VBD a_DT $_$ 100_CD million_CD investment_NN in_IN The_DT cash_NN inflow_NN in_IN respect_NN of_IN the_DT disposal_NN of_IN 02_CD 3,069_CD 17.2_CD Abgenix_NNP Inc._NNP as_IN part_NN of_IN an_DT oncology_NN Marlow_NNP Foods_NNP contributed_VBD $_$ 80_CD million_CD in_IN the_DT collaboration_NN agreement_NN ._.
01_CD 2,687_CD 16.6_CD exchange_NN effects_NNS and_CC underlying_VBG increases_NNS support_NN of_IN newly_RB launched_VBN and_CC rapidly_RB After_IN accounting_VBG for_IN dividends_NNS paid_VBN of_IN $_$ 1,222_CD growing_VBG products_NNS offset_VBN by_IN reductions_NNS in_IN million_CD ,_, net_JJ share_NN re-purchases_NNS of_IN $_$ 1,107_CD Earnings_NNS per_IN Ordinary_NNP Share_NNP $_$ holdings_NNS of_IN mature_JJ products_NNS ._.
Underlying_JJ million_CD and_CC exchange_NN of_IN $_$ 82_CD million_CD ,_, there_EX is_VBZ a_DT debtor_NN balances_NNS increased_VBD through_IN higher_JJR $_$ 348_CD million_CD decrease_NN in_IN net_JJ cash_NN funds_NNS ,_, invoice_NN sales_NNS in_IN the_DT US_NNP in_IN December_NNP ,_, a_DT higher_JJR which_WDT totalled_VBD $_$ 3,496_CD million_CD at_IN 31_CD December_NNP 03_CD proportion_NN of_IN sales_NNS from_IN Europe_NNP where_WRB 2003_CD ._.
1.78_CD average_JJ credit_NN terms_NNS are_VBP longer_RBR than_IN in_IN the_DT 1.78_CD US_NNP and_CC increased_VBD pension_NN prepayments_NNS ._.
Creditors_NNS fell_VBD due_JJ to_TO the_DT settlement_NN of_IN the_DT US_NNP 02_CD Department_NNP of_IN Justice_NNP Zoladex_NNP investigation_NN 1.84_CD provided_VBN for_IN in_IN 2002_CD ,_, the_DT payment_NN of_IN certain_JJ 1.64_CD pension_NN commitments_NNS and_CC lower_JJR trade_NN creditors_NNS offset_VBN by_IN currency_NN impacts_NNS ._.
01_CD 1.73_CD 1.65_CD Key_NNP Earnings_NNS per_IN share_NN before_IN exceptional_JJ items_NNS Group_NNP earnings_NNS per_IN share_NN statutory_JJ FRS_NNP 3_CD AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN 23_CD Summary_NNP financial_JJ Auditors_NNS statement_NN statements_NNS Auditors_NNS statement_NN to_TO the_DT members_NNS of_IN These_DT summary_NN Financial_NNP Statements_NNP are_VBP Basis_NN of_IN opinion_NN a_DT summary_NN of_IN information_NN in_IN the_DT Groups_NNS AstraZeneca_NNP PLC_NNP ,_, pursuant_JJ to_TO section_NN 251_CD We_PRP conducted_VBD our_PRP$ work_NN in_IN accordance_NN with_IN annual_JJ Financial_NNP Statements_NNP ,_, Directors_NNS of_IN the_DT Companies_NNS Act_NNP 1985_CD Bulletin_NNP 1999_CD 6_CD The_DT auditors_NNS statement_NN on_IN Report_NNP and_CC Directors_NNS Remuneration_NNP Report_NNP We_PRP have_VBP examined_VBN the_DT summary_NN Financial_NNP the_DT summary_NN financial_JJ statement_NN issued_VBN by_IN and_CC do_VB not_RB contain_VB sufficient_JJ information_NN to_TO Statements_NNP set_VBD out_RP on_IN pages_NNS 24_CD to_TO 29_CD ._.
This_DT the_DT Auditing_NNP Practices_NNPS Board_NNP for_IN use_NN in_IN the_DT allow_VB for_IN as_RB full_JJ an_DT understanding_NN of_IN the_DT statement_NN is_VBZ made_VBN solely_RB to_TO the_DT Companys_NNPS UK_NNP ._.
Our_PRP$ report_NN on_IN the_DT Groups_NNS full_JJ annual_JJ results_NNS and_CC state_NN of_IN affairs_NNS of_IN the_DT Group_NNP members_NNS ,_, as_IN a_DT body_NN ,_, in_IN accordance_NN with_IN Financial_NNP Statements_NNP describes_VBZ the_DT basis_NN of_IN as_RB would_MD be_VB provided_VBN by_IN the_DT full_JJ annual_JJ section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
Our_PRP$ our_PRP$ audit_NN opinion_NN on_IN those_DT Financial_NNP Financial_NNP Statements_NNP ,_, Directors_NNS Report_NNP work_NN has_VBZ been_VBN undertaken_VBN so_RB that_IN we_PRP might_MD Statements_NNS ._.
state_NN to_TO the_DT Companys_NNPS members_NNS those_DT Shareholders_NNS requiring_VBG more_JJR detailed_JJ matters_NNS we_PRP are_VBP required_VBN to_TO state_NN to_TO them_PRP in_IN Opinion_NNP information_NN have_VBP the_DT right_NN to_TO obtain_VB ,_, free_JJ of_IN such_PDT a_DT statement_NN and_CC for_IN no_DT other_JJ purpose_NN ._.
In_IN our_PRP$ opinion_NN the_DT summary_NN Financial_NNP charge_NN ,_, a_DT copy_NN of_IN the_DT Groups_NNS last_JJ full_JJ Annual_JJ To_TO the_DT fullest_JJS extent_NN permitted_VBN by_IN law_NN ,_, we_PRP do_VBP Statements_NNS are_VBP consistent_JJ with_IN the_DT full_JJ annual_JJ Report_NNP and_CC Form_NN 20-F_JJ Information_NN ,_, available_JJ not_RB accept_VB or_CC assume_VB responsibility_NN to_TO Financial_NNP Statements_NNP ,_, the_DT Directors_NNS Report_VBP from_IN the_DT Secretary_NNP at_IN the_DT registered_JJ office_NN of_IN anyone_NN other_JJ than_IN the_DT Company_NN and_CC the_DT and_CC the_DT Directors_NNS Remuneration_NNP Report_NNP the_DT Company_NN ._.
Companys_NNS members_NNS as_IN a_DT body_NN ,_, for_IN our_PRP$ of_IN AstraZeneca_NNP PLC_NNP for_IN the_DT year_NN ended_VBD work_NN ,_, for_IN this_DT statement_NN ,_, or_CC for_IN the_DT opinions_NNS 31_CD December_NNP 2003_CD and_CC comply_VB with_IN the_DT The_DT summary_NN Financial_NNP Statements_NNP on_IN we_PRP have_VBP formed_VBN ._.
applicable_JJ requirements_NNS of_IN section_NN 251_CD of_IN pages_NNS 24_CD to_TO 29_CD were_VBD approved_VBN by_IN the_DT the_DT Companies_NNS Act_NNP 1985_CD ,_, and_CC the_DT regulations_NNS Board_NNP of_IN Directors_NNS on_IN 29_CD January_NNP 2004_CD Respective_NNP responsibilities_NNS of_IN Directors_NNS made_VBN thereunder_RB ._.
and_CC were_VBD signed_VBN on_IN its_PRP$ behalf_NN by_IN :_: and_CC Auditor_NNP The_DT Directors_NNS are_VBP responsible_JJ for_IN preparing_VBG 29_CD January_NNP 2004_CD the_DT Annual_JJ Review_NNP 2003_CD in_IN accordance_NN with_IN applicable_JJ UK_NNP law_NN ._.
Our_PRP$ responsibility_NN is_VBZ KPMG_NNP Audit_NNP Plc_NNP to_TO report_VB to_TO you_PRP our_PRP$ opinion_NN on_IN the_DT Chartered_NNP Accountants_NNPS consistency_NN of_IN the_DT summary_NN Financial_NNP Registered_NNP Auditor_NNP Statements_NNP within_IN the_DT Annual_JJ Review_NNP 2003_CD 8_CD Salisbury_NNP Square_NNP Sir_NNP Tom_NNP McKillop_NNP ,_, Director_NNP with_IN the_DT full_JJ annual_JJ Financial_NNP Statements_NNP ,_, the_DT London_NNP EC4Y_NNP 8BB_NNP Directors_NNS Report_NNP and_CC the_DT Directors_NNS Remuneration_NNP Report_NNP ,_, and_CC its_PRP$ compliance_NN with_IN the_DT relevant_JJ requirements_NNS of_IN section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC the_DT regulations_NNS made_VBD thereunder_RB ._.
We_PRP also_RB read_VBD the_DT other_JJ information_NN contained_VBN in_IN the_DT Jonathan_NNP Symonds_NNP ,_, Director_NNP summary_NN Annual_JJ Review_NNP and_CC consider_VB the_DT implications_NNS for_IN our_PRP$ report_NN if_IN we_PRP become_VBP aware_JJ of_IN any_DT apparent_JJ misstatements_NNS or_CC material_NN inconsistencies_NNS with_IN the_DT summary_NN Financial_NNP Statements_NNP ._.
com_NN 24_CD Group_NNP profit_NN and_CC loss_NN account_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP Before_IN exceptional_JJ Exceptional_JJ 2003_CD items_NNS items_NNS Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD Group_NNP turnover_NN 18,849_CD 18,849_CD Operating_NN costs_NNS 14,938_CD 14,938_CD Other_JJ operating_NN income_NN 200_CD 200_CD Group_NNP operating_NN profit_NN 4,111_CD 4,111_CD Share_NN of_IN operating_VBG profits_NNS of_IN joint_JJ ventures_NNS and_CC associates_NNS Profits_NNS on_IN sale_NN of_IN fixed_JJ assets_NNS Dividend_NN income_NN 2_CD 2_CD Profit_NN on_IN ordinary_JJ activities_NNS before_IN interest_NN 4,113_CD 4,113_CD Net_JJ interest_NN 89_CD 89_CD Profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 4,202_CD 4,202_CD Taxation_NNP 1,143_CD 1,143_CD Profit_NN on_IN ordinary_JJ activities_NNS after_IN taxation_NN 3,059_CD 3,059_CD Attributable_JJ to_TO minorities_NNS 23_CD 23_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN 3,036_CD 3,036_CD Dividends_NNS to_TO shareholders_NNS 1,350_CD Profit_NN retained_VBN for_IN the_DT financial_JJ year_NN 1,686_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS $_$ 1.78_CD $_$ 1.78_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP basic_JJ $_$ 1.78_CD $_$ 1.78_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP diluted_VBD $_$ 1.78_CD $_$ 1.78_CD Weighted_VBN average_JJ number_NN of_IN Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS 1,709_CD All_DT activities_NNS were_VBD in_IN respect_NN of_IN continuing_VBG operations_NNS ._.
There_EX were_VBD no_DT material_NN differences_NNS between_IN reported_VBN profits_NNS and_CC losses_NNS and_CC historical_JJ cost_NN profits_NNS and_CC losses_NNS on_IN ordinary_JJ activities_NNS before_IN taxation_NN ._.
Group_NNP statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD $_$ m_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN 3,036_CD Foreign_NNP exchange_NN adjustments_NNS on_IN consolidation_NN 1,361_CD Tax_NNP on_IN foreign_JJ exchange_NN adjustments_NNS on_IN consolidation_NN 66_CD Translation_NN differences_NNS on_IN foreign_JJ currency_NN borrowings_NNS Tax_NNP on_IN translation_NN differences_NNS on_IN foreign_JJ currency_NN borrowings_NNS Total_JJ recognized_VBN gains_NNS and_CC losses_NNS relating_VBG to_TO the_DT financial_JJ year_NN 4,463_CD $_$ m_JJ means_NNS millions_NNS of_IN US_NNP dollars_NNS AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN 26_CD Group_NNP balance_NN sheet_NN at_IN 31_CD December_NNP 2003_CD 2002_CD $_$ m_CD $_$ m_CD Fixed_VBN assets_NNS Tangible_JJ fixed_VBN assets_NNS 7,536_CD 6,597_CD Goodwill_NNP and_CC intangible_JJ assets_NNS 2,884_CD 2,807_CD Fixed_VBN asset_NN investments_NNS 220_CD 46_CD 10,640_CD 9,450_CD Current_JJ assets_NNS Stocks_NNS 3,022_CD 2,593_CD Debtors_NNS 5,960_CD 4,845_CD Short_JJ term_NN investments_NNS 3,218_CD 3,962_CD Cash_NN 733_CD 726_CD 12,933_CD 12,126_CD Total_JJ assets_NNS 23,573_CD 21,576_CD Creditors_NNS due_JJ within_IN one_CD year_NN Short_JJ term_NN borrowings_NNS and_CC overdrafts_NNS 152_CD 202_CD Current_JJ instalments_NNS of_IN loans_NNS 314_CD Other_JJ creditors_NNS 7,543_CD 7,699_CD 7,695_CD 8,215_CD Net_JJ current_JJ assets_NNS 5,238_CD 3,911_CD Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 15,878_CD 13,361_CD Creditors_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN Loans_NNPS 303_CD 328_CD Other_JJ creditors_NNS 52 34 355 362_CD Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS 2,266_CD 1,773_CD Net_JJ assets_NNS 13,257_CD 11,226_CD Capital_NN and_CC reserves_NNS Called-up_JJ share_NN capital_NN 423_CD 429_CD Share_NN premium_NN account_NN 449_CD 403_CD Capital_NN redemption_NN reserve_NN 23_CD 16_CD Merger_NN reserve_NN 433_CD 433_CD Other_JJ reserves_NNS 1,401_CD 1,440_CD Profit_NN and_CC loss_NN account_NN 10,449_CD 8,451_CD Shareholders_NNS funds_NNS equity_NN interests_NNS 13,178_CD 11,172_CD Minority_NNP equity_NN interests_NNS 79_CD 54_CD Shareholders_NNS funds_NNS and_CC minority_NN interests_NNS 13,257_CD 11,226_CD The_DT summary_NN Financial_NNP Statements_NNP on_IN pages_NNS 24_CD to_TO 29_CD were_VBD approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS on_IN 29_CD January_NNP 2004_CD and_CC were_VBD signed_VBN on_IN its_PRP$ behalf_NN by_IN :_: Sir_NNP Tom_NNP McKillop_NNP Jonathan_NNP Symonds_NNP Director_NNP Director_NNP AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN 27_CD Statement_NN of_IN Group_NNP cash_NN flow_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD Cash_NN flow_NN from_IN operating_VBG activities_NNS Net_JJ cash_NN inflow_NN from_IN trading_NN operations_NNS 4,617_CD 5,686_CD 4,130_CD Outflow_NNP related_VBN to_TO exceptional_JJ items_NNS 391_CD 93_CD 368_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 4,226_CD 5,593_CD 3,762_CD Returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN Interest_NN received_VBD 117 142 232_CD Interest_NN paid_VBN 32_CD 96_CD 84_CD Dividends_NNS received_VBD 2_CD 8_CD Dividends_NNS paid_VBN by_IN subsidiaries_NNS to_TO minority_NN interests_NNS 11_CD 11_CD 76_CD 35_CD 156_CD Tax_NNP paid_VBD 886 795 792_CD Capital_NNP expenditure_NN and_CC financial_JJ investment_NN Cash_NN expenditure_NN on_IN tangible_JJ fixed_JJ assets_NNS 1,282_CD 1,340_CD 1,385_CD Cash_NN expenditure_NN on_IN intangible_JJ assets_NNS 233 268 197_CD Cash_NN expenditure_NN on_IN fixed_JJ asset_NN investments_NNS 120_CD 1_CD 5_CD Disposals_NNS of_IN fixed_JJ assets_NNS 38_CD 66_CD 44_CD 1,597_CD 1,543_CD 1,543_CD Acquisitions_NNS and_CC disposals_NNS Acquisitions_NNS of_IN subsidiaries_NNS and_CC purchases_NNS of_IN minority_NN interests_NNS 44_CD Disposals_NNS of_IN business_NN operations_NNS 80_CD 80_CD 44_CD Equity_NNP dividends_NNS paid_VBD to_TO shareholders_NNS 1,222_CD 1,234_CD 1,236_CD Net_JJ cash_NN inflow_NN before_IN management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN 677_CD 2,056_CD 303_CD Management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN Movement_NNP in_IN short_JJ term_NN investments_NNS and_CC fixed_VBN deposits_NNS net_JJ 771 806 260_CD Financing_NN 345_CD 118_CD 35_CD Net_JJ share_NN re-purchases_VBZ 1,107_CD 1,154_CD 994_CD Decrease_NN in_IN cash_NN in_IN the_DT year_NN 4_CD 22_CD 396_CD Cash_NN outflow_NN inflow_NN from_IN decrease_NN increase_NN in_IN loans_NNS and_CC short_JJ term_NN borrowings_NNS 345_CD 118_CD 35_CD Cash_NN outflow_NN inflow_NN from_IN increase_NN decrease_NN in_IN short_JJ term_NN investments_NNS 771 806 260_CD Change_NNP in_IN net_JJ funds_NNS resulting_VBG from_IN cash_NN flows_NNS 430 902 691_CD Exchange_NNP movements_NNS 82_CD 75_CD 47_CD Movement_NNP in_IN net_JJ funds_NNS 348 977 738_CD AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN 28_CD Dividends_NNPS 2003 2002 2001 2003_CD 2002_CD 2001_CD Per_IN Per_IN Per_IN Share_NN Share_NN Share_NN $_$ m_CD $_$ m_CD $_$ m_CD Interim_NNP ,_, paid_VBN on_IN 6_CD October_NNP 2003_CD $_$ 0.255_CD $_$ 0.23_CD $_$ 0.23_CD 436 398 405_CD Second_JJ interim_NN ,_, to_TO be_VB confirmed_VBN as_IN final_JJ ,_, payable_JJ 6_CD April_NNP 2004_CD $_$ 0.540_CD $_$ 0.47_CD $_$ 0.47_CD 914 808 820_CD $_$ 0.795_CD $_$ 0.70_CD $_$ 0.70_CD 1,350_CD 1,206_CD 1,225_CD Earnings_NNS per_IN share_NN 2003 2002 2001_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN before_IN exceptional_JJ items_NNS $_$ m_CD 3,036_CD 3,186_CD 3,044_CD Exceptional_JJ items_NNS after_IN tax_NN $_$ m_CD 350_CD 138_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN $_$ m_CD 3,036_CD 2,836_CD 2,906_CD Earnings_NNS per_IN Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS $_$ 1.78_CD $_$ 1.84_CD $_$ 1.73_CD Loss_NN per_IN Ordinary_NNP Share_NN on_IN exceptional_JJ items_NNS $_$ 0.20_CD $_$ 0.08_CD Earnings_NNS per_IN Ordinary_NNP Share_NNP $_$ 1.78_CD $_$ 1.64_CD $_$ 1.65_CD Diluted_VBN earnings_NNS per_IN Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS $_$ 1.78_CD $_$ 1.84_CD $_$ 1.73_CD Diluted_VBN loss_NN per_IN Ordinary_NNP Share_NN on_IN exceptional_JJ items_NNS $_$ 0.20_CD $_$ 0.08_CD Diluted_VBN earnings_NNS per_IN Ordinary_NNP Share_NNP $_$ 1.78_CD $_$ 1.64_CD $_$ 1.65_CD Weighted_VBN average_JJ number_NN of_IN Ordinary_NNP Shares_NNP in_IN issue_NN for_IN basic_JJ earnings_NNS millions_NNS 1,709_CD 1,733_CD 1,758_CD Dilutive_JJ impact_NN of_IN share_NN options_NNS outstanding_JJ millions_NNS 3_CD 23_CD Diluted_VBN average_JJ number_NN of_IN Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS 1,712_CD 1,735_CD 1,761_CD There_EX are_VBP no_DT options_NNS ,_, warrants_NNS or_CC rights_NNS outstanding_JJ in_IN respect_NN of_IN unissued_JJ shares_NNS except_IN for_IN employee_NN share_NN option_NN schemes_NNS ._.
The_DT earnings_NNS figures_NNS used_VBN in_IN the_DT calculations_NNS above_IN are_VBP unchanged_JJ for_IN diluted_JJ earnings_NNS per_IN Ordinary_NNP Share_NNP ._.
Earnings_NNS per_IN Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS have_VBP been_VBN calculated_VBN to_TO eliminate_VB the_DT impact_NN of_IN exceptional_JJ items_NNS on_IN the_DT results_NNS of_IN the_DT business_NN ._.
com_NN 29_CD Emoluments_NNS of_IN Directors_NNS The_DT aggregate_JJ remuneration_NN ,_, excluding_VBG pension_NN contributions_NNS ,_, paid_VBN to_TO or_CC accrued_VBN for_IN all_DT Directors_NNS and_CC officers_NNS of_IN the_DT Company_NN for_IN services_NNS in_IN all_DT capacities_NNS during_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD was_VBD 11_CD million_CD $_$ 18_CD million_CD including_VBG 250,000_CD $_$ 403,000_CD to_TO the_DT Chairman_NNP ._.
Remuneration_NNP of_IN individual_JJ Directors_NNS is_VBZ set_VBN out_RP below_IN in_IN sterling_NN and_CC US_NNP dollars_NNS ._.
Among_IN those_DT Directors_NNS who_WP receive_VBP their_PRP$ remuneration_NN in_IN sterling_NN are_VBP the_DT Chairman_NNP ,_, the_DT Non-Executive_NNP Deputy_NNP Chairman_NNP ,_, the_DT senior_JJ Non-Executive_NNP Director_NNP ,_, the_DT Chief_NNP Executive_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP ._.
Salary_NNP Taxable_NNP Total_NNP Total_NNP Total_NNP and_CC fees_NNS Bonuses_NNS benefits_NNS Other_JJ 2003 2002 2001_CD Sterling_NN 000 000 000 000_CD 000 000 000_CD Percy_NNP Barnevik_NNP 250 250 250 250_CD Hkan_NNP Mogren_NNP 461_CD 450_CD 51_CD 284_CD 1,246_CD 1,347_CD 1,104_CD Sir_NNP Tom_NNP McKillop_NNP 885_CD 860_CD 1_CD 44_CD 1,790_CD 1,479_CD 1,304_CD Jonathan_NNP Symonds_NNPS 534_CD 451_CD 6_CD 80_CD 1,071_CD 909_CD 815_CD Sir_NNP Peter_NNP Bonfield_NNP 74_CD 74_CD 46_CD 38_CD John_NNP Buchanan_NNP 53_CD 53_CD 33_CD Jane_NNP Henney_NNP 49_CD 49_CD 60_CD 9_CD Karl_NNP von_NNP der_NN Heyden_NNP 55_CD 55_CD 47_CD 41_CD Michele_NNP Hooper_NNP 19_CD 19_CD Joe_NNP Jimenez_NNP 19_CD 19_CD Erna_NNP Mller49_NNP 49_CD 62_CD 55_CD Dame_NNP Bridget_NNP Ogilvie_NNP 49_CD 49_CD 62_CD 55_CD Marcus_NNP Wallenberg_NNP 46_CD 46_CD 42_CD 38_CD Former_JJ Directors_NNS ke_VBP Stavling_VBG 81_CD 6_CD 402 489 835 712_CD Others_NNS 621_CD 702_CD Total_JJ 2,624_CD 1,761_CD 64_CD 810_CD 5,259_CD 5,793_CD 5,123_CD Relates_VBZ to_TO relocation_NN allowances_NNS :_: Payment_NN for_IN pension_NN related_VBN tax_NN liabilities_NNS :_: Includes_VBZ settlement_NN on_IN retirement_NN of_IN accrued_VBN holiday_NN entitlement_NN :_: Includes_VBZ provision_NN for_IN accommodation_NN in_IN the_DT UK_NNP :_: Compensation_NNP payment_NN and_CC for_IN accommodation_NN related_VBN tax_NN liabilities_NNS :_: Part_NN year_NN only_RB ._.
Salary_NNP Taxable_NNP Total_NNP Total_NNP Total_NNP and_CC fees_NNS Bonuses_NNS benefits_NNS Other_JJ 2003 2002 2001_CD US_NNP dollars_NNS $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Percy_NNP Barnevik_NNP 403 403 373 368_CD Hkan_NNP Mogren_NNP 743_CD 725_CD 82_CD 458_CD 2,008_CD 2,010_CD 1,623_CD Sir_NNP Tom_NNP McKillop_NNP 1,427_CD 1,387_CD 1_CD 71_CD 2,886_CD 2,208_CD 1,918_CD Jonathan_NNP Symonds_NNPS 861_CD 727_CD 9_CD 129_CD 1,726_CD 1,357_CD 1,199_CD Sir_NNP Peter_NNP Bonfield_NNP 119_CD 119_CD 68_CD 56_CD John_NNP Buchanan_NNP 86_CD 86_CD 49_CD Jane_NNP Henney_NNP 79_CD 79_CD 90_CD 13_CD Karl_NNP von_NNP der_NN Heyden_NNP 89_CD 89_CD 70_CD 60_CD Michele_NNP Hooper_NNP 31_CD 31_CD Joe_NNP Jimenez_NNP 31_CD 31_CD Erna_NNP Mller79_NNP 79_CD 93_CD 81_CD Dame_NNP Bridget_NNP Ogilvie_NNP 79_CD 79_CD 93_CD 81_CD Marcus_NNP Wallenberg_NNP 74_CD 74_CD 63_CD 56_CD Former_JJ Directors_NNS ke_VBP Stavling_VBG 131_CD 9_CD 648_CD 788_CD 1,246_CD 1,047_CD Others_NNS 927_CD 1,032_CD Total_JJ 4,232_CD 2,839_CD 101_CD 1,306_CD 8,478_CD 8,647_CD 7,534_CD Relates_VBZ to_TO relocation_NN allowances_NNS :_: Payment_NN for_IN pension_NN related_VBN tax_NN liabilities_NNS :_: Includes_VBZ settlement_NN on_IN retirement_NN of_IN accrued_VBN holiday_NN entitlement_NN :_: Includes_VBZ provision_NN for_IN accommodation_NN in_IN the_DT UK_NNP :_: Compensation_NNP payment_NN and_CC for_IN accommodation_NN related_VBN tax_NN liabilities_NNS :_: Part_NN year_NN only_RB ._.
Compensation_NNP payments_NNS to_TO Hkan_NNP Mogren_NNP and_CC ke_NNP Stavling_NNP were_VBD 225,000_CD $_$ 363,000_CD and_CC 399,000_CD $_$ 643,000_CD respectively_RB and_CC are_VBP included_VBN within_IN Other_JJ in_IN the_DT above_JJ tables_NNS ._.
com_NN 30_CD Group_NNP financial_JJ record_NN For_IN the_DT years_NNS ended_VBN 31_CD December_NNP 1999 2000 2001 2002_CD 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Turnover_NN and_CC profits_NNS Group_NNP turnover_NN 18,257_CD 17,882_CD 16,222_CD 17,841_CD 18,849_CD Cost_NN of_IN sales_NNS 5,849_CD 5,270_CD 4,232_CD 4,520_CD 4,469_CD Distribution_NN costs_NNS 343 286 122 141_CD 162_CD Research_NNP and_CC development_NN 2,923_CD 2,893_CD 2,773_CD 3,069_CD 3,451_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenses_NNS 6,585_CD 5,691_CD 5,509_CD 6,348_CD 6,856_CD Other_JJ income_NN 189 266 368 243_CD 200_CD Group_NNP operating_NN profit_NN 2,746_CD 4,008_CD 3,954_CD 4,006_CD 4,111_CD Group_NNP operating_NN profit_NN before_IN exceptional_JJ items_NNS 3,908_CD 4,330_CD 4,156_CD 4,356_CD 4,111_CD Exceptional_JJ items_NNS charged_VBN to_TO operating_VBG profit_NN 1,162_CD 322 202 350_CD Share_NN of_IN operating_NN profit_NN of_IN joint_JJ ventures_NNS and_CC associates_NNS 7_CD 149_CD Exceptional_JJ items_NNS 776_CD 150_CD Profits_NNS on_IN sale_NN of_IN fixed_JJ assets_NNS 10_CD Dividend_NN income_NN 3_CD 8_CD 1_CD 2_CD Net_JJ interest_NN 4_CD 135_CD 105_CD 30_CD 89_CD Profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 1,959_CD 3,847_CD 4,077_CD 4,037_CD 4,202_CD Taxation_NNP 661_CD 1,560_CD 1,160_CD 1,177_CD 1,143_CD Profit_NN on_IN ordinary_JJ activities_NNS after_IN taxation_NN 1,298_CD 2,287_CD 2,917_CD 2,860_CD 3,059_CD Attributable_JJ to_TO minorities_NNS 1_CD 10_CD 11_CD 24_CD 23_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN 1,297_CD 2,277_CD 2,906_CD 2,836_CD 3,036_CD Return_NN on_IN sales_NNS Group_NNP operating_NN profit_NN before_IN exceptional_JJ items_NNS as_IN a_DT percentage_NN of_IN sales_NNS 21.4_CD %_NN 24.2_CD %_NN 25.6_CD %_NN 24.4_CD %_NN 21.8_CD %_NN Ratio_NN of_IN earnings_NNS to_TO fixed_JJ charges_NNS UK_NNP GAAP_NNP 10.1_CD 25.2_CD 42.8_CD 45.6_CD 103.5_CD At_IN 31_CD December_NNP 1999 2000 2001 2002_CD 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Balance_NN sheet_NN Fixed_VBN assets_NNS tangible_JJ and_CC intangible_JJ and_CC goodwill_NN 9,717_CD 7,908_CD 8,109_CD 9,404_CD 10,420_CD Fixed_VBN asset_NN investments_NNS 185_CD 11_CD 23_CD 46_CD 220_CD Current_JJ assets_NNS 10,393_CD 10,938_CD 10,364_CD 12,126_CD 12,933_CD Total_JJ assets_NNS 20,295_CD 18,857_CD 18,496_CD 21,576_CD 23,573_CD Creditors_NNS due_JJ within_IN one_CD year_NN 7,019_CD 6,897_CD 6,480_CD 8,215_CD 7,695_CD Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 13,276_CD 11,960_CD 12,016_CD 13,361_CD 15,878_CD Creditors_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN 1,202_CD 927 787 362 355_CD Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS 1,765_CD 1,617_CD 1,600_CD 1,773_CD 2,266_CD Minority_NNP equity_NN interests_NNS 46_CD 27_CD 43_CD 54_CD 79_CD Shareholders_NNS funds_NNS equity_NN interests_NNS 10,263_CD 9,389_CD 9,586_CD 11,172_CD 13,178_CD Shareholders_NNS funds_NNS and_CC minority_NN interests_NNS 10,309_CD 9,416_CD 9,629_CD 11,226_CD 13,257_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP 1999 2000 2001 2002_CD 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Cash_NN flow_NN Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 3,113_CD 4,183_CD 3,762_CD 5,593_CD 4,226_CD Dividends_NNS received_VBN from_IN joint_JJ ventures_NNS and_CC associates_NNS 3_CD Returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN 29_CD 19_CD 156_CD 35_CD 76_CD Tax_NNP paid_VBD 1,020_CD 648 792 795 886_CD Capital_NN expenditure_NN and_CC financial_JJ investment_NN 2,731_CD 1,426_CD 1,543_CD 1,543_CD 1,597_CD Acquisitions_NNS and_CC disposals_NNS 1,978_CD 740_CD 44_CD 80_CD Equity_NNP dividends_NNS paid_VBD to_TO shareholders_NNS 1,216_CD 1,220_CD 1,236_CD 1,234_CD 1,222_CD Net_JJ cash_NN inflow_NN before_IN management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN 156_CD 1,648_CD 303_CD 2,056_CD 677_CD AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
In_IN addition_NN ,_, shareholders_NNS received_VBD a_DT distribution_NN of_IN shares_NNS in_IN Syngenta_NNP AG_NNP as_IN a_DT dividend_NN in_IN specie_NN in_IN respect_NN of_IN the_DT demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS ._.
Zeneca_NNP 1999_CD Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS At_IN period_NN end_NN 953_CD Weighted_JJ average_NN for_IN period_NN 951_CD Stock_NNP market_NN price_NN per_IN 25_CD pence_NN Ordinary_NNP Share_NNP Highest_NNP pence_NN 3037_CD Lowest_NNP pence_NN 2406_CD At_IN period_NN end_NN pence_NN 3037_CD For_IN the_DT period_NN from_IN 1_CD January_NNP 1999_CD to_TO 6_CD April_NNP 1999_CD Astra_NNP 1999_CD Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS At_IN period_NN end_NN 1,643_CD Weighted_VBN average_NN for_IN period_NN 1,643_CD Stock_NNP market_NN price_NN per_IN Astra_NNP A_NNP Share_NNP Highest_NNP SEK_NNP 190_CD Lowest_NNP SEK_NNP 154_CD At_IN period_NN end_NN SEK_NNP 190_CD Stock_NNP market_NN price_NN per_IN Astra_NNP B_NNP Share_NNP Highest_NNP SEK_NNP 190_CD Lowest_NNP SEK_NNP 154_CD At_IN period_NN end_NN SEK_NNP 190_CD For_IN the_DT period_NN from_IN 1_CD January_NNP 1999_CD to_TO 6_CD April_NNP 1999_CD AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN 32_CD Shareholder_NN information_NN Percentage_NN analysis_NN at_IN 31_CD December_NNP 2003_CD of_IN issued_VBN share_NN capital_NN By_IN size_NN of_IN account_NN 2003_CD No._NN ._.
In_IN addition_NN ,_, there_EX were_VBD approximately_RB 41,000_CD holders_NNS of_IN American_JJ Depositary_NNP Receipts_NNPS ADRs_NNPS representing_VBG 7.53_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN and_CC 161,000_CD holders_NNS of_IN shares_NNS held_VBN under_IN the_DT VPC_NNP Services_NNPS Agreement_NNP representing_VBG 22.13_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN ._.
The_DT ADRs_NNPS ,_, each_DT of_IN which_WDT is_VBZ equivalent_JJ to_TO one_CD Ordinary_NNP Share_NN ,_, are_VBP issued_VBN by_IN JPMorgan_NNP Chase_NNP Bank_NNP ._.
AstraZenecas_RB largest_JJS shareholders_NNS Percentage_NN of_IN issued_VBN Shareholder_NN Number_NN of_IN shares_NNS share_VBP capital_NN The_DT Capital_NNP Group_NNP Companies_NNS ,_, Inc._NNP 254,143,676_CD 15.01_CD %_NN Investor_NN AB_NNP 91,545,308_CD 5.41_CD %_NN Putnam_NNP Investment_NNP Management_NNP ,_, LLC_NNP and_CC The_DT Putnam_NNP Advisory_NNP Company_NNP ,_, LLC_NNP 52,643,485_CD 3.11_CD %_NN Legal_NNP &_CC General_NNP Investment_NNP Management_NNP Limited_NNP 52,518,020_CD 3.10_CD %_NN Financial_JJ calendar_NN 2004_CD 29_CD April_NNP 2004_CD Annual_JJ General_NNP Meeting_VBG and_CC announcement_NN of_IN first_JJ quarter_NN 2004_CD results_NNS 22_CD July_NNP 2004_CD Announcement_NN of_IN second_JJ quarter_NN and_CC half_DT year_NN 2004_CD results_NNS 13_CD August_NNP 2004_CD Record_NNP date_NN for_IN first_JJ interim_JJ dividend_NN 2004_CD 20_CD September_NNP 2004_CD First_NNP interim_JJ dividend_NN payment_NN date_NN Dividend_NN payments_NNS The_DT record_NN date_NN for_IN the_DT second_JJ interim_JJ dividend_NN for_IN 2003_CD payable_JJ on_IN 6_CD April_NNP 2004_CD in_IN the_DT UK_NNP ,_, the_DT US_NNP and_CC Sweden_NNP is_VBZ 20_CD February_NNP 2004_CD ._.
Shares_NNP trade_NN ex-dividend_NN on_IN the_DT London_NNP and_CC Stockholm_NNP Stock_NNP Exchanges_NNPS from_IN 18_CD February_NNP 2004_CD and_CC ADRs_NNPS trade_NN ex-dividend_NN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP from_IN the_DT same_JJ date_NN ._.
From_IN 2004_CD ,_, dividends_NNS will_MD normally_RB be_VB paid_VBN as_IN follows_VBZ :_: First_NNP interim_JJ :_: Announced_JJ end_NN of_IN July_NNP and_CC paid_VBN in_IN September_NNP Second_NNP interim_NN :_: Announced_JJ end_NN of_IN January_NNP and_CC paid_VBN in_IN March_NNP The_NNP record_NN date_NN for_IN the_DT first_JJ interim_JJ dividend_NN for_IN 2004_CD payable_JJ on_IN 20_CD September_NNP 2004_CD in_IN the_DT UK_NNP ,_, the_DT US_NNP and_CC Sweden_NNP is_VBZ 13_CD August_NNP 2004_CD ._.
2003_CD dividend_NN $_$ pence_NN SEK_NNP Payment_NN date_NN First_NNP interim_JJ dividend_NN 0.255_CD 15.9_CD 2.07_CD 6_CD October_NNP 2003_CD Second_JJ interim_JJ dividend_NN 0.540_CD 29.4_CD 3.91_CD 6_CD April_NNP 2004_CD Total_JJ dividend_NN 0.795_CD 45.3_CD 5.98_CD AstraZeneca_NNP Annual_JJ Review_NNP 2003_CD astrazeneca_NN ._.
com_NN Shareview_NNP The_NNP contents_NNS of_IN this_DT AstraZeneca_NNP Annual_JJ Review_NNP are_VBP derived_VBN wholly_RB and_CC exclusively_RB from_IN the_DT AstraZenecas_NNP shareholders_NNS with_IN internet_NN AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ access_NN may_MD visit_VB www_NN ._.
co._JJ uk_NN and_CC Information_NN for_IN the_DT financial_JJ year_NN ended_VBD register_VB their_PRP$ details_NNS to_TO create_VB a_DT portfolio_NN ._.
31_CD December_NNP 2003_CD ,_, to_TO which_WDT the_DT reader_NN is_VBZ referred_VBN for_IN additional_JJ analytical_JJ information_NN ._.
Shareview_NNP is_VBZ a_DT free_JJ and_CC secure_JJ on-line_JJ service_NN from_IN Lloyds_NNP TSB_NNP Registrars_NNPS that_WDT Trade_NNP marks_NNS gives_VBZ access_NN to_TO shareholdings_NNS including_VBG Trade_NNP marks_NNS of_IN the_DT AstraZeneca_NNP group_NN of_IN companies_NNS appear_VBP throughout_IN this_DT document_NN in_IN balance_NN movements_NNS ,_, indicative_JJ share_NN prices_NNS italics_NNS ._.
AstraZeneca_NNP ,_, the_DT AstraZeneca_NNP logotype_NN and_CC information_NN about_IN recent_JJ dividends_NNS ._.
and_CC the_DT AstraZeneca_NNP symbol_NN are_VBP all_DT trade_NN marks_NNS of_IN the_DT AstraZeneca_NNP group_NN of_IN companies_NNS ._.
ShareGift_NNP Use_NNP of_IN terms_NNS AstraZeneca_NNP welcomes_VBZ and_CC values_VBZ all_DT its_PRP$ In_IN this_DT Annual_JJ Review_NNP 2003_CD ,_, unless_IN the_DT context_NN shareholders_NNS ,_, no_DT matter_NN how_WRB many_JJ or_CC how_WRB otherwise_RB requires_VBZ ,_, AstraZeneca_NNP ,_, the_DT Group_NNP ,_, the_DT Company_NN ,_, we_PRP ,_, us_PRP and_CC our_PRP$ refer_VBP to_TO few_JJ shares_NNS they_PRP own_VBP ._.
However_RB ,_, AstraZeneca_NNP PLC_NNP and_CC its_PRP$ consolidated_JJ entities_NNS ._.
shareholders_NNS who_WP have_VBP only_RB a_DT small_JJ number_NN of_IN shares_NNS whose_WP$ value_NN makes_VBZ it_PRP Cautionary_JJ statement_NN regarding_VBG forwardlooking_VBG statements_NNS uneconomic_JJ to_TO sell_VB them_PRP ,_, either_RB now_RB or_CC at_IN In_IN order_NN to_TO utilise_VB the_DT safe_JJ harbor_NN provisions_NNS of_IN some_DT stage_NN in_IN the_DT future_NN ,_, may_MD wish_VB to_TO the_DT US_NNP Private_NNP Securities_NNP Litigation_NNP Reform_NNP Act_NNP consider_VBP donating_VBG them_PRP to_TO charity_NN through_IN 1995_CD ,_, we_PRP are_VBP providing_VBG the_DT following_VBG cautionary_JJ statement_NN :_: This_DT Annual_JJ Review_NNP 2003_CD contains_VBZ ShareGift_NNP ,_, an_DT independent_JJ charity_NN share_NN certain_JJ forward-looking_JJ statements_NNS about_IN donation_NN scheme_NN ._.
One_CD of_IN the_DT advantages_NNS of_IN AstraZeneca_NNP ._.
Although_IN we_PRP believe_VBP our_PRP$ expectations_NNS the_DT scheme_NN is_VBZ that_IN there_EX is_VBZ no_DT gain_NN or_CC loss_NN are_VBP based_VBN on_IN reasonable_JJ assumptions_NNS ,_, any_DT forward-looking_JJ statements_NNS may_MD be_VB influenced_VBN by_IN for_IN capital_NN gains_NNS tax_NN purposes_NNS on_IN gifts_NNS of_IN factors_NNS that_WDT could_MD cause_VB actual_JJ outcomes_NNS and_CC shares_NNS through_IN ShareGift_NNP and_CC it_PRP may_MD now_RB results_VBZ to_TO be_VB materially_RB different_JJ from_IN those_DT also_RB be_VB possible_JJ to_TO obtain_VB income_NN tax_NN relief_NN predicted_VBD ._.
We_PRP identify_VBP the_DT forward-looking_JJ statements_NNS by_IN using_VBG the_DT words_NNS anticipates_VBZ ,_, on_IN the_DT donation_NN ._.
Further_JJ information_NN about_IN believes_VBZ ,_, expects_VBZ ,_, intends_VBZ and_CC similar_JJ ShareGift_NNP can_MD be_VB found_VBN on_IN its_PRP$ website_NN ,_, expressions_NNS in_IN such_JJ statements_NNS ._.
org_NN ,_, or_CC by_IN contacting_VBG looking_VBG statements_NNS are_VBP subject_JJ to_TO numerous_JJ risks_NNS and_CC uncertainties_NNS ._.
Important_JJ factors_NNS that_WDT could_MD ShareGift_VB on_IN 020 7337 0501_CD or_CC at_IN 46_CD cause_NN actual_JJ results_NNS to_TO differ_VB materially_RB from_IN those_DT Grosvenor_NNP Street_NNP ,_, London_NNP W1K_NNP 3HN_NNP ._.
More_RBR contained_VBN in_IN forward-looking_JJ statements_NNS ,_, certain_JJ information_NN about_IN the_DT tax_NN position_NN on_IN gifts_NNS of_IN of_IN which_WDT are_VBP beyond_IN our_PRP$ control_NN ,_, include_VBP ,_, among_IN other_JJ things_NNS :_: the_DT loss_NN or_CC expiration_NN of_IN patents_NNS ,_, shares_NNS to_TO ShareGift_NNP can_MD be_VB obtained_VBN from_IN marketing_NN exclusivity_NN or_CC trade_NN marks_NNS :_: exchange_NN the_DT Inland_NNP Revenue_NN whose_WP$ website_JJ address_NN rate_NN fluctuations_NNS :_: the_DT risk_NN that_IN R&D_NNP will_MD not_RB yield_VB is_VBZ www_VB ._.
The_DT share_NN new_JJ products_NNS that_WDT achieve_VBP commercial_JJ success_NN :_: the_DT impact_NN of_IN competition_NN ,_, price_NN controls_NNS and_CC transfer_VB form_NN needed_VBN to_TO make_VB a_DT donation_NN price_NN reductions_NNS :_: taxation_NN risks_NNS :_: the_DT risk_NN of_IN may_MD be_VB obtained_VBN from_IN the_DT AstraZeneca_NNP substantial_JJ product_NN liability_NN claims_NNS :_: the_DT impact_NN of_IN Registrar_NNP ,_, Lloyds_NNP TSB_NNP Registrars_NNPS whose_WP$ any_DT failure_NN by_IN third_JJ parties_NNS to_TO supply_VB materials_NNS or_CC services_NNS :_: the_DT risk_NN of_IN delay_NN to_TO new_JJ product_NN address_NN can_MD be_VB found_VBN on_IN the_DT back_JJ cover_NN of_IN launches_NNS :_: the_DT difficulties_NNS of_IN obtaining_VBG and_CC this_DT document_NN ._.
ShareGift_NNP is_VBZ administered_VBN by_IN maintaining_VBG governmental_JJ approvals_NNS for_IN The_DT Orr_NNP Mackintosh_NNP Foundation_NNP ,_, registered_VBD products_NNS :_: and_CC the_DT risk_NN of_IN environmental_JJ liabilities_NNS ._.
Statements_NNS of_IN competitive_JJ position_NN Except_IN as_IN otherwise_RB stated_VBN ,_, market_NN information_NN in_IN The_DT Unclaimed_NNP Assets_NNPS Register_NNP this_DT Annual_JJ Review_NNP 2003_CD regarding_VBG the_DT position_NN of_IN our_PRP$ business_NN or_CC products_NNS relative_JJ to_TO its_PRP$ or_CC their_PRP$ AstraZeneca_NNP supplies_NNS unclaimed_JJ dividend_NN competition_NN is_VBZ based_VBN upon_IN published_VBN statistical_JJ data_NNS to_TO the_DT Unclaimed_NNP Assets_NNPS Register_NNP data_NNS for_IN the_DT 12_CD months_NNS ended_VBD 30_CD September_NNP UAR_NNP which_WDT provides_VBZ investors_NNS who_WP have_VBP 2003_CD ,_, or_CC the_DT month_NN of_IN November_NNP 2003_CD ,_, obtained_VBN from_IN IMS_NNP Health_NNP ,_, a_DT leading_VBG supplier_NN of_IN statistical_JJ lost_VBN track_NN of_IN shareholdings_NNS with_IN an_DT data_NN to_TO the_DT pharmaceutical_JJ industry_NN ._.
Except_IN as_IN opportunity_NN to_TO search_VB the_DT UARs_NNS database_NN otherwise_RB stated_VBD ,_, this_DT market_NN share_NN and_CC industry_NN of_IN unclaimed_JJ financial_JJ assets_NNS on_IN payment_NN of_IN data_NNS from_IN IMS_NNP Health_NNP has_VBZ been_VBN derived_VBN by_IN comparing_VBG our_PRP$ sales_NNS revenue_NN to_TO competitors_NNS and_CC a_DT small_JJ ,_, fixed_JJ fee_NN ._.
The_DT UAR_NNP donates_VBZ part_NN of_IN total_JJ market_NN sales_NNS revenues_NNS for_IN that_DT period_NN ._.
the_DT search_NN fee_NN to_TO charity_NN ._.
The_DT UAR_NNP can_MD be_VB contacted_VBN at_IN Leconfield_NNP House_NNP ,_, Curzon_NNP Statements_NNP of_IN growth_NN rates_NNS Except_IN as_IN otherwise_RB stated_VBN ,_, growth_NN rates_NNS in_IN this_DT Street_NNP ,_, London_NNP W1J_NNP 5JA_NNP and_CC at_IN Annual_JJ Review_NNP 2003_CD are_VBP given_VBN at_IN constant_JJ www_NN ._.
AstraZeneca_NNP website_JJ Information_NN on_IN our_PRP$ website_NN ,_, astrazeneca_NN ._.
com_NN ,_, does_VBZ not_RB form_VB part_NN of_IN this_DT document_NN ._.
AstraZeneca_NNP PLC_NNP 2004_CD Designed_VBN by_IN Addison_NNP Corporate_NNP Marketing_NNP Ltd_NNP astrazeneca_NN ._.
com_NN Contact_NN information_NN Registered_NNP office_NN Registrar_NNP and_CC transfer_VB office_NN :_: and_CC corporate_JJ headquarters_NNS address_NN :_: Lloyds_NNP TSB_NNP Registrars_NNPS AstraZeneca_NNP PLC_NNP The_NNP Causeway_NNP 15_CD Stanhope_NNP Gate_NNP Worthing_NNP London_NNP W1K_NNP 1LN_NNP West_NNP Sussex_NNP UK_NNP BN99_NNP 6DA_NNP Tel_NNP :_: 44_CD 0_CD 20 7304 5000_CD UK_NNP Fax_NNP :_: 44_CD 0_CD 20 7304 5183_CD Tel_NNP in_IN the_DT UK_NNP :_: 0870 600 3956_CD Tel_NNP outside_IN the_DT UK_NNP :_: 44_CD 0_CD 121 415 7033_CD R&D_NNP headquarters_NN address_NN :_: AstraZeneca_NNP AB_NNP Swedish_NNP securities_NNS registration_NN center_NN :_: R&D_NNP Headquarters_NNP VPC_NNP AB_NNP SE-151_NNP 85_CD Sdertlje_NNP PO_NNP Box_NNP 7822_CD Sweden_NNP SE-103_NNP 97_CD Stockholm_NNP Tel_NNP :_: 46_CD 0_CD 8_CD 553_CD 260_CD 00_CD Sweden_NNP Fax_NNP :_: 46_CD 0_CD 8_CD 553_CD 290_CD 00_CD Tel_NNP :_: 46_CD 0_CD 8_CD 402_CD 9000_CD Investor_NNP relations_NNS contacts_NNS :_: US_NNP depositary_NN :_: UK_NNP and_CC Sweden_NNP :_: As_IN above_IN or_CC e-mail_VB :_: JPMorgan_NNP Chase_NNP Bank_NNP IR@astrazeneca_NNP ._.
com_NN PO_NNP Box_NNP 43013_CD US_NNP :_: Providence_NNP Investor_NNP Relations_NNP RI_NNP 02940-3013_CD AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP US_NNP 1800_CD Concord_NNP Pike_NNP Tel_NNP toll_NN free_JJ in_IN the_DT US_NNP :_: 888 697 8018_CD PO_NNP Box_NNP 15438_CD Tel_NNP :_: 1_CD 781 575 4328_CD Wilmington_NNP fide_NN 19850-5438_CD US_NNP Tel_NNP :_: 1_CD 302 886 3000_CD Fax_NNP :_: 1_CD 302 886 2972_CD Delivering_VBG our_PRP$ values_NNS Corporate_JJ Responsibility_NN Summary_NNP Report_NNP 2003_CD AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN At_IN the_DT heart_NN of_IN our_PRP$ commitment_NN to_TO corporate_JJ responsibility_NN are_VBP AstraZenecas_NNP core_NN values_NNS ._.
Our_PRP$ continuing_VBG challenge_NN is_VBZ to_TO ensure_VB that_IN these_DT high_JJ level_NN values_NNS are_VBP translated_VBN into_IN consistent_JJ and_CC appropriate_JJ actions_NNS and_CC behavior_NN worldwide_NN ._.
This_DT Summary_NNP Report_NNP is_VBZ designed_VBN to_TO capture_VB the_DT main_JJ points_NNS of_IN our_PRP$ approach_NN to_TO managing_VBG this_DT challenge_NN and_CC to_TO present_VB a_DT brief_JJ overview_NN of_IN our_PRP$ 2003_CD performance_NN in_IN the_DT three_CD areas_NNS of_IN sustainable_JJ development_NN :_: economic_JJ ,_, environmental_JJ and_CC social_JJ responsibility_NN ._.
Detailed_JJ statistics_NNS and_CC further_JJ information_NN about_IN our_PRP$ policies_NNS ,_, principles_NNS and_CC commitment_NN are_VBP provided_VBN on_IN our_PRP$ website_NN ,_, astrazeneca_NN ._.
com_NN ,_, which_WDT also_RB provides_VBZ a_DT feedback_NN facility_NN ._.
AstraZeneca_NNP core_NN values_NNS :_: Integrity_NN and_CC high_JJ ethical_JJ standards_NNS Respect_NN for_IN the_DT individual_JJ and_CC diversity_NN Openness_NN ,_, honesty_NN ,_, trust_NN and_CC support_NN for_IN each_DT other_JJ Leadership_NN by_IN example_NN at_IN all_DT levels_NNS Chief_NNP Executives_NNS message_NN 01_CD AstraZeneca_NNP in_IN brief_JJ One_CD of_IN the_DT worlds_NNS leading_VBG pharmaceutical_JJ companies_NNS Our_PRP$ commitment_NN 02_CD Turns_VBZ ideas_NNS into_IN innovative_JJ ,_, effective_JJ medicines_NNS for_IN Our_PRP$ goals_NNS 04_CD important_JJ areas_NNS of_IN healthcare_NN Economic_NNP performance_NN 06_CD Powerful_JJ product_NN range_NN including_VBG many_JJ world_NN leaders_NNS Environmental_JJ performance_NN 08_CD Spends_VBZ over_IN $_$ 14_CD million_CD each_DT working_VBG day_NN on_IN research_NN and_CC development_NN Social_NNP performance_NN 10_CD Corporate_JJ HQ_NNP London_NNP ,_, UK_NNP :_: R&D_NNP HQ_NNP Sdertlje_NNP ,_, Performance_NNP summary_NN 16_CD Sweden_NNP :_: strong_JJ presence_NN in_IN key_JJ US_NNP market_NN Sales_NNS in_IN over_IN 100_CD countries_NNS Manufacturing_NNP in_IN 20_CD countries_NNS Research_NNP in_IN 7_CD countries_NNS Over_IN 60,000_CD employees_NNS worldwide_JJ AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN 01_CD Chief_NNP Executives_NNS message_NN Respect_NN for_IN the_DT individual_JJ and_CC diversity_NN of_IN appropriate_JJ programs_NNS in_IN their_PRP$ areas_NNS We_PRP value_VBP the_DT different_JJ backgrounds_NNS and_CC of_IN responsibility_NN ._.
An_DT important_JJ step_NN in_IN skills_NNS that_WDT our_PRP$ global_JJ workforce_NN brings_VBZ to_TO 2003_CD was_VBD the_DT inclusion_NN in_IN our_PRP$ annual_JJ our_PRP$ business_NN and_CC are_VBP committed_VBN to_TO compliance_NN report_NN by_IN senior_JJ management_NN ensuring_VBG that_IN diversity_NN is_VBZ appropriately_RB to_TO the_DT AstraZeneca_NNP Board_NNP the_DT letter_NN of_IN supported_VBN in_IN the_DT workplace_NN at_IN all_DT levels_NNS ._.
assurance_NN of_IN a_DT requirement_NN to_TO develop_VB At_IN the_DT end_NN of_IN 2003_CD ,_, we_PRP had_VBD around_IN 28_CD local_JJ CR_NNP implementation_NN plans_NNS ._.
diversity_NN programs_NNS in_IN place_NN within_IN the_DT Group_NNP and_CC a_DT number_NN of_IN awareness_NN Our_PRP$ business_NN is_VBZ focused_VBN on_IN the_DT discovery_NN raising_VBG initiatives_NNS took_VBD place_NN during_IN the_DT and_CC development_NN of_IN life-saving_NN and_CC year_NN ,_, mainly_RB within_IN R&D_NNP and_CC our_PRP$ US_NNP life-enhancing_NN medicines_NNS ._.
Historically_NNP ,_, Our_PRP$ reputation_NN is_VBZ built_VBN on_IN the_DT trust_NN and_CC business_NN ._.
Further_JJ work_NN is_VBZ needed_VBN to_TO the_DT markets_NNS for_IN these_DT therapies_NNS have_VBP confidence_NN of_IN all_DT our_PRP$ stakeholders_NNS and_CC ensure_VB that_IN the_DT benefits_NNS of_IN diversity_NN are_VBP been_VBN in_IN developed_JJ countries_NNS but_CC as_IN the_DT is_VBZ one_CD of_IN AstraZenecas_NNP most_RBS valuable_JJ fully_RB recognized_VBN across_IN the_DT Group_NNP ._.
economies_NNS of_IN developing_VBG countries_NNS assets_NNS ._.
Along_IN with_IN our_PRP$ commitment_NN grow_VB ,_, new_JJ markets_NNS for_IN our_PRP$ prescription_NN to_TO competitiveness_NN and_CC performance_NN ,_, Openness_NN ,_, honesty_NN ,_, trust_NN and_CC support_NN medicines_NNS emerge_VBP ._.
Our_PRP$ strategy_NN for_IN we_PRP will_MD continue_VB to_TO be_VB led_VBN by_IN our_PRP$ core_NN for_IN each_DT other_JJ expansion_NN in_IN these_DT emerging_VBG markets_NNS is_VBZ values_NNS to_TO achieve_VB sustainable_JJ success_NN ._.
Our_PRP$ Code_NNP of_IN Conduct_NNP has_VBZ been_VBN revised_VBN designed_VBN to_TO ensure_VB that_IN through_IN timely_JJ and_CC re-published_JJ during_IN the_DT year_NN and_CC a_DT investment_NN ,_, we_PRP are_VBP well_RB placed_VBN to_TO meet_VB Stakeholder_NNP expectations_NNS are_VBP constantly_RB formal_JJ ,_, confidential_JJ helpline_NN procedure_NN the_DT needs_NNS of_IN patients_NNS in_IN these_DT countries_NNS ._.
evolving_VBG and_CC we_PRP continuously_RB monitor_VBP our_PRP$ is_VBZ now_RB in_IN place_NN for_IN employees_NNS wishing_VBG As_IN part_NN of_IN this_DT ,_, we_PRP are_VBP committed_VBN to_TO internal_JJ and_CC external_JJ environment_NN for_IN to_TO raise_VB concerns_NNS on_IN integrity_NN issues_NNS or_CC playing_VBG a_DT role_NN in_IN targeting_VBG improved_JJ issues_NNS relating_VBG to_TO our_PRP$ business_NN that_IN affect_VB report_NN inappropriate_JJ behavior_NN ._.
We_PRP also_RB treatment_NN of_IN the_DT highest_JJS priority_NN or_CC concern_NN society_NN today_NN ._.
We_PRP use_VBP a_DT formal_JJ concentrated_JJ on_IN reviewing_VBG and_CC refining_VBG diseases_NNS ._.
In_IN June_NNP 2003_CD ,_, we_PRP opened_VBD risk_NN assessment_NN process_NN to_TO identify_VB both_DT our_PRP$ corporate_JJ governance_NN controls_NNS and_CC our_PRP$ new_JJ state_NN of_IN the_DT art_NN laboratories_NNS the_DT opportunities_NNS and_CC the_DT challenges_NNS that_WDT reporting_VBG procedures_NNS to_TO ensure_VB that_IN we_PRP in_IN Bangalore_NNP ,_, India_NNP ._.
Work_NN there_EX is_VBZ these_DT issues_NNS present_RB ,_, and_CC to_TO plan_VB the_DT are_VBP meeting_VBG new_JJ laws_NNS and_CC regulatory_JJ dedicated_VBN to_TO finding_VBG the_DT first_JJ new_JJ actions_NNS needed_VBN to_TO ensure_VB our_PRP$ response_NN is_VBZ requirements_NNS ._.
This_DT includes_VBZ the_DT ability_NN treatment_NN in_IN 40_CD years_NNS for_IN tuberculosis_NN ,_, appropriate_JJ and_CC consistent_JJ ._.
Our_PRP$ current_JJ to_TO meet_VB the_DT appropriate_JJ executive_NN one_CD of_IN the_DT worlds_NNS greatest_JJS causes_NNS of_IN Priority_NNP Action_NNP Plan_NNP is_VBZ shown_VBN on_IN page_NN 4_CD ._.
certification_NN requirements_NNS of_IN the_DT death_NN from_IN infectious_JJ disease_NN ._.
Sarbanes-Oxley_NNP legislation_NN in_IN the_DT US_NNP AstraZeneca_NNP will_MD make_VB any_DT treatment_NN Corporate_JJ responsibility_NN CR_NNP is_VBZ not_RB an_DT and_CC the_DT changes_NNS introduced_VBN in_IN 2003_CD invented_VBD in_IN these_DT laboratories_NNS available_JJ optional_JJ extra_JJ it_PRP must_MD be_VB integral_JJ by_IN the_DT revised_VBN Combined_NNP Code_NNP on_IN for_IN clinical_JJ development_NN and_CC supply_NN to_TO to_TO all_DT that_IN we_PRP do_VBP ._.
Our_PRP$ strategy_NN to_TO Corporate_JJ Governance_NN of_IN the_DT UK_NNP the_DT worlds_NNS poorest_JJS countries_NNS at_IN low_JJ include_VB considerations_NNS of_IN corporate_JJ Financial_NNP Reporting_NNP Council_NNP ._.
prices_NNS in_IN partnership_NN with_IN governments_NNS ,_, responsibility_NN across_IN all_DT our_PRP$ activities_NNS is_VBZ healthcare_NN systems_NNS ,_, international_JJ beginning_NN to_TO take_VB effect_NN ._.
In_IN particular_JJ ,_, Integrity_NN and_CC high_JJ ethical_JJ standards_NNS agencies_NNS and_CC others_NNS all_DT of_IN whom_WP have_VBP a_DT relevant_JJ aspects_NNS are_VBP being_VBG increasingly_RB During_IN the_DT year_NN ,_, we_PRP added_VBD sales_NNS and_CC part_NN to_TO play_VB in_IN bringing_VBG essential_JJ medicines_NNS integrated_VBN into_IN our_PRP$ risk_NN assessments_NNS ,_, marketing_NN practices_NNS to_TO the_DT Priority_NNP Action_NNP to_TO the_DT patients_NNS who_WP need_VBP them_PRP ._.
scenario_NN planning_NN ,_, training_NN ,_, purchasing_VBG Plan_NN to_TO ensure_VB they_PRP continue_VBP to_TO get_VB the_DT practices_NNS and_CC market_NN access_NN strategy_NN ._.
In_IN appropriate_JJ high_JJ level_NN of_IN attention_NN and_CC Good_JJ corporate_JJ responsibility_NN enhances_VBZ 2003_CD ,_, we_PRP made_VBD some_DT good_JJ progress_NN ,_, that_IN we_PRP develop_VBP ways_NNS of_IN improving_VBG our_PRP$ the_DT benefits_NNS of_IN our_PRP$ medicines_NNS ,_, the_DT quality_NN but_CC recognize_VBP that_IN there_EX is_VBZ more_JJR work_NN to_TO global_JJ reporting_NN in_IN this_DT area_NN ._.
The_DT of_IN our_PRP$ financial_JJ performance_NN and_CC the_DT do_VBP to_TO ensure_VB that_IN a_DT sense_NN of_IN corporate_JJ settlement_NN of_IN the_DT Zoladex_NNP investigation_NN significance_NN of_IN our_PRP$ contributions_NNS to_TO our_PRP$ responsibility_NN is_VBZ consistently_RB embedded_VBN in_IN the_DT US_NNP see_VB page_NN 13_CD strengthened_VBD local_JJ communities_NNS ._.
I_PRP am_VBP committed_VBN to_TO throughout_IN the_DT Group_NNP and_CC actively_RB our_PRP$ commitment_NN to_TO deliver_VB high_JJ the_DT high_JJ standards_NNS necessary_JJ for_IN our_PRP$ interpreted_VBN and_CC managed_VBN at_IN a_DT local_JJ level_NN ._.
standards_NNS of_IN ethical_JJ behavior_NN in_IN the_DT continued_JJ business_NN success_NN and_CC for_IN marketing_NN of_IN our_PRP$ medicines_NNS worldwide_VBP ._.
maintaining_VBG the_DT value_NN of_IN our_PRP$ contribution_NN Because_IN corporate_JJ responsibility_NN spans_NNS to_TO society_NN ._.
a_DT wide_JJ range_NN of_IN issues_NNS ,_, they_PRP can_MD not_RB Leadership_VB by_IN example_NN at_IN all_DT levels_NNS all_DT be_VB covered_VBN in_IN this_DT brief_JJ introduction_NN ._.
Good_JJ corporate_JJ responsibility_NN depends_VBZ However_RB ,_, I_PRP will_MD highlight_VB under_IN each_DT on_IN the_DT right_JJ level_NN of_IN commitment_NN from_IN of_IN our_PRP$ core_NN values_VBZ some_DT areas_NNS of_IN all_DT employees_NNS ,_, led_VBN by_IN the_DT AstraZeneca_NNP progress_NN and_CC some_DT where_WRB further_JJ work_NN Board_NNP ,_, who_WP approve_VBP the_DT strategic_JJ is_VBZ needed_VBN ._.
More_JJR information_NN is_VBZ available_JJ direction_NN ,_, and_CC our_PRP$ Senior_NNP Executive_NNP Team_NNP in_IN this_DT Summary_NNP Report_NNP and_CC on_IN our_PRP$ and_CC management_NN ,_, who_WP are_VBP accountable_JJ Sir_NNP Tom_NNP McKillop_NNP website_NN ,_, astrazeneca_NN ._.
for_IN the_DT development_NN and_CC implementation_NN Chief_NNP Executive_NNP AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD 02_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN Our_PRP$ commitment_NN Making_VBG it_PRP happen_VB We_PRP believe_VB that_DT good_JJ corporate_JJ We_PRP plan_VBP to_TO build_VB and_CC extend_VB these_DT responsibility_NN CR_NN performance_NN During_IN 2003_CD ,_, we_PRP continued_VBD to_TO drive_VB activities_NNS to_TO ensure_VB that_IN CR_NNP is_VBZ depends_VBZ on_IN the_DT effective_JJ managethe_NN integration_NN of_IN CR_NNP into_IN business_NN consistently_RB embedded_VBN at_IN a_DT local_JJ ment_NN of_IN the_DT economic_JJ ,_, environmental_JJ processes_NNS and_CC consolidate_VB the_DT level_NN throughout_IN the_DT Group_NNP ._.
and_CC social_JJ priorities_NNS of_IN sustainable_JJ framework_NN for_IN local_JJ implementation_NN development_NN ._.
This_DT can_MD only_RB be_VB of_IN our_PRP$ global_JJ standards_NNS to_TO ensure_VB Improving_NN understanding_VBG achieved_VBN through_IN the_DT successful_JJ consistent_JJ and_CC appropriate_JJ behavior_NN Communication_NNP is_VBZ essential_JJ to_TO integration_NN of_IN CR_NNP considerations_NNS worldwide_VBP ._.
We_PRP continue_VBP into_IN all_DT of_IN our_PRP$ business_NN activities_NNS ._.
to_TO communicate_VB our_PRP$ CR_NNP objectives_NNS to_TO Senior_JJ managers_NNS throughout_IN the_DT build_VB awareness_NN and_CC commitment_NN ._.
We_PRP Our_PRP$ Global_JJ CR_NNP Committee_NNP leads_VBZ the_DT Company_NN are_VBP accountable_JJ for_IN the_DT have_VBP made_VBN progress_NN but_CC more_JJR work_NN development_NN of_IN CR_NNP management_NN development_NN and_CC implementation_NN needs_VBZ to_TO be_VB done_VBN ._.
The_DT Committee_NNP reports_NNS to_TO of_IN CR_NN programs_NNS in_IN their_PRP$ areas_NNS of_IN communications_NNS focused_VBN on_IN improving_VBG Dame_NNP Bridget_NNP Ogilvie_NNP ,_, Non-Executive_JJ responsibility_NN ._.
Based_VBN on_IN the_DT global_JJ CR_NNP the_DT understanding_NN of_IN what_WP corporate_JJ Director_NNP with_IN responsibility_NN for_IN policy_NN ,_, these_DT programs_NNS are_VBP required_VBN responsibility_NN means_VBZ in_IN practice_NN for_IN all_DT overseeing_VBG CR_NN in_IN AstraZeneca_NNP ._.
to_TO take_VB account_NN of_IN regional_JJ ,_, site_NN or_CC levels_NNS of_IN the_DT organization_NN ._.
In_IN particular_JJ ,_, in_IN functional_JJ priorities_NNS and_CC objectives_NNS ._.
todays_NNS demanding_VBG world_NN ,_, we_PRP need_VBP to_TO Identifying_VBG the_DT priorities_NNS Our_PRP$ CR_NNP Management_NNP Standards_NNPS help_VBP continue_VB to_TO promote_VB an_DT understanding_NN We_PRP use_VBP a_DT risk_NN assessment_NN process_NN to_TO managers_NNS to_TO understand_VB the_DT issues_NNS ,_, that_IN CR_NNP implementation_NN does_VBZ not_RB help_VB us_PRP identify_VB the_DT opportunities_NNS and_CC outline_VB the_DT framework_NN for_IN managing_VBG necessarily_RB depend_VB on_IN extra_JJ resource_NN challenges_NNS associated_VBN with_IN our_PRP$ our_PRP$ commitments_NNS and_CC provide_VB advice_NN but_CC on_IN the_DT consistent_JJ adoption_NN and_CC corporate_JJ responsibility_NN ._.
Our_PRP$ Corporate_JJ on_IN putting_VBG the_DT standards_NNS into_IN practice_NN ._.
integration_NN of_IN CR_NNP considerations_NNS into_IN Responsibility_NNP Priority_NNP Action_NNP Plan_NNP set_VBD everyday_JJ business_NN thinking_NN ._.
out_RB on_IN page_NN 4_CD provides_VBZ a_DT framework_NN The_DT size_NN and_CC scale_NN of_IN AstraZeneca_NNP and_CC for_IN managing_VBG these_DT in_IN line_NN with_IN our_PRP$ core_NN its_PRP$ business_NN mean_VB that_DT developments_NNS To_TO help_VB build_VB corporate_JJ skills_NNS in_IN CR_NNP values_NNS ,_, including_VBG defined_VBN objectives_NNS and_CC ,_, such_JJ as_IN these_DT take_VB time_NN to_TO embed_VBN ._.
Local_JJ management_NN ,_, we_PRP are_VBP in_IN the_DT process_NN of_IN where_WRB possible_JJ ,_, appropriate_JJ key_JJ CR_NN committees_NNS in_IN the_DT US_NNP and_CC Sweden_NNP integrating_VBG CR_NNP into_IN our_PRP$ Leadership_NN performance_NN indicators_NNS KPIs_NNS ._.
have_VBP been_VBN established_VBN and_CC one_CD is_VBZ Development_NNP programs_NNS ._.
This_DT planned_VBN for_IN 2004_CD in_IN the_DT UK_NNP ,_, representing_VBG includes_VBZ using_VBG case_NN studies_NNS to_TO This_DT year_NN ,_, we_PRP have_VBP added_VBN sales_NNS and_CC three_CD cornerstones_NNS of_IN our_PRP$ global_JJ demonstrate_VBP the_DT importance_NN of_IN good_JJ marketing_NN practices_NNS and_CC access_NN to_TO presence_NN ._.
These_DT cross-functional_JJ CR_NN performance_NN ,_, to_TO raise_VB awareness_NN medicines_NNS to_TO the_DT Plan_NN and_CC we_PRP continue_VBP committees_NNS have_VBP an_DT ongoing_JJ role_NN for_IN and_CC to_TO stimulate_VB discussion_NN of_IN how_WRB to_TO monitor_VB our_PRP$ internal_JJ and_CC external_JJ setting_NN ,_, monitoring_NN and_CC reviewing_VBG CR_NN we_PRP can_MD all_DT contribute_VBP to_TO delivering_VBG environment_NN for_IN emerging_VBG issues_NNS that_WDT programs_NNS that_WDT are_VBP relevant_JJ and_CC our_PRP$ values_NNS ._.
may_MD require_VB attention_NN and_CC inclusion_NN in_IN appropriate_JJ for_IN their_PRP$ areas_NNS ._.
work_NN closely_RB with_IN the_DT Global_JJ CR_NNP Committee_NNP to_TO share_VB best_JJS practice_NN and_CC ensure_VB that_IN local_JJ and_CC global_JJ objectives_NNS are_VBP aligned_VBN ._.
AstraZeneca_NNP Corporate_NNP AstraZeneca_NNP safety_NN ,_, health_NN and_CC the_DT individuality_NN ,_, ethical_JJ issues_NNS are_VBP Responsibility_NNP Policy_NNP aims_VBZ to_TO set_VB ,_, promote_VB environmental_JJ diverse_JJ talent_NN and_CC dealt_VBD with_IN in_IN an_DT Through_IN the_DT provision_NN of_IN innovative_JJ new_JJ and_CC maintain_VB considerations_NNS creative_JJ potential_JJ effective_JJ and_CC medicines_NNS ,_, AstraZeneca_NNP improves_VBZ human_JJ high_JJ standards_NNS continue_VBP to_TO be_VB that_IN every_DT transparent_JJ way_NN health_NN and_CC enhances_VBZ peoples_NNS lives_NNS ._.
Our_PRP$ of_IN corporate_JJ a_DT fundamental_JJ employee_NN brings_VBZ activities_NNS impact_NN not_RB just_RB on_IN the_DT patients_NNS responsibility_NN company_NN to_TO the_DT business_NN our_PRP$ CR_NN we_PRP serve_VBP and_CC our_PRP$ investors_NNS but_CC also_RB on_IN worldwide_NN which_WDT consideration_NN are_VBP fully_RB valued_VBN commitments_NNS our_PRP$ employees_NNS and_CC on_IN society_NN as_IN a_DT whole_NN ._.
will_MD ensure_VB that_IN :_: and_CC respected_VBN are_VBP expanded_VBN Our_PRP$ continued_VBN long_JJ term_NN success_NN depends_VBZ we_PRP make_VBP a_DT positive_JJ by_IN encouraging_VBG on_IN our_PRP$ ability_NN to_TO integrate_VB successfully_RB our_PRP$ as_IN a_DT minimum_NN ,_, contribution_NN to_TO the_DT sales_NNS and_CC suppliers_NNS financial_JJ obligations_NNS with_IN our_PRP$ social_JJ and_CC we_PRP meet_VBP national_JJ communities_NNS in_IN marketing_NN to_TO embrace_VB environmental_JJ responsibilities_NNS ._.
and_CC international_JJ which_WDT we_PRP operate_VBP practices_NNS are_VBP standards_NNS similar_JJ regulations_NNS reputable_JJ to_TO our_PRP$ own_JJ AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN 03_CD We_PRP also_RB plan_VBP to_TO publish_VB our_PRP$ first_JJ US_NNP CR_NNP Our_PRP$ rolling_VBG program_NN of_IN AstraZeneca_NNP Stakeholder_NNP dialogue_NN We_PRP encourage_VBP constructive_JJ dialogue_NN Report_NNP in_IN 2004_CD which_WDT will_MD outline_VB the_DT site_NN audits_NN included_VBD 14_CD in_IN 2003_CD ,_, 11_CD of_IN with_IN all_DT our_PRP$ stakeholders_NNS and_CC others_NNS who_WP commitment_NN and_CC progress_NN to_TO date_NN in_IN which_WDT covered_VBD CR_NNP ,_, helping_VBG us_PRP to_TO have_VB an_DT interest_NN in_IN our_PRP$ activities_NNS ._.
monitor_NN progress_NN and_CC identify_VB areas_NNS Feedback_NNP opportunities_NNS are_VBP integrated_VBN for_IN improvement_NN in_IN the_DT consistent_JJ into_IN our_PRP$ employee_NN communication_NN Measuring_VBG progress_NN adoption_NN of_IN our_PRP$ standards_NNS ._.
Of_IN the_DT 11_CD programs_NNS to_TO help_VB us_PRP identify_VB areas_NNS of_IN Measuring_VBG our_PRP$ performance_NN is_VBZ essential_JJ sites_NNS audited_VBD ,_, five_CD were_VBD marketing_VBG both_DT satisfaction_NN and_CC concern_NN ._.
We_PRP hold_VBP to_TO understanding_VBG the_DT progress_NN we_PRP are_VBP companies_NNS ,_, four_CD were_VBD manufacturing_VBG face-to-face_JJ meetings_NNS with_IN investors_NNS making_VBG and_CC identifying_VBG potential_JJ areas_NNS sites_NNS and_CC two_CD were_VBD research_NN facilities_NNS ._.
mainstream_NN and_CC ethical_JJ investor_NN for_IN improvement_NN ._.
We_PRP have_VBP for_IN some_DT time_NN In_IN particular_JJ ,_, the_DT audits_NN highlighted_VBD the_DT groups_NNS ._.
Our_PRP$ site-based_JJ community_NN had_VBD processes_NNS in_IN place_NN for_IN monitoring_VBG need_NN to_TO continue_VB to_TO support_VB managers_NNS liaison_NN staff_NN ensure_VB that_IN our_PRP$ local_JJ our_PRP$ economic_JJ ,_, environmental_JJ ,_, safety_NN with_IN clear_JJ guidance_NN on_IN what_WP is_VBZ required_VBN communities_NNS including_VBG local_JJ and_CC health_NN performance_NN ._.
More_RBR recently_RB ,_, of_IN them_PRP in_IN these_DT early_JJ days_NNS of_IN local_JJ CR_NNP committees_NNS and_CC politicians_NNS are_VBP kept_VBN we_PRP have_VBP been_VBN focusing_VBG on_IN developing_VBG implementation_NN ._.
informed_VBN of_IN our_PRP$ business_NN activities_NNS and_CC KPIs_NNS in_IN other_JJ areas_NNS of_IN social_JJ plans_NNS and_CC given_VBN the_DT opportunity_NN to_TO raise_VB performance_NN ._.
These_DT are_VBP listed_VBN in_IN the_DT A_DT new_JJ CR_NNP Audit_NNP Handbook_NNP that_WDT provides_VBZ any_DT concerns_NNS ._.
The_DT regular_JJ contact_NN we_PRP Priority_NNP Action_NNP Plan_NNP and_CC discussed_VBN guidance_NN and_CC support_NN in_IN the_DT new_JJ areas_NNS have_VBP with_IN customers_NNS in_IN our_PRP$ day-to-day_JJ further_JJ in_IN the_DT narrative_NN of_IN this_DT report_NN for_IN our_PRP$ internal_JJ auditors_NNS was_VBD published_VBN business_NN activities_NNS provides_VBZ them_PRP with_IN and_CC on_IN our_PRP$ website_NN ._.
Establishing_VBG KPIs_NNS during_IN the_DT year_NN and_CC we_PRP are_VBP now_RB working_VBG opportunities_NNS to_TO comment_VB on_IN CR_NN issues_NNS ._.
in_IN some_DT areas_NNS of_IN social_JJ responsibility_NN to_TO build_VB on_IN this_DT with_IN further_JJ guidelines_NNS is_VBZ proving_VBG to_TO be_VB a_DT challenge_NN for_IN industry_NN and_CC training_NN to_TO ensure_VB an_DT appropriate_JJ During_IN 2003_CD ,_, our_PRP$ CR_NNP Committee_NNP in_IN in_IN general_JJ and_CC AstraZeneca_NNP is_VBZ no_DT focus_NN on_IN CR_NNP in_IN all_DT of_IN our_PRP$ audits_NN ._.
Sweden_NNP held_VBD dialogue_NN sessions_NNS with_IN exception_NN ._.
We_PRP are_VBP continually_RB exploring_VBG internal_JJ and_CC external_JJ stakeholders_NNS in_IN the_DT ways_NNS in_IN which_WDT we_PRP can_MD meaningfully_RB Additionally_RB ,_, AstraZenecas_NNP Group_NNP their_PRP$ country_NN to_TO help_VB them_PRP understand_VB benchmark_JJ our_PRP$ performance_NN ._.
Internal_NNP Audit_NNP function_NN works_VBZ to_TO review_VB ,_, better_JJR the_DT challenges_NNS of_IN their_PRP$ local_JJ CR_NN among_IN other_JJ things_NNS ,_, compliance_NN with_IN implementation_NN programs_NNS ._.
Issues_NNS Auditing_VBG compliance_NN laws_NNS ,_, regulations_NNS and_CC Group_NNP policies_NNS ._.
raised_VBN by_IN stakeholders_NNS included_VBD supply_NN An_DT important_JJ step_NN in_IN 2003_CD was_VBD the_DT During_IN 2003_CD ,_, a_DT number_NN of_IN reviews_NNS were_VBD chain_NN management_NN ,_, pharmaceuticals_NNS inclusion_NN of_IN a_DT requirement_NN to_TO develop_VB conducted_VBN and_CC reported_VBN to_TO the_DT Audit_NNP in_IN the_DT environment_NN and_CC the_DT extent_NN to_TO local_JJ CR_NNP implementation_NN plans_NNS in_IN our_PRP$ Committee_NNP of_IN the_DT Board_NNP ._.
Areas_NNS covered_VBD which_WDT our_PRP$ core_NN values_NNS are_VBP reflected_VBN in_IN annual_JJ compliance_NN report_NN by_IN senior_JJ included_VBN our_PRP$ Code_NNP of_IN Conduct_NNP and_CC our_PRP$ our_PRP$ behavior_NN and_CC strategic_JJ decisionmanagement_NN to_TO the_DT AstraZeneca_NNP Code_NNP of_IN Sales_NNS and_CC Marketing_NNP Practices_NNPS ._.
The_DT Swedish_NNP CR_NNP Committee_NNP Board_NNP the_DT letter_NN of_IN assurance_NN ._.
is_VBZ currently_RB updating_VBG the_DT Swedish_JJ CR_NNP Action_NNP Plan_NNP in_IN the_DT light_NN of_IN these_DT Alongside_IN this_DT ,_, we_PRP are_VBP building_VBG on_IN the_DT discussions_NNS ._.
experience_NN of_IN our_PRP$ long_JJ standing_NN safety_NN ,_, health_NN and_CC environment_NN audit_NN In_IN the_DT US_NNP ,_, the_DT CR_NNP Committee_NNP has_VBZ program_NN to_TO include_VB additional_JJ areas_NNS interviews_NNS with_IN key_JJ stakeholders_NNS of_IN CR_NNP ,_, such_JJ as_IN purchasing_VBG principles_NNS ,_, scheduled_VBN for_IN the_DT first_JJ quarter_NN of_IN 2004_CD ,_, labor_NN practices_NNS and_CC community_NN the_DT outcomes_NNS of_IN which_WDT will_MD help_VB shape_VB support_NN ._.
the_DT US_NNP Priority_NNP Action_NNP Plan_NNP ._.
Dame_NNP Bridget_NNP Ogilvie_NNP Non-Executive_NNP Director_NNP with_IN responsibility_NN for_IN overseeing_VBG CR_NNP in_IN AstraZeneca_NNP AstraZeneca_NNP continues_VBZ to_TO make_VB progress_NN in_IN the_DT integration_NN of_IN CR_NNP into_IN all_DT its_PRP$ activities_NNS ._.
Staying_VBG in_IN tune_NN with_IN the_DT changing_VBG expectations_NNS of_IN its_PRP$ stakeholders_NNS is_VBZ an_DT ever_RB present_JJ challenge_NN ._.
AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD 04_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN Our_PRP$ goals_NNS Corporate_JJ Responsibility_NN Priority_NN Action_NNP Plan_NNP Issue_NNP Objective_NNP Action_NNP plan_NN Integration_NNP of_IN CR_NNP into_IN all_DT activities_NNS CR_NNP considerations_NNS are_VBP included_VBN in_IN all_DT relevant_JJ strategies_NNS Continued_VBN internal_JJ communication_NN of_IN policies_NNS ,_, framework_NN ,_, and_CC decisions_NNS management_NN standards_NNS and_CC guidelines_NNS Continued_VBN local_JJ implementation_NN and_CC global_JJ auditing_NN Integration_NNP of_IN CR_NNP into_IN learning_VBG and_CC development_NN programs_NNS Sampling_VBG employee_NN understanding_NN and_CC opinion_NN Corporate_JJ governance_NN Deal_NNP with_IN all_DT stakeholders_NNS with_IN the_DT highest_JJS ethical_JJ standards_NNS Internal_NNP communication_NN and_CC training_NN in_IN our_PRP$ revised_VBN Code_NNP of_IN Conduct_NNP for_IN all_DT employees_NNS Improve_VBP systems_NNS for_IN reporting_VBG concerns_NNS To_TO consider_VB access_NN to_TO medicines_NNS when_WRB defining_VBG pricing_NN and_CC Communication_NNP of_IN our_PRP$ framework_NN for_IN considering_VBG access_NN Access_NN to_TO medicines_NNS market_NN access_NN strategies_NNS for_IN new_JJ brands_NNS to_TO medicines_NNS early_RB in_IN product_NN development_NN Monitor_NNP local_JJ alignment_NN with_IN global_JJ principles_NNS Share_NN good_JJ practice_NN High_NNP ethical_JJ standards_NNS of_IN sales_NNS and_CC marketing_NN in_IN all_DT countries_NNS Further_JJ develop_VB mechanisms_NNS for_IN monitoring_NN and_CC reporting_VBG Sales_NNS and_CC marketing_NN practices_NNS of_IN operation_NN compliance_NN Establish_VB KPIs_NNP Compliance_NNP Global_NNP consistency_NN of_IN implementation_NN of_IN CR_NN standards_NNS Continued_VBN development_NN of_IN audit_NN processes_NNS to_TO include_VB CR_NNP including_VBG new_JJ governance_NN laws_NNS and_CC regulations_NNS Human_JJ rights_NNS Ensure_VBP that_IN we_PRP consistently_RB live_VBP up_RP to_TO our_PRP$ core_NN values_NNS and_CC our_PRP$ Establish_VB a_DT means_NN of_IN collecting_VBG Human_NNP Resources_NNPS data_NNS commitment_NN to_TO the_DT principles_NNS of_IN the_DT UN_NNP Declaration_NNP of_IN Human_NNP on_IN a_DT consistent_JJ global_JJ basis_NN Rights_NNS worldwide_VBP Establish_JJ KPIs_NNS based_VBN on_IN the_DT planned_VBN areas_NNS of_IN data_NNS collection_NN Diversity_NN equal_JJ opportunity_NN Ensure_VB diversity_NN is_VBZ appropriately_RB supported_VBN in_IN our_PRP$ global_JJ Creation_NN of_IN diversity_NN programs_NNS workforce_NN and_CC reflected_VBN in_IN our_PRP$ leadership_NN Ensure_VB recruitment_NN processes_NNS are_VBP appropriate_JJ Establish_VB a_DT means_NN of_IN collecting_VBG Human_NNP Resources_NNPS data_NNS on_IN a_DT consistent_JJ global_JJ basis_NN Use_NN of_IN laboratory_NN animals_NNS Minimise_VBP the_DT number_NN of_IN animals_NNS used_VBN Continued_VBN adoption_NN of_IN alternative_NN techniques_NNS where_WRB possible_JJ Animal_NNP welfare_NN Ensure_NNP high_JJ standards_NNS of_IN care_NN for_IN those_DT that_WDT are_VBP used_VBN Continued_VBN monitoring_VBG using_VBG established_VBN procedures_NNS Suppliers_NNS Encourage_VBP our_PRP$ suppliers_NNS to_TO embrace_VB CR_NNP standards_NNS similar_JJ to_TO Build_VB CR_NNP into_IN the_DT external_JJ spend_VBP and_CC supplier_NN our_PRP$ own_JJ and_CC working_VBG with_IN them_PRP to_TO share_VB best_JJS practice_NN and_CC management_NN processes_NNS that_IN we_PRP are_VBP developing_VBG help_VB them_PRP improve_VB ,_, if_IN appropriate_JJ Community_NN support_NN Ensure_VB optimum_JJ effectiveness_NN of_IN our_PRP$ commitment_NN to_TO Continued_VBN communication_NN of_IN our_PRP$ Community_NNP Support_NN community_NN support_NN ,_, which_WDT focuses_VBZ on_IN health_NN ,_, science_NN Policy_NN worldwide_NN and_CC education_NN Monitoring_NN activity_NN and_CC sharing_VBG best_JJS practice_NN through_IN Enable_NNP the_DT sharing_NN of_IN best_JJS practice_NN the_DT global_JJ community_NN support_NN database_NN Compliance_NN with_IN the_DT SHE_NNP Policy_NNP Aim_NNP to_TO eliminate_VB all_DT injuries_NNS and_CC accidents_NNS Safety_NNP ,_, health_NN and_CC environment_NN SHE_NNP No_NNP hurt_NN ,_, harm_NN or_CC alarm_NN Economise_NNP on_IN the_DT use_NN of_IN natural_JJ resources_NNS and_CC work_NN to_TO minimize_VB our_PRP$ impact_NN on_IN the_DT environment_NN Be_VB among_IN the_DT industry_NN leaders_NNS in_IN SHE_NNP performance_NN As_IN part_NN of_IN the_DT overall_JJ CR_NN integration_NN objective_NN ,_, ensure_VB that_IN SHE_NNP considerations_NNS continue_VBP to_TO be_VB integrated_VBN into_IN all_DT activities_NNS across_IN the_DT Group_NNP AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN 05_CD KPI_NNP where_WRB appropriate_JJ Progress_NNP in_IN 2003_CD 2_CD yearly_JJ global_JJ employee_NN survey_NN plus_CC ad_NN hoc_FW pulse_NN surveys_NNS CR_NNP implementation_NN included_VBD in_IN letter_NN of_IN assurance_NN process_NN CR_NNP included_VBD in_IN global_JJ risk_NN assessment_NN Local_JJ CR_NN committees_NNS established_VBN in_IN the_DT US_NNP and_CC Sweden_NNP CR_NNP module_NN approved_VBD for_IN inclusion_NN in_IN leadership_NN development_NN program_NN See_VB page_NN 2_CD 2_CD yearly_JJ global_JJ employee_NN survey_NN Code_NNP of_IN Conduct_NNP revised_VBD and_CC re-published_VBD International_NNP ,_, confidential_JJ employee_NN telephone_NN helpline_NN established_VBN See_VB page_NN 7_CD Candidate_NNP drug_NN identified_VBD for_IN development_NN as_IN a_DT new_JJ tuberculosis_NN Collective_NNP global_JJ approach_NN agreed_VBD treatment_NN Appointment_NN of_IN Access_NNP to_TO Medicines_NNP Director_NNP Oncology_NNP and_CC Infection_NNP See_VB page_NN 14_CD Under_IN discussion_NN Network_NNP of_IN promotional_JJ standards_NNS experts_NNS established_VBN See_VB page_NN 13_CD Number_NN of_IN audits_NN conducted_VBN 11_CD CR_NN audits_NN carried_VBD out_RP by_IN SHE_NNP auditors_NNS ,_, complemented_VBN by_IN Group_NNP Internal_NNP Audit_NNP reviews_VBZ See_VB page_NN 3_CD Under_IN discussion_NN Human_NNP Resources_NNP global_JJ database_NN project_NN on_IN track_NN See_VB page_NN 11_CD Number_NN of_IN diversity_NN programs_NNS Around_IN 28_CD diversity_NN programs_NNS in_IN place_NN Percent_NN of_IN women_NNS at_IN senior_JJ levels_NNS 13_CD %_NN of_IN our_PRP$ 200_CD most_RBS senior_JJ managers_NNS are_VBP women_NNS Human_NNP Resources_NNPS global_JJ database_NN project_NN on_IN track_NN See_VB page_NN 12_CD Number_NN of_IN animals_NNS used_VBN 242,000_CD animals_NNS used_VBN in_IN 2002_CD 2003_CD figure_NN not_RB yet_RB available_JJ See_VB page_NN 14_CD Number_NN of_IN business_NN control_NN meetings_NNS including_VBG CR_NNP 150_CD business_NN control_NN meetings_NNS included_VBD CR_NNP considerations_NNS CR_NNP built_VBD into_IN contracts_NNS and_CC master_NN agreements_NNS See_VB page_NN 11_CD Percent_NN of_IN community_NN programs_NNS focused_VBD on_IN our_PRP$ priorities_NNS of_IN 90_CD %_NN of_IN community_NN programs_NNS focused_VBD on_IN our_PRP$ priorities_NNS health_NN ,_, science_NN and_CC education_NN Inclusion_NN in_IN the_DT UKs_NNP Business_NNP in_IN the_DT Community_NNP One_CD Per_IN Cent_NNP Club_NNP See_VB page_NN 15_CD Accidents_NNS with_IN injury_NN Target_NNP :_: 30_CD %_NN reduction_NN by_IN 2005_CD 14_CD %_NN reduction_NN in_IN accidents_NNS with_IN injury_NN ,_, relative_JJ to_TO hours_NNS worked_VBD New_NNP cases_NNS of_IN occupational_JJ illness_NN Target_NNP :_: 30_CD %_NN reduction_NN by_IN 2005_CD 52_CD %_NN reduction_NN in_IN new_JJ cases_NNS of_IN occupational_JJ illness_NN ,_, relative_JJ to_TO hours_NNS worked_VBD Unplanned_JJ releases_NNS to_TO the_DT environment_NN not_RB contained_VBD within_IN site_NN 18_CD %_NN reduction_NN in_IN unplanned_JJ releases_NNS boundary_NN Target_NNP :_: 50_CD %_NN reduction_NN by_IN 2005_CD 15_CD %_NN reduction_NN in_IN waste_NN ,_, relative_JJ to_TO sales_NNS Total_JJ waste_NN produced_VBD Target_NNP :_: 10_CD %_NN reduction_NN by_IN 2005_CD 3_CD %_NN reduction_NN in_IN greenhouse_NN gas_NN emissions_NNS Global_JJ warming_VBG potential_JJ Target_NNP :_: 10_CD %_NN reduction_NN by_IN 2005_CD 18_CD %_NN reduction_NN in_IN ODP_NNP emissions_NNS Ozone_NN depletion_NN potential_JJ ODP_NNP Target_NNP :_: 30_CD %_NN reduction_NN by_IN 2005_CD See_VB pages_NNS 9_CD ,_, 12_CD and_CC 16_CD Against_IN 2001_CD 2002_CD reference_NN point_NN AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD 06_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN Economic_NNP performance_NN Our_PRP$ business_NN is_VBZ focused_VBN on_IN delivering_VBG value_NN for_IN our_PRP$ shareholders_NNS and_CC for_IN society_NN by_IN maintaining_VBG a_DT flow_NN of_IN new_JJ medicines_NNS designed_VBN to_TO meet_VB the_DT needs_NNS of_IN patients_NNS and_CC the_DT healthcare_NN professionals_NNS who_WP treat_VBP them_PRP ._.
Jonathan_NNP Symonds_NNP AstraZeneca_NNP is_VBZ listed_VBN Chief_NNP Financial_NNP Officer_NNP in_IN the_DT 2004_CD Dow_NNP You_PRP can_MD read_VB regularly_RB in_IN the_DT newspapers_NNS Jones_NNP Sustainability_NN about_IN companies_NNS that_WDT have_VBP lost_VBN value_NN Indexes_NNS World_NNP through_IN failing_VBG to_TO manage_VB some_DT aspects_NNS and_CC European_JJ ._.
These_DT aspects_NNS Participation_NN in_IN this_DT can_MD be_VB far_RB more_RBR important_JJ to_TO the_DT market_NN type_NN of_IN survey_NN is_VBZ than_IN decisions_NNS that_WDT directly_RB affect_VBP a_DT an_DT important_JJ means_NNS companys_NNS profits_NNS ._.
of_IN evaluating_VBG our_PRP$ performance_NN and_CC understanding_NN better_RB the_DT demands_NNS of_IN sustainable_JJ development_NN ._.
AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN 07_CD Shareholders_NNS naturally_RB look_VBP for_IN a_DT We_PRP also_RB reviewed_VBD and_CC re-published_VBD our_PRP$ good_JJ return_NN on_IN their_PRP$ investment_NN but_CC Code_NNP of_IN Conduct_NNP to_TO make_VB sure_JJ that_IN it_PRP increasingly_RB people_NNS want_VBP assurance_NN continues_VBZ to_TO be_VB appropriate_JJ ._.
Compliance_NN that_IN they_PRP are_VBP investing_VBG in_IN a_DT company_NN with_IN the_DT Code_NNP is_VBZ mandatory_JJ and_CC is_VBZ that_DT delivers_VBZ a_DT return_NN in_IN a_DT responsible_JJ monitored_VBN through_IN the_DT annual_JJ letter_NN way_NN ._.
The_DT establishment_NN of_IN ethical_JJ of_IN assurance_NN process_NN and_CC Group_NNP investment_NN indices_NNS such_JJ as_IN Dow_NNP Internal_NNP Audit_NNP reviews_VBZ ._.
The_DT revised_VBN Jones_NNP Sustainability_NN reflects_VBZ these_DT version_NN is_VBZ being_VBG widely_RB circulated_VBN to_TO rising_VBG expectations_NNS ._.
employees_NNS and_CC communication_NN tools_NNS provided_VBN to_TO managers_NNS to_TO support_VB Failure_NN to_TO deliver_VB our_PRP$ core_NN values_NNS could_MD discussions_NNS with_IN their_PRP$ teams_NNS about_IN seriously_RB impact_NN our_PRP$ reputation_NN ,_, which_WDT what_WP is_VBZ expected_VBN of_IN them_PRP ._.
we_PRP recognize_VBP is_VBZ an_DT important_JJ driver_NN of_IN the_DT Companys_NNP worth_NN ._.
The_DT Code_NNP of_IN Conduct_NNP includes_VBZ procedures_NNS for_IN employees_NNS to_TO raise_VB Managing_VBG risk_NN integrity_NN concerns_NNS ,_, including_VBG a_DT AstraZenecas_NNP Risk_NNP Advisory_NNP Group_NNP ,_, confidential_JJ telephone_NN helpline_NN number_NN ._.
led_VBN by_IN our_PRP$ Chief_NNP Financial_NNP Officer_NNP ,_, Jonathan_NNP Symonds_NNP ,_, looks_VBZ at_IN the_DT risks_NNS Contributing_VBG to_TO economic_JJ the_DT Company_NN faces_VBZ and_CC how_WRB they_PRP are_VBP development_NN being_VBG addressed_VBN ._.
Increasingly_RB we_PRP are_VBP Our_PRP$ medicines_NNS are_VBP designed_VBN to_TO improve_VB integrating_VBG reputational_JJ risk_NN ,_, including_VBG health_NN and_CC quality_NN of_IN life_NN ._.
They_PRP also_RB bring_VBP CR_NNP ,_, into_IN our_PRP$ risk_NN management_NN processes_VBZ other_JJ benefits_NNS to_TO society_NN ._.
Reducing_VBG the_DT and_CC aim_NN to_TO ensure_VB that_IN managers_NNS build_VBP it_PRP incidence_NN of_IN disease_NN or_CC the_DT time_NN needed_VBN into_IN their_PRP$ everyday_JJ thinking_NN ._.
Appropriate_JJ for_IN treatment_NN relieves_VBZ pressure_NN on_IN tools_NNS are_VBP available_JJ in_IN the_DT form_NN of_IN a_DT shared_VBN healthcare_NN systems_NNS and_CC helps_VBZ to_TO risk_VB management_NN philosophy_NN ,_, principles_NNS improve_VBP productivity_NN ._.
and_CC a_DT framework_NN that_IN all_DT managers_NNS can_MD use_VB to_TO reflect_VB on_IN behaviors_NNS ,_, assess_VBP As_IN the_DT economic_JJ burden_NN of_IN funding_VBG risks_NNS and_CC positively_RB shape_VB their_PRP$ decision_NN therapies_NNS grows_VBZ ,_, we_PRP are_VBP increasingly_RB making_VBG ._.
including_VBG explanation_NN of_IN the_DT economic_JJ ,_, as_RB well_RB as_IN the_DT therapeutic_JJ ,_, advantages_NNS Corporate_JJ governance_NN of_IN our_PRP$ medicines_NNS to_TO help_VB ensure_VB that_IN the_DT An_DT essential_JJ part_NN of_IN our_PRP$ corporate_JJ full_JJ benefit_NN to_TO healthcare_NN providers_NNS and_CC responsibility_NN is_VBZ to_TO continue_VB to_TO operate_VB to_TO society_NN is_VBZ understood_VBN ._.
high_JJ standards_NNS of_IN corporate_JJ governance_NN ._.
Our_PRP$ business_NN activities_NNS also_RB benefit_VBP the_DT During_IN the_DT year_NN ,_, we_PRP reviewed_VBD and_CC communities_NNS around_IN us_PRP through_IN local_JJ refined_VBN our_PRP$ corporate_JJ governance_NN employment_NN and_CC wages_NNS ,_, taxes_NNS ,_, controls_VBZ to_TO ensure_VB that_IN we_PRP are_VBP meeting_VBG community_NN support_NN and_CC local_JJ and_CC new_JJ laws_NNS and_CC regulatory_JJ requirements_NNS ._.
national_JJ sourcing_VBG of_IN materials_NNS and_CC This_DT includes_VBZ the_DT ability_NN to_TO meet_VB the_DT services_NNS ._.
appropriate_JJ executive_NN certification_NN requirements_NNS of_IN the_DT Sarbanes-Oxley_NNP Investing_VBG in_IN innovation_NN legislation_NN in_IN the_DT US_NNP and_CC the_DT changes_NNS AstraZeneca_NNP spends_VBZ around_IN $_$ 14_CD million_CD introduced_VBN in_IN 2003_CD by_IN the_DT revised_VBN each_DT working_VBG day_NN on_IN research_NN and_CC Combined_NNP Code_NNP on_IN Corporate_JJ development_NN which_WDT is_VBZ an_DT important_JJ Governance_NN of_IN the_DT UK_NNP Financial_NNP contribution_NN to_TO the_DT combined_VBN commitReporting_NNP Council_NNP ._.
ment_NN of_IN the_DT pharmaceutical_JJ industry_NN ,_, which_WDT is_VBZ the_DT source_NN of_IN the_DT vast_JJ majority_NN AstraZenecas_NNP senior_JJ Non-Executive_NNP of_IN medical_JJ innovation_NN ,_, researching_VBG and_CC Director_NNP ,_, Sir_NNP Peter_NNP Bonfield_NNP ,_, was_VBD developing_VBG over_IN 90_CD %_NN of_IN new_JJ medicines_NNS ._.
nominated_VBN in_IN 2002_CD as_IN the_DT contact_NN for_IN investors_NNS wishing_VBG to_TO raise_VB high_JJ level_NN concerns_NNS about_IN any_DT potential_JJ corporate_JJ governance_NN issues_NNS ._.
AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD 08_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN Environmental_NNP performance_NN We_PRP continue_VBP to_TO pursue_VB sustained_JJ improvement_NN in_IN areas_NNS where_WRB we_PRP believe_VBP our_PRP$ global_JJ business_NN has_VBZ the_DT greatest_JJS potential_JJ impact_NN on_IN the_DT environment_NN :_: climate_NN change_NN ,_, ozone_NN depletion_NN and_CC waste_NN production_NN ._.
The_DT installation_NN Leading_VBG by_IN In_IN Sweden_NNP ,_, as_IN part_NN An_DT energy_NN efficient_JJ At_IN our_PRP$ US_NNP headquarters_NN in_IN Wilmington_NNP ,_, of_IN two_CD new_JJ large_JJ example_NN in_IN the_DT of_IN our_PRP$ commitment_NN HVAC_NNP heating_NN ,_, Delaware_NNP ,_, our_PRP$ employees_NNS have_VBP formed_VBN energy_NN efficient_JJ use_NN of_IN alternatives_NNS to_TO ensuring_VBG correct_JJ ventilation_NN and_CC an_DT environmental_JJ awareness_NN team_NN ,_, which_WDT combined_VBN heat_NN and_CC to_TO business_NN disposal_NN of_IN preair_NN conditioning_NN participated_VBD in_IN a_DT range_NN of_IN projects_NNS during_IN power_NN CHP_NNP plants_NNS in_IN travel_NN ,_, our_PRP$ 2003_CD scribed_VBD treatments_NNS ,_, system_NN has_VBZ been_VBN the_DT year_NN including_VBG the_DT re-forestation_NN of_IN the_DT UK_NNP and_CC Puerto_NNP Senior_NNP Managers_NNPS we_PRP supported_VBD installed_VBN at_IN our_PRP$ 10,000_CD acres_NNS of_IN biologically_RB critical_JJ habitat_NN Rico_NNP will_MD reduce_VB our_PRP$ Conference_NN ,_, a_DT major_JJ campaign_NN ,_, new_JJ research_NN in_IN the_DT state_NN of_IN Delaware_NNP ._.
CO2_CD emissions_NNS by_IN an_DT involving_VBG over_RP in_IN partnership_NN with_IN laboratories_NNS in_IN estimated_VBN 50,000_CD 200_CD AstraZeneca_NNP other_JJ interested_JJ Bangalore_NNP ,_, India_NNP ,_, tonnes_VBZ each_DT year_NN ._.
leaders_NNS from_IN parties_NNS ,_, to_TO encourage_VB opened_VBN in_IN 2003_CD ._.
CHP_NNP is_VBZ the_DT simularound_JJ the_DT world_NN ,_, patients_NNS to_TO return_VB taneous_JJ generation_NN took_VBD place_NN as_IN a_DT surplus_NN medicines_NNS of_IN heat_NN and_CC power_NN video-conference_NN ._.
com_NN 09_CD A_DT detailed_JJ analysis_NN in_IN 2001_CD of_IN the_DT potential_NN expected_VBN to_TO be_VB maintained_VBN ,_, we_PRP are_VBP Unplanned_JJ releases_NNS environmental_JJ impacts_NNS of_IN our_PRP$ business_NN ,_, committed_VBN to_TO maximizing_VBG other_JJ ways_NNS of_IN Unplanned_JJ releases_NNS can_MD cause_VB damage_NN combined_VBN with_IN stakeholder_NN discussions_NNS ,_, reducing_VBG our_PRP$ reliance_NN on_IN air_NN and_CC road_NN both_DT to_TO the_DT environment_NN and_CC to_TO our_PRP$ helped_VBD us_PRP to_TO identify_VB our_PRP$ priority_NN action_NN transport_NN ,_, including_VBG rationalising_VBG our_PRP$ relationships_NNS with_IN our_PRP$ local_JJ communities_NNS areas_NNS ._.
We_PRP have_VBP clear_JJ targets_NNS for_IN reducing_VBG product_NN distribution_NN networks_NNS and_CC using_VBG and_CC regulators_NNS ._.
We_PRP aim_VBP to_TO eliminate_VB such_JJ our_PRP$ impact_NN ,_, as_IN set_VBN out_RP on_IN page_NN 5_CD ,_, and_CC alternatives_NNS to_TO business_NN travel_NN ,_, such_JJ as_IN incidents_NNS by_IN ensuring_VBG that_IN our_PRP$ processes_NNS here_RB we_PRP summarise_VBP our_PRP$ progress_NN ._.
In_IN 2003_CD ,_, we_PRP had_VBD information_NN and_CC detailed_JJ statistics_NNS are_VBP nine_CD unplanned_JJ releases_NNS that_WDT were_VBD not_RB available_JJ on_IN our_PRP$ website_NN ._.
Ozone_NN depletion_NN contained_VBD within_IN the_DT site_NN boundary_NN Some_DT of_IN our_PRP$ products_NNS ,_, such_JJ as_IN asthma_NN compared_VBN to_TO 10_CD in_IN 2002_CD ._.
Our_PRP$ challenge_NN is_VBZ to_TO sustain_VB improvement_NN therapies_NNS ,_, are_VBP presented_VBN in_IN a_DT pressurized_VBN ,_, as_IN we_PRP grow_VBP our_PRP$ business_NN ._.
There_EX is_VBZ no_DT metered_JJ dose_NN inhaler_NN that_WDT uses_VBZ non-toxic_JJ ,_, Pharmaceuticals_NNS in_IN the_DT environment_NN completely_RB satisfactory_JJ measure_NN that_WDT can_MD stable_JJ gases_NNS to_TO propel_VB the_DT treatment_NN Traces_NNS of_IN pharmaceuticals_NNS can_MD somebe_VB used_VBN to_TO relate_VB resource_NN consumption_NN safely_RB and_CC effectively_RB to_TO a_DT patients_NNS times_NNS be_VB found_VBN in_IN the_DT environment_NN ._.
to_TO the_DT size_NN of_IN a_DT complex_JJ global_JJ business_NN airways_NNS ._.
The_DT most_RBS commonly_RB used_VBN Studies_NNS in_IN recent_JJ years_NNS by_IN industry_NN ,_, such_JJ as_IN ours_JJ ._.
In_IN common_JJ with_IN other_JJ propellants_NNS have_VBP been_VBN CFCs_NNP ,_, which_WDT academic_JJ and_CC regulatory_JJ bodies_NNS suggest_VBP similar_JJ companies_NNS and_CC in_IN line_NN with_IN the_DT contribute_VBP to_TO ozone_NN depletion_NN as_RB well_RB as_IN that_IN the_DT concentrations_NNS being_VBG found_VBN in_IN Global_JJ Reporting_NNP Initiative_NNP ,_, we_PRP use_VBP being_VBG greenhouse_NN gases_NNS ._.
watercourses_NNS are_VBP many_JJ times_NNS less_RBR than_IN reported_VBN sales_NNS to_TO calculate_VB our_PRP$ resource_NN those_DT that_WDT would_MD pose_VB significant_JJ risk_NN to_TO efficiency_NN ._.
This_DT is_VBZ because_IN reported_VBN sales_NNS AstraZeneca_NNP has_VBZ been_VBN very_RB active_JJ in_IN humans_NNS and_CC are_VBP not_RB high_JJ enough_RB to_TO is_VBZ a_DT transparent_JJ ,_, audited_JJ number_NN that_IN the_DT development_NN of_IN alternatives_NNS to_TO cause_VB immediate_JJ or_CC short_JJ term_NN harm_NN to_TO enables_VBZ comparison_NN over_IN time_NN ,_, as_IN shown_VBN CFC-driven_JJ inhalers_NNS such_JJ as_IN dry_JJ powder_NN aquatic_JJ life_NN ._.
Nevertheless_RB ,_, we_PRP recognize_VBP on_IN page_NN 16_CD but_CC it_PRP should_MD be_VB noted_VBN that_IN inhalers_NNS and_CC pump_VB sprays_NNS ._.
We_PRP have_VBP that_DT stakeholders_NNS may_MD be_VB concerned_JJ exchange_NN rate_NN fluctuations_NNS can_MD have_VB an_DT also_RB now_RB begun_VBN the_DT regulatory_JJ approval_NN about_RB longer_JJR term_NN effects_NNS and_CC this_DT is_VBZ one_CD effect_NN on_IN reported_VBN sales_NNS ._.
process_NN for_IN a_DT new_JJ generation_NN of_IN of_IN our_PRP$ priority_NN areas_NNS of_IN study_NN ._.
We_PRP continue_VBP respiratory_JJ HFC_NNP inhalers_NNS that_WDT do_VBP not_RB to_TO work_VB alongside_IN other_JJ pharmaceutical_JJ Climate_NN change_NN damage_NN the_DT ozone_NN layer_NN ._.
However_RB ,_, companies_NNS and_CC regulatory_JJ bodies_NNS to_TO Our_PRP$ global_JJ warming_NN emissions_NNS arise_VBP CFC-driven_JJ inhalers_NNS continue_VBP to_TO be_VB used_VBN provide_VB further_JJ improvement_NN to_TO the_DT primarily_RB from_IN the_DT use_NN of_IN energy_NN at_IN our_PRP$ by_IN patients_NNS who_WP can_MD not_RB tolerate_VB ,_, or_CC do_VB existing_VBG techniques_NNS used_VBN to_TO assess_VB the_DT facilities_NNS ,_, transport_NN and_CC the_DT propellant_NN gas_NN not_RB have_VB the_DT choice_NN of_IN ,_, alternatives_NNS ._.
In_IN environmental_JJ risk_NN associated_VBN with_IN used_VBN in_IN some_DT of_IN our_PRP$ inhalation_NN products_NNS ._.
2003_CD ,_, decreased_VBD sales_NNS of_IN our_PRP$ CFC-driven_JJ pharmaceuticals_NNS ._.
inhalers_NNS resulted_VBD in_IN an_DT 11_CD %_NN decrease_NN in_IN During_IN the_DT year_NN ,_, we_PRP completed_VBD a_DT strategic_JJ our_PRP$ overall_JJ release_NN of_IN ozone_NN depleting_NN Consistent_NNP with_IN our_PRP$ commitment_NN to_TO strengthening_VBG of_IN our_PRP$ product_NN portfolio_NN substances_NNS ._.
We_PRP are_VBP still_RB planning_VBG to_TO reach_VB product_NN stewardship_NN ,_, we_PRP also_RB aim_VBP to_TO with_IN a_DT range_NN of_IN new_JJ high_JJ quality_NN medicines_NNS our_PRP$ target_NN of_IN reducing_VBG CFC_NNP emissions_NNS by_IN minimize_VBP the_DT amounts_NNS of_IN any_DT of_IN our_PRP$ that_WDT will_MD drive_VB AstraZenecas_NNP future_JJ 30_CD %_NN against_IN the_DT 2001_CD 2002_CD reference_NN products_NNS being_VBG released_VBN into_IN the_DT success_NN ._.
Planning_NNP for_IN the_DT new_JJ products_NNS point_NN by_IN 2005_CD ._.
Exact_JJ timing_NN will_MD depend_VB environment_NN from_IN our_PRP$ facilities_NNS ._.
We_PRP are_VBP has_VBZ included_VBN making_VBG necessary_JJ changes_NNS on_IN gaining_VBG regulatory_JJ approvals_NNS for_IN the_DT improving_VBG our_PRP$ effluent_JJ treatment_NN processes_VBZ to_TO our_PRP$ manufacturing_NN processes_NNS and_CC new_JJ inhalation_NN devices_NNS ._.
globally_RB including_VBG the_DT installation_NN of_IN a_DT $_$ 36_CD increasing_VBG the_DT size_NN of_IN our_PRP$ sales_NNS forces_NNS million_CD state_NN of_IN the_DT art_NN biological_JJ treatment_NN and_CC consequently_RB the_DT distance_NN traveled_VBD Our_PRP$ use_NN of_IN ozone_NN depleting_NN substances_NNS facility_NN at_IN our_PRP$ plant_NN in_IN Bristol_NNP ,_, UK_NNP ._.
Despite_IN these_DT changes_NNS ,_, for_IN refrigeration_NN and_CC fire_NN suppression_NN has_VBZ improvements_NNS in_IN efficiency_NN and_CC lower_JJR been_VBN substantially_RB reduced_VBN and_CC is_VBZ being_VBG Proposed_VBN EU_NNP chemicals_NNS policy_NN carbon_NN intensity_NN of_IN our_PRP$ fuel_NN sources_NNS ,_, phased_VBD out_RP completely_RB ._.
In_IN October_NNP 2003_CD ,_, the_DT EU_NNP Commission_NNP coupled_VBN with_IN a_DT reduced_VBN use_NN of_IN our_PRP$ CFCpublished_JJ draft_NN legislation_NN regarding_VBG the_DT driven_VBN inhalers_NNS ,_, led_VBD to_TO total_VB emissions_NNS from_IN Minimising_VBG waste_NN approval_NN of_IN chemicals_NNS in_IN Europe_NNP ,_, a_DT key_NN all_DT sources_NNS decreasing_VBG by_IN 2_CD %_NN in_IN 2003_CD ._.
We_PRP aim_VBP to_TO use_VB materials_NNS efficiently_RB and_CC component_NN of_IN which_WDT is_VBZ the_DT introduction_NN of_IN We_PRP are_VBP still_RB working_VBG hard_RB to_TO meet_VB our_PRP$ maximize_VB re-use_NN and_CC re-cycling_NN ._.
Where_WRB a_DT new_JJ regulatory_JJ system_NN called_VBN REACH_NNP target_NN of_IN a_DT 10_CD %_NN reduction_NN in_IN our_PRP$ global_JJ possible_JJ ,_, we_PRP avoid_VBP the_DT use_NN of_IN the_DT most_RBS Registration_NNP ,_, Evaluation_NNP and_CC Authorisation_NNP warming_VBG potential_JJ over_IN the_DT 2001_CD 2002_CD hazardous_JJ substances_NNS and_CC are_VBP of_IN Chemicals_NNS ._.
AstraZeneca_NNP supports_VBZ the_DT reference_NN point_NN by_IN the_DT end_NN of_IN 2005_CD ._.
developing_VBG avoidance_NN and_CC substitution_NN Commissions_NNS efforts_NNS to_TO overhaul_VB the_DT strategies_NNS to_TO assist_VB this_DT process_NN ._.
regulatory_JJ framework_NN for_IN approval_NN of_IN We_PRP continue_VBP to_TO implement_VB programs_NNS Approaches_NNS to_TO reducing_VBG the_DT amount_NN of_IN chemicals_NNS in_IN Europe_NNP and_CC through_IN EFPIA_NNP ,_, to_TO maximize_VB energy_NN efficiency_NN ._.
We_PRP are_VBP waste_NN we_PRP generate_VBP include_VBP the_DT improved_VBN the_DT pharmaceutical_JJ industrys_NNS trade_NN also_RB working_VBG to_TO increase_VB the_DT amount_NN of_IN operation_NN of_IN existing_VBG production_NN association_NN in_IN Europe_NNP ,_, we_PRP are_VBP actively_RB energy_NN purchased_VBN from_IN renewable_JJ processes_NNS and_CC the_DT better_JJR design_NN of_IN new_JJ contributing_VBG to_TO the_DT dialogue_NN on_IN this_DT issue_NN ._.
resources_NNS and_CC most_JJS of_IN our_PRP$ sites_NNS around_IN ones_NNS ,_, improved_VBD purchasing_VBG processes_NNS We_PRP agree_VBP with_IN the_DT principles_NNS of_IN the_DT the_DT world_NN have_VBP local_JJ programs_NNS in_IN place_NN and_CC internal_JJ waste_NN awareness_NN proposal_NN but_CC ,_, working_VBG with_IN EFPIA_NNP and_CC to_TO improve_VB energy_NN efficiency_NN ._.
In_IN 2003_CD ,_, we_PRP reduced_VBD our_PRP$ other_JJ industry_NN trade_NN associations_NNS ,_, we_PRP total_VBP waste_NN by_IN 3_CD %_NN including_VBG a_DT 9_CD %_NN seek_VBP to_TO ensure_VB that_IN the_DT eventual_JJ Whilst_NNP the_DT current_JJ level_NN of_IN travel_NN activity_NN reduction_NN in_IN hazardous_JJ waste_NN ._.
regulation_NN is_VBZ not_RB only_RB effective_JJ but_CC also_RB of_IN our_PRP$ sales_NNS forces_NNS up_IN 10_CD %_NN in_IN 2003_CD is_VBZ workable_JJ and_CC avoids_VBZ obstacles_NNS that_WDT may_MD unnecessarily_RB harm_VB our_PRP$ competitiveness_NN ._.
AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD 10_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN Social_NNP performance_NN Managing_VBG our_PRP$ business_NN in_IN a_DT constructive_JJ and_CC responsible_JJ way_NN means_VBZ understanding_NN and_CC responding_VBG appropriately_RB to_TO the_DT issues_NNS relating_VBG to_TO our_PRP$ activities_NNS that_WDT affect_VBP or_CC concern_NN society_NN ._.
During_IN 2003_CD ,_, we_PRP Our_PRP$ overall_JJ We_PRP continue_VBP to_TO As_IN part_NN of_IN our_PRP$ We_PRP strengthened_VBD developed_VBN a_DT new_JJ contribution_NN to_TO our_PRP$ make_VB progress_NN ,_, commitment_NN our_PRP$ commitment_NN automated_VBN system_NN local_JJ communities_NNS but_CC recognize_VBP to_TO employee_NN to_TO high_JJ ethical_JJ for_IN collecting_VBG through_IN charitable_JJ there_EX is_VBZ still_RB work_VB wellbeing_JJ ,_, at_IN least_JJS standards_NNS in_IN Human_NNP Resources_NNPS donations_NNS and_CC to_TO do_VB in_IN ensuring_VBG 60_CD %_NN of_IN our_PRP$ staff_NN the_DT sales_NNS and_CC data_NNS globally_RB ._.
sponsorships_NNS that_WDT diversity_NN worldwide_NN now_RB marketing_VBG of_IN our_PRP$ totalled_JJ $_$ 22_CD million_CD is_VBZ appropriately_RB have_VBP access_NN medicines_NNS globally_RB ._.
in_IN 2003_CD ._.
supported_VBN in_IN to_TO confidential_JJ our_PRP$ workforce_NN ._.
com_NN 11_CD Here_RB we_PRP describe_VBP our_PRP$ approach_NN to_TO some_DT We_PRP have_VBP been_VBN working_VBG to_TO improve_VB our_PRP$ of_IN the_DT social_JJ issues_NNS relating_VBG to_TO our_PRP$ global_JJ reporting_NN processes_NNS ,_, building_NN business_NN ._.
You_PRP can_MD read_VB more_JJR about_IN on_IN our_PRP$ long_JJ standing_NN systems_NNS for_IN these_DT and_CC other_JJ areas_NNS of_IN our_PRP$ social_JJ monitoring_NN compliance_NN wherever_WRB we_PRP performance_NN on_IN our_PRP$ website_NN ._.
During_IN 2003_CD ,_, we_PRP developed_VBD a_DT new_JJ automated_VBN information_NN system_NN for_IN Human_JJ rights_NNS collating_VBG ,_, reporting_VBG and_CC analyzing_VBG With_IN over_IN 60,000_CD people_NNS working_VBG in_IN employee_NN demographics_NNS globally_RB ._.
By_IN 45_CD countries_NNS ,_, AstraZeneca_NNP is_VBZ a_DT major_JJ the_DT end_NN of_IN the_DT year_NN ,_, this_DT was_VBD operational_JJ employer_NN worldwide_NN ._.
Our_PRP$ core_NN values_NNS across_IN the_DT UK_NNP ,_, the_DT US_NNP and_CC Sweden_NNP reflect_VBP our_PRP$ commitment_NN to_TO ensuring_VBG that_IN where_WRB more_JJR than_IN 60_CD %_NN of_IN our_PRP$ employees_NNS all_DT of_IN our_PRP$ people_NNS are_VBP treated_VBN with_IN integrity_NN are_VBP located_VBN and_CC the_DT rest_NN of_IN the_DT world_NN is_VBZ and_CC respect_NN within_IN a_DT working_VBG environexpected_VBN to_TO be_VB brought_VBN into_IN the_DT system_NN ment_NN that_WDT recognizes_VBZ the_DT freedom_NN of_IN the_DT during_IN 2004_CD ._.
individual_NN ._.
Working_VBG with_IN suppliers_NNS AstraZeneca_NNP supports_VBZ the_DT principles_NNS set_VBN In_IN 2003_CD ,_, we_PRP published_VBD a_DT revised_VBN CR_NNP out_IN in_IN the_DT UN_NNP Declaration_NNP of_IN Human_NNP Principles_NNPS in_IN Purchasing_NNP guide_NN which_WDT Rights_NNPS ._.
Our_PRP$ Code_NNP of_IN Conduct_NNP and_CC our_PRP$ included_VBN further_JJ guidance_NN for_IN our_PRP$ Global_JJ Human_NNP Resources_NNPS policies_NNS detail_NN purchasing_VBG community_NN in_IN working_VBG with_IN the_DT high_JJ standards_NNS of_IN ethical_JJ behavior_NN suppliers_NNS to_TO encourage_VB similar_JJ standards_NNS with_IN which_WDT everyone_NN in_IN AstraZeneca_NNP is_VBZ to_TO our_PRP$ own_JJ ,_, share_NN best_JJS practice_NN and_CC expected_VBN to_TO comply_VB ,_, both_DT in_IN spirit_NN and_CC stimulate_VB improved_VBN CR_NNP performance_NN ._.
Time_NNP will_MD be_VB required_VBN to_TO fully_RB implement_VB these_DT guidelines_NNS ._.
This_DT includes_VBZ only_RB employing_VBG adults_NNS ,_, as_IN defined_VBN by_IN the_DT labor_NN laws_NNS in_IN the_DT During_IN the_DT year_NN ,_, we_PRP continued_VBD our_PRP$ countries_NNS in_IN which_WDT we_PRP operate_VBP and_CC ,_, program_NN of_IN priority_NN audit_NN of_IN main_JJ as_IN a_DT minimum_NN ,_, compliance_NN with_IN national_JJ suppliers_NNS ._.
In_IN total_JJ ,_, 14_CD sites_NNS were_VBD audited_JJ legal_JJ requirements_NNS regarding_VBG wages_NNS and_CC at_IN our_PRP$ major_JJ chemical_NN suppliers_NNS ._.
All_DT our_PRP$ employees_NNS have_VBP potential_JJ new_JJ chemical_NN suppliers_NNS were_VBD the_DT right_NN to_TO be_VB a_DT member_NN of_IN a_DT trade_NN also_RB audited_VBD and_CC at_IN one_CD of_IN these_DT ,_, we_PRP union_NN ._.
We_PRP have_VBP agreements_NNS with_IN trade_NN identified_VBD the_DT need_NN for_IN an_DT improvement_NN unions_NNS in_IN a_DT number_NN of_IN countries_NNS where_WRB in_IN standards_NNS before_IN any_DT work_NN could_MD be_VB collective_JJ bargaining_NN is_VBZ customary_JJ commissioned_VBN by_IN AstraZeneca_NNP ._.
practice_NN within_IN a_DT countrys_NNS legal_JJ framework_NN and_CC where_WRB employees_NNS CR_NNP is_VBZ also_RB being_VBG integrated_VBN into_IN the_DT support_NN it_PRP ._.
regular_JJ business_NN control_NN meetings_NNS that_WDT are_VBP being_VBG introduced_VBN into_IN our_PRP$ purchasing_VBG We_PRP also_RB work_VBP closely_RB with_IN our_PRP$ major_JJ practice_NN ._.
In_IN 2003_CD ,_, approximately_RB 150_CD suppliers_NNS and_CC use_VB purchasing_VBG practices_NNS meetings_NNS that_WDT took_VBD place_NN included_VBD CR_NNP to_TO encourage_VB similar_JJ standards_NNS to_TO our_PRP$ considerations_NNS ._.
We_PRP do_VBP not_RB think_VB it_PRP is_VBZ appropriate_JJ for_IN AstraZeneca_NNP to_TO promote_VB individual_JJ rights_NNS and_CC freedoms_NNS more_RBR widely_RB in_IN society_NN ,_, but_CC we_PRP believe_VBP that_IN we_PRP can_MD and_CC do_VB influence_VB others_NNS through_IN leading_VBG by_IN example_NN ._.
AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD 12_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN Social_NNP performance_NN continued_VBD To_TO that_DT end_NN ,_, we_PRP are_VBP increasing_VBG the_DT Employee_NN safety_NN ,_, health_NN and_CC particularly_RB encouraging_JJ decrease_NN in_IN the_DT wellbeing_JJ emphasis_NN on_IN the_DT management_NN of_IN driving_VBG two_CD major_JJ areas_NNS of_IN work-related_JJ upper_JJ We_PRP believe_VBP that_IN if_IN we_PRP are_VBP to_TO expect_VB activities_NNS in_IN our_PRP$ marketing_NN companies_NNS limb_NN disorder_NN and_CC work-related_JJ stress_NN peoples_NNS continued_VBD energy_NN and_CC around_IN the_DT world_NN ._.
commitment_NN at_IN work_NN ,_, we_PRP must_MD provide_VB a_DT common_JJ cause_NN for_IN concern_NN for_IN many_JJ the_DT right_JJ environment_NN in_IN which_WDT they_PRP feel_VBP companies_NNS and_CC we_PRP are_VBP working_VBG together_RB Diversity_NNP safe_JJ and_CC well_RB and_CC positive_JJ and_CC with_IN other_JJ organizations_NNS to_TO share_VB Our_PRP$ approach_NN to_TO diversity_NN takes_VBZ account_NN enthusiastic_JJ about_IN what_WP they_PRP are_VBP doing_VBG ._.
of_IN all_PDT the_DT ways_NNS in_IN which_WDT our_PRP$ employees_NNS Our_PRP$ broad_JJ range_NN of_IN occupational_JJ safety_NN are_VBP different_JJ not_RB just_RB in_IN terms_NNS of_IN gender_NN and_CC health_NN programs_NNS is_VBZ focused_VBN on_IN In_IN 2003_CD ,_, our_PRP$ overall_JJ frequency_NN rate_NN for_IN and_CC race_NN ,_, but_CC also_RB culture_NN ,_, age_NN ,_, ability_NN continuous_JJ improvement_NN in_IN the_DT accidents_NNS with_IN fatal_JJ and_CC serious_JJ injuries_NNS to_TO and_CC family_NN situation_NN ._.
We_PRP value_VBP the_DT frequency_NN rates_NNS for_IN accidents_NNS with_IN injury_NN AstraZeneca_NNP employees_NNS and_CC contractors_NNS creative_JJ energy_NN that_IN these_DT differences_NNS and_CC for_IN new_JJ cases_NNS of_IN occupational_NN fell_VBD by_IN 13_CD %_NN ._.
This_DT is_VBZ largely_RB due_JJ to_TO an_DT bring_VB to_TO our_PRP$ business_NN ._.
illness_NN ,_, with_IN a_DT target_NN for_IN achieving_VBG a_DT 30_CD %_NN improvement_NN in_IN contractor_NN performance_NN ._.
reduction_NN against_IN the_DT 2001_CD 2002_CD In_IN 2002_CD ,_, we_PRP identified_VBD that_IN we_PRP had_VBD reference_NN point_NN by_IN the_DT end_NN of_IN 2005_CD ._.
To_TO Our_PRP$ wellbeing_JJ programs_NNS are_VBP designed_VBN work_NN to_TO do_VB to_TO ensure_VB that_IN diversity_NN is_VBZ help_VB us_PRP meet_VB this_DT target_NN ,_, we_PRP continue_VBP to_TO to_TO promote_VB physical_JJ and_CC psychological_JJ appropriately_RB supported_VBN in_IN our_PRP$ workdevelop_NN behaviour-based_JJ safety_NN and_CC welfare_NN and_CC include_VBP physical_JJ fitness_NN force_NN and_CC reflected_VBN in_IN our_PRP$ leadership_NN ._.
health_NN programs_NNS and_CC make_VB them_PRP activities_NNS ,_, nutrition_NN advice_NN and_CC stress_NN We_PRP made_VBD some_DT progress_NN during_IN 2003_CD ._.
widely_RB available_JJ ._.
When_WRB accidents_NNS occur_VBP ,_, management_NN courses_NNS ._.
Examples_NNS of_IN good_JJ Our_PRP$ R&D_NNP community_NN ,_, which_WDT has_VBZ been_VBN we_PRP investigate_VBP thoroughly_RB to_TO ensure_VB we_PRP practice_VB from_IN Europe_NNP ,_, Asia_NNP ,_, North_NNP and_CC active_JJ for_IN some_DT time_NN in_IN this_DT area_NN ,_, understand_VBP the_DT root_NN causes_VBZ ,_, take_VB steps_NNS South_NNP America_NNP feature_NN prominently_RB in_IN our_PRP$ introduced_VBN an_DT innovative_JJ ,_, interactive_JJ to_TO avoid_VB repetition_NN in_IN the_DT future_NN and_CC improvement_NN plans_NNS and_CC are_VBP shared_VBN diversity_NN program_NN which_WDT is_VBZ being_VBG communicate_VBP to_TO build_VB awareness_NN and_CC worldwide_NN through_IN our_PRP$ Wellbeing_VBG in_IN rolled_VBN out_RP to_TO the_DT R&D_NNP workforce_NN ._.
Programmes_NNP vary_VBP depending_VBG on_IN country_NN ,_, In_IN addition_NN ,_, diversity_NN improvement_NN plans_VBZ Although_IN our_PRP$ overall_JJ accident_NN frequency_NN culture_NN and_CC need_NN ._.
They_PRP include_VBP flexible_JJ were_VBD created_VBN and_CC implemented_VBN for_IN the_DT rate_NN for_IN employees_NNS improved_VBN by_IN 5_CD %_NN in_IN working_VBG arrangements_NNS ,_, access_NN to_TO fitness_NN six_CD major_JJ areas_NNS of_IN R&D_NNP ._.
Our_PRP$ Operations_NNP 2003_CD ,_, we_PRP are_VBP disappointed_VBN that_IN we_PRP and_CC social_JJ activities_NNS and_CC support_NN for_IN staff_NN group_NN included_VBD as_IN one_CD of_IN their_PRP$ three_CD showed_VBD little_JJ improvement_NN in_IN our_PRP$ vehicle_NN experiencing_VBG stress_NN ._.
Communications_NNPS to_TO global_JJ people_NNS targets_VBZ the_DT requirement_NN accident_NN record_NN ._.
Around_IN a_DT third_JJ of_IN the_DT help_NN ensure_VB that_IN employee_NN wellbeing_VBG that_IN each_DT of_IN our_PRP$ 20_CD manufacturing_NN sites_NNS total_VBP accidents_NNS reported_VBD including_VBG one_CD remains_VBZ high_JJ on_IN the_DT agenda_NN include_VBP faceshould_JJ prepare_VBP priority_NN action_NN plans_VBZ fatal_JJ accident_NN in_IN Germany_NNP were_VBD related_VBN to-face_JJ discussions_NNS with_IN the_DT top_JJ 200_CD addressing_VBG their_PRP$ diversity_NN needs_VBZ ._.
This_DT remains_VBZ the_DT greatest_JJS managers_NNS in_IN the_DT Company_NN ,_, addressing_VBG the_DT year_NN ,_, around_IN 15_CD plans_NNS were_VBD cause_NN of_IN accidents_NNS with_IN injury_NN to_TO their_PRP$ personal_JJ wellbeing_NN and_CC that_IN of_IN their_PRP$ completed_VBN ._.
With_IN seven_CD diversity_NN plans_NNS in_IN AstraZeneca_NNP employees_NNS ._.
place_NN in_IN the_DT US_NNP ,_, our_PRP$ total_NN is_VBZ now_RB around_RB has_VBZ always_RB been_VBN a_DT core_NN feature_NN of_IN our_PRP$ 28_CD programs_NNS ._.
safety_NN education_NN programs_NNS ,_, but_CC we_PRP In_IN 2003_CD ,_, our_PRP$ overall_JJ frequency_NN rate_NN of_IN recognize_VB ,_, and_CC take_VB seriously_RB ,_, the_DT need_NN occupational_JJ illnesses_NNS per_IN million_CD hours_NNS Our_PRP$ challenge_NN is_VBZ to_TO build_VB on_IN this_DT work_NN and_CC to_TO improve_VB our_PRP$ performance_NN in_IN this_DT area_NN ._.
worked_VBD improved_VBN by_IN 47_CD %_NN ,_, with_IN a_DT continue_VBP to_TO drive_VB improvement_NN in_IN other_JJ Pilot_NN projects_NNS that_WDT aim_VBP In_IN the_DT US_NNP ,_, our_PRP$ to_TO build_VB understanding_NN senior_JJ managers_NNS of_IN the_DT causes_NNS of_IN minor_JJ and_CC their_PRP$ direct_JJ vehicle_NN accidents_NNS to_TO reports_NNS all_DT reduce_VBP the_DT likelihood_NN attended_VBD diversity_NN of_IN more_JJR serious_JJ ones_NNS training_NN and_CC occurring_VBG will_MD be_VB started_VBN work_NN implemented_VBN in_IN on_IN developing_VBG Europe_NNP ,_, Asia_NNP Pacific_NNP diversity_NN action_NN and_CC the_DT Americas_NNPS ._.
plans_NNS for_IN their_PRP$ This_DT is_VBZ in_IN addition_NN to_TO functional_JJ areas_NNS ._.
the_DT defensive_JJ driver_NN Seven_CD plans_NNS were_VBD training_NN programs_NNS completed_VBN by_IN the_DT that_WDT are_VBP already_RB end_NN of_IN the_DT year_NN ._.
com_NN 13_CD we_PRP added_VBD sales_NNS and_CC marketing_NN practices_NNS areas_NNS of_IN our_PRP$ organization_NN ,_, at_IN all_DT levels_NNS ._.
For_IN example_NN ,_, direct_JJ to_TO Senior_NNP Executive_NNP Team_NNP has_VBZ responsibility_NN to_TO the_DT Corporate_JJ Responsibility_NN Priority_NN consumer_NN advertising_NN of_IN prescription_NN for_IN reviewing_VBG the_DT diversity_NN among_IN the_DT top_JJ Action_NNP Plan_NNP to_TO ensure_VB they_PRP continue_VBP to_TO medicines_NNS is_VBZ illegal_JJ in_IN many_JJ countries_NNS ,_, management_NN of_IN the_DT Company_NN ,_, including_VBG get_VB the_DT appropriate_JJ high_JJ level_NN of_IN attention_NN yet_CC it_PRP is_VBZ not_RB only_JJ legal_JJ in_IN the_DT US_NNP but_CC also_RB the_DT percentage_NN of_IN women_NNS at_IN a_DT senior_JJ globally_RB ._.
Our_PRP$ AstraZeneca_NNP Code_NNP of_IN Sales_NNS considered_VBN by_IN many_JJ to_TO have_VB a_DT positive_JJ level_NN ._.
In_IN 2003_CD ,_, 13_CD %_NN of_IN our_PRP$ 200_CD most_RBS and_CC Marketing_NNP Practices_NNPS outlines_VBZ the_DT influence_NN on_IN patient_JJ welfare_NN ._.
During_IN senior_JJ managers_NNS were_VBD women_NNS ._.
high_JJ standards_NNS of_IN ethical_JJ behavior_NN we_PRP 2003_CD ,_, we_PRP tested_VBD draft_NN reporting_VBG criteria_NNS demand_NN in_IN the_DT marketing_NN of_IN our_PRP$ which_WDT we_PRP hope_VBP will_MD lay_VB a_DT basis_NN for_IN a_DT Sales_NNS and_CC marketing_NN practices_NNS medicines_NNS ._.
It_PRP is_VBZ based_VBN on_IN the_DT global_JJ meaningful_JJ global_JJ promotional_JJ During_IN 2003_CD ,_, AstraZeneca_NNP settled_VBD an_DT industry_NN code_NN of_IN conduct_NN the_DT IFPMA_NNP regulatory_JJ monitoring_NN system_NN which_WDT investigation_NN into_IN US_NNP sales_NNS and_CC Code_NNP of_IN Pharmaceutical_NNP Marketing_NNP takes_VBZ account_NN of_IN the_DT different_JJ national_JJ marketing_NN practices_NNS for_IN Zoladex_NNP prostate_NN Practice_NNP ,_, as_RB well_RB as_IN the_DT codes_NNS of_IN environments_NNS ._.
We_PRP have_VBP established_VBN a_DT cancer_NN treatment_NN ,_, admitting_VBG violation_NN of_IN marketing_NN practice_NN ,_, laws_NNS and_CC regulations_NNS global_JJ network_NN of_IN promotional_JJ standards_NNS the_DT Prescription_NNP Drug_NNP Marketing_NNP Act_NNP by_IN applicable_JJ in_IN each_DT of_IN the_DT countries_NNS in_IN contacts_NNS in_IN our_PRP$ marketing_NN companies_NNS providing_VBG free_JJ samples_NNS of_IN the_DT product_NN to_TO which_WDT we_PRP operate_VBP ._.
The_DT IFPMA_NNP Code_NNP and_CC known_VBN as_IN Nominated_VBN Signatories_NNS and_CC physicians_NNS between_IN 1993_CD and_CC 1996_CD ,_, our_PRP$ own_JJ Code_NNP of_IN Practice_NNP embody_VBP the_DT have_VBP begun_VBN to_TO share_VB experience_NN and_CC with_IN the_DT understanding_NN that_IN these_DT principles_NNS proposed_VBN in_IN the_DT World_NNP Health_NNP best_JJS practice_NN amongst_IN this_DT group_NN ._.
physicians_NNS would_MD bill_VB Medicare_NNP for_IN Organisations_NNP Ethical_NNP Criteria_NNP for_IN reimbursement_NN ._.
AstraZeneca_NNP also_RB Medicinal_NNP Drug_NNP Promotion_NNP ,_, although_IN the_DT Clinical_JJ trials_NNS settled_VBD civil_JJ claims_NNS ,_, without_IN admitting_VBG WHO_WP suggestion_NN that_IN advertising_NN of_IN A_DT potential_JJ new_JJ medicine_NN enters_VBZ clinical_JJ liability_NN ,_, involving_VBG allegations_NNS that_IN the_DT prescription_NN medicines_NNS to_TO the_DT public_JJ studies_NNS only_RB after_IN its_PRP$ potential_JJ efficacy_NN Company_NN provided_VBD inducements_NNS to_TO should_MD not_RB generally_RB be_VB permitted_VBN is_VBZ not_RB and_CC adequate_JJ safety_NN has_VBZ been_VBN confirmed_VBN physicians_NNS to_TO purchase_VB Zoladex_NNP and_CC for_IN consistent_JJ with_IN the_DT law_NN or_CC self-regulatory_JJ in_IN pre-clinical_JJ trials_NNS ,_, which_WDT include_VBP animal_JJ improperly_RB setting_VBG and_CC reporting_VBG its_PRP$ standards_NNS in_IN certain_JJ countries_NNS notably_RB testing_VBG ._.
All_DT proposed_VBN clinical_JJ trials_NNS are_VBP price_NN ._.
The_DT settlement_NN provides_VBZ for_IN a_DT five_CD the_DT US_NNP ._.
reviewed_VBN and_CC approved_VBN including_VBG year_NN Corporate_JJ Integrity_NN Agreement_NN with_IN consideration_NN of_IN the_DT pre-clinical_JJ data_NNS ,_, the_DT Office_NNP of_IN the_DT Inspector_NNP General_NNP OIG_NNP Compliance_NN with_IN our_PRP$ Code_NNP is_VBZ the_DT safety_NN of_IN the_DT trial_NN and_CC the_DT nature_NN and_CC for_IN the_DT Department_NNP of_IN Health_NNP and_CC mandatory_JJ ._.
Whilst_IN we_PRP have_VBP local_JJ amount_NN of_IN information_NN given_VBN to_TO trial_NN Human_NNP Services_NNP under_IN which_WDT monitoring_NN systems_NNS in_IN place_NN ,_, including_VBG volunteers_NNS ._.
We_PRP have_VBP strict_JJ guidelines_NNS to_TO AstraZeneca_NNP is_VBZ required_VBN to_TO keep_VB in_IN place_NN auditing_NN of_IN our_PRP$ marketing_NN companies_NNS ensure_VB that_IN volunteers_NNS and_CC patients_NNS taking_VBG its_PRP$ current_JJ compliance_NN program_NN and_CC by_IN Group_NNP Internal_NNP Audit_NNP ,_, we_PRP are_VBP now_RB part_NN in_IN trials_NNS understand_VBP their_PRP$ purpose_NN provide_VB periodic_JJ reports_NNS to_TO the_DT OIG_NNP on_IN looking_VBG to_TO establish_VB KPIs_NNS in_IN this_DT area_NN and_CC are_VBP not_RB exposed_VBN to_TO unnecessary_JJ risks_NNS the_DT status_NN of_IN compliance_NN activities_NNS ._.
The_DT that_WDT will_MD enable_VB improved_VBN reporting_NN of_IN and_CC that_IN the_DT privacy_NN of_IN health_NN information_NN total_JJ payment_NN associated_VBN with_IN the_DT our_PRP$ global_JJ performance_NN ._.
A_DT variety_NN of_IN of_IN individuals_NNS taking_VBG part_NN is_VBZ protected_VBN ._.
legal_JJ ,_, regulatory_JJ and_CC self-regulatory_JJ mechanisms_NNS are_VBP applied_VBN to_TO pharmaWe_VB continue_VB to_TO monitor_VB the_DT safety_NN of_IN our_PRP$ We_PRP are_VBP committed_VBN to_TO ensuring_VBG that_IN ceutical_JJ marketing_NN activities_NNS around_IN products_NNS after_IN they_PRP have_VBP been_VBN approved_VBN improper_JJ practice_NN such_JJ as_IN this_DT is_VBZ not_RB the_DT world_NN and_CC different_JJ interpretations_NNS as_IN new_JJ medicines_NNS ,_, including_VBG collection_NN repeated_VBN ._.
In_IN addition_NN to_TO the_DT strong_JJ US_NNP of_IN what_WP constitutes_VBZ acceptable_JJ practice_NN of_IN data_NNS on_IN any_DT adverse_JJ reactions_NNS to_TO a_DT compliance_NN program_NN ,_, during_IN the_DT year_NN exist_VBP according_VBG to_TO national_JJ cultures_NNS and_CC treatment_NN ._.
Within_IN the_DT UK_NNP During_IN 2003_CD ,_, FTSE100_CD ,_, an_DT employee_NN AstraZeneca_NNP is_VBZ one_CD assistance_NN of_IN two_CD companies_NNS program_NN ,_, CALM_NNP with_IN the_DT highest_JJS Counselling_NN and_CC representation_NN of_IN Life_NNP Management_NNP women_NNS on_IN the_DT was_VBD made_VBN available_JJ Board_NNP four_CD out_IN to_TO staff_NN in_IN Japan_NNP ._.
of_IN 13_CD Board_NNP members_NNS are_VBP women_NNS ._.
Jane_NNP Henney_NNP Dame_NNP Bridget_NNP Ogilvie_NNP Erna_NNP Mller_NNP Michele_NNP Hooper_NNP AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD 14_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN Social_NNP performance_NN continued_VBD reduction_NN include_VBP our_PRP$ commitment_NN to_TO Animal_NNP welfare_NN our_PRP$ products_NNS whilst_VBP continuing_VBG our_PRP$ Laboratory_NN animals_NNS continue_VBP to_TO play_VB a_DT adopting_VBG alternative_NN techniques_NNS ._.
investment_NN in_IN research_NN and_CC ensuring_VBG vital_JJ and_CC necessary_JJ role_NN in_IN the_DT research_NN that_WDT wherever_WRB possible_JJ medicines_NNS are_VBP and_CC development_NN of_IN new_JJ medicines_NNS for_IN The_DT welfare_NN of_IN the_DT animals_NNS we_PRP use_VBP is_VBZ available_JJ to_TO those_DT that_WDT need_VBP them_PRP ._.
important_JJ areas_NNS of_IN human_JJ healthcare_NN ._.
Our_PRP$ research_NN sites_NNS are_VBP This_DT includes_VBZ early_JJ testing_NN of_IN the_DT effects_NNS of_IN subject_JJ to_TO formal_JJ inspections_NNS by_IN our_PRP$ Although_IN essential_JJ medicines_NNS are_VBP new_JJ compounds_NNS and_CC the_DT requirement_NN by_IN own_JJ staff_NN every_DT two_CD years_NNS in_IN addition_NN to_TO becoming_VBG increasingly_RB available_JJ to_TO those_DT regulatory_JJ authorities_NNS for_IN the_DT submission_NN the_DT mandatory_JJ visits_NNS by_IN government_NN that_WDT need_VBP them_PRP in_IN developing_VBG countries_NNS ,_, of_IN safety_NN data_NNS from_IN animal_JJ studies_NNS before_IN authorities_NNS around_IN the_DT world_NN ._.
Meeting_VBG there_EX are_VBP still_RB many_JJ other_JJ factors_NNS such_PDT a_DT new_JJ medicine_NN can_MD be_VB tested_VBN in_IN healthy_JJ local_JJ regulatory_JJ requirements_NNS is_VBZ a_DT as_RB basic_JJ hygiene_NN ,_, healthcare_NN infravolunteers_NNS and_CC then_RB patients_NNS ._.
minimum_JJ baseline_NN and_CC we_PRP have_VBP our_PRP$ structure_NN and_CC training_NN and_CC education_NN own_JJ strict_JJ guidelines_NNS on_IN animal_NN welfare_NN that_WDT are_VBP also_RB pre-requisites_NNS before_IN As_IN we_PRP continue_VBP to_TO expand_VB our_PRP$ R&D_NNP as_IN outlined_VBN in_IN our_PRP$ Bioethics_NNPS Policy_NNP and_CC significant_JJ progress_NN can_MD be_VB made_VBN in_IN activity_NN ,_, we_PRP aim_VBP to_TO manage_VB the_DT potential_JJ supported_VBN by_IN programs_NNS such_JJ as_IN delivering_VBG medicines_NNS to_TO patients_NNS in_IN increase_NN in_IN use_NN of_IN animals_NNS by_IN adopting_VBG animal_NN care_NN training_NN for_IN our_PRP$ laboratory_NN these_DT countries_NNS ._.
alternative_NN techniques_NNS such_JJ as_IN technicians_NNS ._.
computer_NN simulations_NNS ,_, informatics_NNS and_CC Each_DT of_IN our_PRP$ development_NN products_NNS is_VBZ high_JJ throughput_NN screening_NN ,_, which_WDT Where_WRB we_PRP outsource_VBP animal_JJ studies_NNS to_TO reviewed_VBN independently_RB in_IN relation_NN to_TO eliminate_VB the_DT use_NN of_IN animals_NNS or_CC reduce_VB give_VB us_PRP access_NN to_TO additional_JJ expertise_NN pricing_NN and_CC access_NN in_IN all_DT markets_NNS ,_, so_IN the_DT number_NN needed_VBN ._.
As_RB well_RB as_IN or_CC capacity_NN ,_, inspections_NNS to_TO ensure_VB that_IN plans_NNS can_MD be_VB put_VBN in_IN place_NN early_RB for_IN developing_VBG our_PRP$ own_JJ alternatives_NNS ,_, we_PRP also_RB compliance_NN with_IN our_PRP$ own_JJ standards_NNS those_DT which_WDT may_MD be_VB regarded_VBN as_IN adopt_VB those_DT successfully_RB developed_VBN by_IN are_VBP a_DT significant_JJ part_NN of_IN our_PRP$ animal_NN essential_JJ medicines_NNS either_CC because_IN others_NNS and_CC we_PRP continue_VBP to_TO work_VB ,_, welfare_NN program_NN ._.
they_PRP address_VBP diseases_NNS prevalent_JJ in_IN alongside_IN the_DT rest_NN of_IN the_DT pharmaceutical_JJ developing_VBG countries_NNS or_CC because_IN they_PRP industry_NN ,_, with_IN regulatory_JJ authorities_NNS to_TO Access_NNP to_TO medicines_NNS are_VBP potentially_RB a_DT leading_VBG or_CC unique_JJ agree_VBP reductions_NNS wherever_WRB possible_JJ in_IN The_DT increasing_VBG demand_NN for_IN new_JJ product_NN in_IN their_PRP$ class_NN ,_, offering_VBG the_DT animals_NNS required_VBN by_IN their_PRP$ protocols_NNS ._.
medicines_NNS that_WDT improve_VBP and_CC extend_VBP lives_NNS significant_JJ patient_NN benefit_NN in_IN a_DT serious_JJ is_VBZ driven_VBN both_DT by_IN the_DT ageing_JJ population_NN or_CC life_NN threatening_JJ condition_NN ._.
In_IN these_DT In_IN 2002_CD ,_, we_PRP used_VBD around_IN 242,000_CD and_CC advances_NNS in_IN technology_NN ._.
At_IN the_DT circumstances_NNS ,_, we_PRP aim_VBP to_TO make_VB animals_NNS ,_, a_DT small_JJ reduction_NN on_IN 2001_CD same_JJ time_NN infectious_JJ diseases_NNS such_JJ as_IN arrangements_NNS to_TO ensure_VB patient_JJ access_NN 248,000_CD ._.
Some_DT 98_CD %_NN of_IN these_DT were_VBD HIV_NNP AIDS_NNP are_VBP threatening_VBG to_TO overwhelm_VB to_TO these_DT medicines_NNS through_IN charitable_JJ rodents_NNS and_CC fish_NN ._.
Approximately_RB 4_CD %_NN were_VBD the_DT populations_NNS of_IN some_DT of_IN the_DT least_JJS donation_NN ,_, expanded_VBD access_NN used_VBN by_IN external_JJ contractors_NNS ._.
Governments_NNS are_VBP programs_NNS or_CC differential_JJ pricing_NN ._.
number_NN of_IN animals_NNS we_PRP use_VBP each_DT year_NN will_MD responding_VBG in_IN different_JJ ways_NNS to_TO balance_VB continue_VB to_TO fluctuate_VB ._.
Increases_NNS can_MD result_VB healthcare_NN budgets_NNS against_IN the_DT ever_RB The_DT appointment_NN in_IN January_NNP 2004_CD of_IN from_IN a_DT rise_NN in_IN the_DT number_NN of_IN compounds_NNS increasing_VBG demand_NN for_IN wider_JJR access_NN an_DT Access_NN to_TO Medicines_NNP Director_NNP ,_, a_DT new_JJ in_IN development_NN and_CC from_IN our_PRP$ further_JJ to_TO medicines_NNS ._.
The_DT challenge_NN for_IN position_NN in_IN the_DT Company_NN ,_, strengthens_VBZ adoption_NN of_IN tests_NNS using_VBG genetically_RB AstraZeneca_NNP is_VBZ to_TO address_VB the_DT continued_VBN our_PRP$ commitment_NN ._.
Working_VBG in_IN the_DT modified_VBN animals_NNS ._.
Factors_NNS influencing_VBG a_DT downward_JJ pressure_NN on_IN the_DT costs_NNS of_IN Oncology_NNP and_CC Infection_NNP therapy_NN areas_NNS ,_, In_IN the_DT UK_NNP ,_, AstraZeneca_NNP supports_VBZ the_DT Prior_RB to_TO its_PRP$ launch_NN ,_, we_PRP implemented_VBD an_DT Brightside_NNP Trust_NNP ,_, a_DT charity_NN that_WDT aims_VBZ to_TO help_VB expanded_JJ access_NN program_NN for_IN Iressa_NNP ,_, underprivileged_JJ young_JJ people_NNS enter_VBP the_DT our_PRP$ new_JJ treatment_NN for_IN lung_NN cancer_NN ,_, which_WDT medical_JJ and_CC healthcare_NN professions_NNS ._.
This_DT made_VBD the_DT therapy_NN available_JJ to_TO patients_NNS with_IN addresses_NNS a_DT particular_JJ issue_NN for_IN modern_JJ lung_NN cancer_NN for_IN whom_WP no_DT other_JJ treatment_NN medical_JJ practice_NN that_IN most_JJS disadvantaged_JJ had_VBD been_VBN successful_JJ ._.
During_IN 2002_CD and_CC communities_NNS do_VBP not_RB have_VB access_NN to_TO 2003_CD ,_, over_IN 42,000_CD patients_NNS in_IN 70_CD countries_NNS doctors_NNS with_IN a_DT similar_JJ background_NN ._.
Our_PRP$ received_VBN Iressa_NNP through_IN this_DT route_NN ._.
support_NN includes_VBZ a_DT one_CD year_NN secondment_NN to_TO the_DT charity_NN as_RB well_RB as_IN a_DT $_$ 160,000_CD financial_JJ contribution_NN over_IN three_CD years_NNS ._.
com_NN 15_CD In_IN all_DT cases_NNS of_IN facilitating_VBG access_NN to_TO our_PRP$ the_DT role_NN will_MD initially_RB focus_VB on_IN Iressa_NNP ,_, our_PRP$ In_IN 2003_CD ,_, our_PRP$ spend_VBP on_IN community_NN new_JJ lung_NN cancer_NN treatment_NN ,_, and_CC other_JJ medicines_NNS ,_, we_PRP can_MD only_RB be_VB successful_JJ sponsorships_NNS and_CC charitable_JJ donations_NNS emerging_VBG treatments_NNS for_IN cancer_NN ._.
if_IN we_PRP can_MD ensure_VB that_IN the_DT product_NN is_VBZ not_RB totalled_VBN $_$ 22_CD million_CD ._.
diverted_VBN away_RB from_IN those_DT who_WP need_VBP it_PRP Whilst_IN we_PRP support_VBP the_DT concept_NN of_IN and_CC that_IN we_PRP retain_VBP intellectual_JJ property_NN Improving_NN data_NNS collection_NN differential_JJ pricing_NN in_IN this_DT context_NN ,_, we_PRP rights_NNS which_WDT enable_VBP us_PRP to_TO protect_VB our_PRP$ In_IN 2002_CD ,_, we_PRP introduced_VBD a_DT central_JJ continue_VBP to_TO seek_VB safeguards_NNS that_WDT core_NN business_NN and_CC provide_VB for_IN future_JJ database_NN to_TO improve_VB our_PRP$ processes_NNS differentially_RB priced_VBN products_NNS are_VBP not_RB investment_NN in_IN the_DT discovery_NN and_CC for_IN capturing_VBG the_DT full_JJ extent_NN of_IN our_PRP$ diverted_VBN from_IN the_DT patients_NNS who_WP need_VBP development_NN of_IN new_JJ medicines_NNS for_IN community_NN support_NN initiatives_NNS ,_, product_NN them_PRP ,_, to_TO be_VB sold_VBN and_CC used_VBN in_IN more_JJR a_DT wide_JJ range_NN of_IN diseases_NNS ._.
donations_NNS and_CC patient_JJ access_NN affluent_JJ markets_NNS ._.
Differential_NNP pricing_NN can_MD programs_NNS around_IN the_DT world_NN and_CC only_RB be_VB of_IN benefit_NN in_IN countries_NNS where_WRB Product_NNP donations_NNS and_CC patient_NN to_TO ensure_VB the_DT information_NN can_MD be_VB healthcare_NN systems_NNS can_MD deliver_VB assistance_NN programs_NNS shared_VBN internally_RB to_TO promote_VB best_JJS medicines_NNS to_TO the_DT patients_NNS that_WDT need_VBP Our_PRP$ product_NN donations_NNS and_CC patient_JJ practice_NN ._.
In_IN 2003_CD ,_, over_IN 1,000_CD projects_NNS them_PRP and_CC ensure_VB that_IN they_PRP are_VBP used_VBN assistance_NN programs_NNS make_VBP products_NNS were_VBD entered_VBN into_IN the_DT database_NN ,_, appropriately_RB ._.
available_JJ free_JJ of_IN charge_NN or_CC at_IN reduced_JJ covering_VBG activities_NNS in_IN 34_CD countries_NNS ._.
In_IN 2003_CD ,_, our_PRP$ expanded_VBN patient_NN Research_NN into_IN neglected_VBN diseases_NNS of_IN the_DT assistance_NN programs_NNS in_IN the_DT US_NNP For_IN the_DT first_JJ time_NN ,_, in_IN 2003_CD AstraZeneca_NNP developing_VBG world_NN is_VBZ essential_JJ to_TO the_DT contributed_VBN to_TO a_DT total_JJ spend_VBP of_IN was_VBD included_VBN in_IN the_DT UK_NNP Business_NNP in_IN the_DT effective_JJ treatment_NN of_IN these_DT diseases_NNS in_IN $_$ 724_CD million_CD in_IN this_DT area_NN ,_, at_IN average_JJ Communitys_NNP One_CD Per_IN Cent_NNP Club_NNP ,_, an_DT the_DT future_NN ._.
AstraZeneca_NNP has_VBZ recently_RB wholesale_JJ price_NN ._.
index_NN of_IN companies_NNS that_WDT contribute_VBP 1_CD %_NN made_VBD a_DT substantial_JJ investment_NN in_IN new_JJ or_CC more_JJR of_IN their_PRP$ annual_JJ operating_NN profit_NN research_NN facilities_NNS in_IN Bangalore_NNP ,_, India_NNP ,_, that_IN Community_NNP support_NN to_TO community_NN support_NN ._.
are_VBP focused_VBN on_IN finding_VBG a_DT new_JJ treatment_NN Wherever_NNP AstraZeneca_NNP is_VBZ located_VBN for_IN tuberculosis_NN a_DT major_JJ and_CC increasing_VBG worldwide_NN ,_, we_PRP aim_VBP to_TO make_VB a_DT positive_JJ threat_NN to_TO life_NN in_IN developing_VBG countries_NNS ._.
contribution_NN to_TO our_PRP$ local_JJ communities_NNS through_IN charitable_JJ donations_NNS ,_, sponsorShould_NN we_PRP be_VB successful_JJ in_IN identifying_VBG ships_NNS and_CC other_JJ initiatives_NNS that_WDT help_VBP to_TO a_DT potential_JJ new_JJ medicine_NN ,_, a_DT key_JJ priority_NN make_VB a_DT difference_NN ._.
In_IN particular_JJ ,_, we_PRP will_MD be_VB to_TO develop_VB it_PRP in_IN partnership_NN with_IN focus_NN on_IN bringing_VBG benefits_NNS in_IN ways_NNS that_WDT governments_NNS ,_, local_JJ organizations_NNS and_CC are_VBP consistent_JJ with_IN our_PRP$ business_NN of_IN international_JJ bodies_NNS in_IN order_NN to_TO achieve_VB improving_VBG health_NN and_CC quality_NN of_IN life_NN the_DT earliest_JJS possible_JJ approval_NN according_VBG and_CC on_IN promoting_VBG the_DT value_NN of_IN science_NN to_TO global_JJ standards_NNS ._.
We_PRP hope_VBP that_IN we_PRP among_IN young_JJ people_NNS ._.
can_MD then_RB again_RB work_VB in_IN partnership_NN with_IN the_DT relevant_JJ global_JJ and_CC local_JJ organizations_NNS to_TO ensure_VB that_IN any_DT new_JJ treatment_NN reaches_VBZ the_DT patients_NNS who_WP need_VBP it_PRP ._.
The_DT Together_RB Rx_JJ program_NN in_IN the_DT US_NNP ,_, run_VBP In_IN December_NNP 2003_CD ,_, AstraZeneca_NNP announced_VBD by_IN AstraZeneca_NNP and_CC six_CD other_JJ pharmaa_JJ $_$ 360,000_CD three-year_JJ partnership_NN with_IN ceutical_JJ companies_NNS ,_, provides_VBZ eligible_JJ Peking_NNP Universitys_NNP Guanghua_NNP School_NNP Medicare_NNP patients_NNS with_IN up_RB to_TO 40_CD %_NN savings_NNS of_IN Management_NN to_TO fund_VB the_DT China_NNP Center_NNP on_IN medicines_NNS used_VBN to_TO treat_VB a_DT range_NN of_IN for_IN Pharmacoeconomics_NNP and_CC Outcomes_NNP common_JJ conditions_NNS that_WDT affect_VBP older_JJR people_NNS ._.
Research_NNP in_IN a_DT series_NN of_IN research_NN and_CC educational_JJ programs_NNS aimed_VBN at_IN supporting_VBG Chinas_NNP continued_VBD reform_NN of_IN its_PRP$ healthcare_NN system_NN ._.
In_IN particular_JJ ,_, the_DT programs_NNS will_MD focus_VB on_IN building_NN research_NN skills_NNS and_CC expertise_NN in_IN health_NN economics_NNS ._.
Sir_NNP Tom_NNP McKillop_NNP AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD 16_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN 2003_CD performance_NN summary_NN 2001 2002 2003 2005_CD target_NN Economic_JJ $_$ m_CD where_WRB relevant_JJ Sales_NNS 16,222_CD 17,841_CD 18,849_CD Operating_NN profit_NN 4,156_CD 4,356_CD 4,111_CD Dividends_NNS 1,225_CD 1,206_CD 1,350_CD Ratio_NN of_IN market_NN capitalization_NN to_TO book_NN value_NN of_IN net_JJ assets_NNS 8.0_CD 5.5_CD 6.1_CD R&D_NNP investment_NN 2,687_CD 3,069_CD 3,451_CD Total_JJ wages_NNS 3,542_CD 3,993_CD 4,745_CD Taxation_NNP 1,214_CD 1,177_CD 1,143_CD Environmental_NNP 1_CD Greenhouse_NN gases_NNS CO2-equivalents_NNS million_CD tonnes_NNS 1.87_CD 1.77_CD 1.72_CD 1.59_CD Index_NNP tonnes_VBZ $_$ m_JJ sales_NNS 115_CD 99_CD 92_CD Energy_NNP GWh_NNP 2,170_CD 2,240_CD 2,440_CD Index_NNP MWh_NNP $_$ m_JJ sales_NNS 134 126 129_CD CFCs_NNP Total_NNP ozone_NN depletion_NN potential_JJ CFC11_NNP equivalent_NN tonnes_VBZ 110_CD 99_CD 88_CD 75_CD Index_NNP kg_FW $_$ m_JJ sales_NNS 7.0_CD 5.6_CD 4.7_CD Waste_NNP Hazardous_NNP waste_NN kte_NN 36.7_CD 31.1_CD 28.3_CD Total_JJ waste_NN kte_NN 65.5_CD 60.3_CD 58.4_CD Index_NNP total_JJ waste_NN tonnes_VBZ $_$ m_JJ sales_NNS 4.04_CD 3.38_CD 3.10_CD 3.26_CD Unplanned_JJ releases_NNS Contained_VBN within_IN site_NN boundary_NN 24_CD 17_CD 8_CD Not_RB contained_VBN within_IN site_NN boundary_NN 12_CD 10_CD 9_CD 6_CD Social_NNP Safety_NNP and_CC health_NN :_: AstraZeneca_NNP employees_NNS Number_NNP of_IN accidents_NNS with_IN injury_NN per_IN million_CD hours_NNS 4.16_CD 3.84_CD 3.64_CD Number_NN of_IN accidents_NNS with_IN injury_NN and_CC days_NNS lost_VBD per_IN million_CD hours_NNS 2.86_CD 2.84_CD 2.66_CD Cases_NNS of_IN occupational_JJ illnesses_NNS per_IN million_CD hours_NNS 3.83_CD 3.15_CD 1.67_CD 2.44_CD Safety_NN and_CC health_NN :_: AstraZeneca_NNP employees_NNS and_CC contractors_NNS Number_NNP of_IN accidents_NNS with_IN injury_NN per_IN million_CD hours_NNS 4.18_CD 4.11_CD 3.57_CD 2.90_CD 2_CD Number_NN of_IN animals_NNS used_VBN in_IN research_NN 248,000_CD 242,000_CD Site_NN audits_NN that_WDT included_VBD CR_NNP 11_NNP Community_NNP support_NN $_$ m_CD Sponsorships_NNP n_VBD a_DT 9.7_CD 16.4_CD Charitable_JJ contributions_NNS n_VBP a_DT 3.3_CD 5.6_CD Total_JJ n_NN a_DT 13.0_CD 22.0_CD Product_NNP donations_NNS and_CC patient_JJ assistance_NN programs_NNS at_IN average_JJ wholesale_JJ price_NN $_$ m_CD n_NN a_DT 303.0_CD 724.0_CD Regulatory_NNP infringements_NNS safety_NN ,_, health_NN and_CC environment_NN Prosecutions_NNS 1_CD 1_CD 1_CD Legal_NNP sanctions_NNS 4_CD 7_CD 4_CD Failures_NNS to_TO obtain_VB correct_JJ permits_NNS 1_CD 0_CD 0_CD Infringements_NNP of_IN operating_VBG permits_NNS 7_CD 6_CD 12_CD Total_JJ 13_CD 14_CD 17_CD 1_CD 2_CD Figures_NNS are_VBP calculated_VBN in_IN line_NN with_IN the_DT Greenhouse_NNP Gas_NNP GhG_NNP Protocol_NNP guidance_NN ghgprotocol_NN ._.
org_NN 2003_CD figure_NN not_RB yet_RB available_JJ n_IN a_DT Not_RB applicable_JJ AstraZeneca_NNP Corporate_NNP Responsibility_NNP Summary_NNP Report_NNP 2003_CD For_IN more_JJR information_NN visit_NN astrazeneca_NN ._.
com_NN During_IN 2003_CD ,_, AstraZeneca_NNP sold_VBD its_PRP$ Marlow_NNP Foods_NNP operation_NN ._.
Although_IN no_DT changes_NNS have_VBP been_VBN made_VBN to_TO the_DT absolute_JJ performance_NN figures_NNS ,_, the_DT SHE_NNP improvement_NN targets_NNS and_CC their_PRP$ reference_NN points_NNS have_VBP been_VBN modified_VBN in_IN line_NN with_IN the_DT WRI_NNP WBCSD_NNP protocol_NN ._.
This_DT avoids_VBZ incorporating_VBG the_DT reduction_NN in_IN emissions_NNS resulting_VBG from_IN the_DT divestment_NN as_IN part_NN of_IN our_PRP$ improvement_NN process_NN ._.
With_IN the_DT exception_NN of_IN the_DT economic_JJ data_NNS ,_, the_DT above_JJ represents_VBZ preliminary_JJ figures_NNS only_RB ._.
Final_JJ statistics_NNS will_MD be_VB published_VBN on_IN our_PRP$ website_NN ,_, astrazeneca_NN ._.
com_NN Designed_VBN by_IN Addison_NNP Corporate_NNP Marketing_NNP Ltd_NNP astrazeneca_NN ._.
